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Abbreviation list 
⁰C    degrees Celsius (centigrade) 
AA   attenuated arterioles 
AAV   adeno-associated virus 
ABCA4  adenosine triphosphate-binding cassette, subfamily A, member 4 
ACHM  achromatopsia 
ad   autosomal dominant 
ADAM9  a disintegrin and metalloproteinase domain, 9 
ADAMTS18 a disintegrin and metalloproteinase with thrombospondin type 1 motif, 18 
AIPL1  arylhydrocarbon-interacting receptor protein-like 1 
ALMS1  Alström syndrome 1 
APEX  arrayed primer extension 
ar   autosomal recessive 
ARL2BP  adenosine diphosphate-ribosylation factor-like 2 binding protein 
ARMS  amplification refractory mutation system 
ATP   adenosine triphosphate 
BBS   Bardet-Biedl syndrome 
BC   before Christ (before the Common Era) 
BE   both eyes 
BIF   Drosophila melanogaster bifocal domain 
BRCA  breast cancer, early onset 
BSP   bone spicule pigmentation 
C2orf71  chromosome 2 open reading frame 71 
C8orf37  chromosome 8 open reading frame 37 
C18orf25  chromosome 18 open reading frame 25 
CABP4  calcium binding protein 4 
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 
CADM2  cell adhesion molecule 2 
CBR   CRX-binding region 
CD   cone dystrophy 
cDNA  complementary DNA 
CEP250  centrosomal protein 250kDa 
CEP290  centrosomal protein 290kDa 
CERKL  ceramide kinase-like 
CF   counting fingers 
CFTR  cystic fibrosis 
cGMP  cyclic guanosine monophosphate 
ChIP-seq  chromatin immunoprecipitation with massively parallel DNA sequencing 
CHM  choroideremia 
chr   chromosome 
CLN3  ceroid lipofuscinosis, neuronal 3 
CLRN1  clarin 1 
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CMV   cytomegalovirus 
CNG   cyclic nucleotide gated channels 
CNOT3 chemokine (C-C motif) receptor-negative regulator of transcription 
complex, subunit 3 
CNV   copy number variation 
CPLX4  complexin 4 
CRALBP  cellular retinaldehyde binding protein 1 
CRB1  crumbs homolog 1 (Drosophila) 
CRD   cone-rod dystrophy 
CROCC  ciliary rootlet coiled-coil; rootletin 
CRY2  cryptochrome 2 
CRX   cone-rod homeobox 
CSNB  congenital stationary night blindness 
CTBP2  C-terminal binding protein 2 
CYP4V2  cytochrome P450, family 4, subfamily V, polypeptide 2 
DBD   DNA binding domain 
DCX   doublecortin domain 
DFP   digital fundus photography 
DHDDS  dehydrodolichyl diphosphate synthase 
DNA   deoxyribonucleic acid 
dNTPs  deoxyribonucleotide triphosphates 
DSAP   disseminated superficial actinic porokeratosis 
DTT   dithiothreitol 
EMC1  endoplasmic reticulum membrane protein complex subunit 1 
ERG   electroretinography 
EYS   eyes shut homolog (Drosophila) 
ex   exon 
ExNGS  exome NGS 
FA   fluorescein angiography 
FAF   fundus autofluorescence 
FAM161A  family 161 member A 
FNTA  farnesyltransferase (gene) 
FRYL  furry homolog (Drosophila)-like 
FSCN2  fascin homolog 2 
FTase  farnesyltransferase (protein) 
FZD5  frizzled 5 
g   gram 
GC   guanine and cytosine 
GCL   ganglion cell layer 
GDP   guanosine diphosphate 
GFP   green fluorescent protein 
GGTase  geranylgeranyltransferase 
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GNAT1 guanine nucleotide binding protein (G protein), alpha transducing activity 
polypeptide 1 
GNBT1 guanine nucleotide binding protein (G protein), beta transducing activity 
polypeptide 1 
GNGT1 guanine nucleotide binding protein (G protein), gamma transducing activity 
polypeptide 1 
GNB1  guanine nucleotide binding protein (G protein), beta polypeptide 1 
GRK1  G protein-coupled receptor kinase 1 
GTP   guanosine triphosphate 
GUCY2D  guanylate cyclase 2D 
hg18   human genome version 18 (March 2006) 
hg19   human genome version 19 (February 2009) 
HEPES  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HFE   hereditary hemochromatosis (protein) 
HIDS  hyper-immunoglobulin D and periodic fever syndrome 
HM   hand motion 
HMCN1  hemicentin 1 
HMG-CoA  3-hydroxy-3-methyl-glutaryl-Coenzyme A 
HMGCR  3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase 
hr   hour(s) 
HRA   Heidelberg retinal angiograph 
HRP   horseradish peroxidase 
Hz   hertz 
IBD   identity-by-descent 
ilm   inner limiting membrane 
IMPG2  inter photoreceptor matrix proteoglycan 2 
ING2  inhibitor of growth family, member 2 
INL   inner nuclear layer 
IQCB1  IQ motif containing B1 
iPSCs  induced pluripotent stem cells 
IRBP  interphotoreceptor retinoid-binding protein 
IRD   inherited retinal disease / inherited retinal dystrophy 
iRP   isolated retinitis pigmentosa 
ISCEV  International Society for Clinical Electrophysiology of Vision 
IU   International Unit 
JS   Joubert syndrome 
kb   kilobases 
kDa   kilodaltons 
KCNJ13  potassium inwardly-rectifying channel, subfamily J, member 13 
KLHL7  kelch-like family member 7 
LBD   ligand-binding domain 
LCA   Leber congenital amaurosis 
LCA5  lebercilin 
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LG   laminin A G-like 
LOD   logarithm of odds 
LP   light perception 
LRAT  lecithin retinol acyltransferase 
MAK   male germ cell-associated kinase 
MAP   mitogen-activated protein 
MASS  Mutation Assessor 
Mb   megabases 
MC   Müller glia cells 
MERTK  C-mer tyrosine kinase proto-oncogene 
MEVA  mevalonic aciduria 
MGI   Mouse Genome Informatics 
MIM   Mendelian Inheritance in Man 
MIP   molecular inversion probe 
MK   mevalonate kinase (protein) 
MKD   mevalonate kinase deficiency 
µCi   microcurie 
µg   microgram 
mM   millimolar 
mRNA  messenger ribonucleic acid 
MVK   mevalonate kinase (gene) 
MYO7A  myosin VIIA 
MyRip  myosin VIIA and Rab-interacting protein 
n.a.   not available 
n.d.   not determined 
n.p.   not performed 
NA   not affected 
NAD   nicotinamide adenine dinucleotide 
NEK2  never in mitosis gene A-related kinase 2 
NGS   next-generation sequencing 
NHLBI  National Heart, Lung, and Blood Institute 
nm   nanometer 
NMD  nonsense-mediated mRNA decay 
NMNAT1  nicotinamide nucleotide adenylyltransferase 1 
MSI1  Musashi RNA-binding protein 1 
NP-40  nonyl phenoxypolyethoxylethanol 
NR2E3  nuclear receptor subfamily 2, group E, member 3 
NRL   neural retina leucine zipper 
OMIM  Online Mendelian Inheritance in Man 
OAT   ornithine aminotransferase 
OCT   optical coherence tomography 
OD   oculus dexter, right eye 
OFD1  oral-facial-digital syndrome 1 
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ONL   outer nuclear layer 
OS   oculus sinister, left eye 
OTX   orthodenticle homeobox 
P0   postnatal day zero 
PBS   phosphate buffer saline 
PC   photoreceptor 
PCR   polymerase chain reaction 
PDE   phosphodiesterase 
POD   pale optic disc 
PolyPhen  Polymorphism Phenotyping 
PPP2R2B  protein phosphatase 2, regulatory subunit B, beta 
PRCD  progressive rod-cone degeneration 
PROM1  prominin 1 
PRPH2  peripherin 2 
PRPF  pre-mRNA processing factor 
RAB28  member RAS oncogene family 28 
RABGGTA Rab geranylgeranyltransferase, α subunit 
RAL    retinal 
RBP   serum retinol binding protein 
RD   retinal dystrophy / retinal degeneration 
RD3   retinal degeneration 3 
RDH   retinol dehydrogenase 
RE   retinyl esther 
RefSeq  reference sequence 
REP   Rab escort protein 
RetNet  Retinal Information Network 
RFLP  restriction fragment length polymorphism 
RFX1  regulatory factor X 1 
RGR   retinal G protein-coupled receptor 
RHO   rhodopsin 
RIPA  radioimmunoprecipitation 
RLBP1  retinaldehyde binding protein 1 
RNA   ribonucleic acid 
RNA-i  RNA interference (interfering RNA) 
ROH   runs of homozygosity 
ROL   retinol 
ROM1  retinal outer segment membrane protein 1 
RP   retinitis pigmentosa 
RP1   retinitis pigmentosa 1 
RP1L1  retinitis pigmentosa-like 1 
RP2   retinitis pigmentosa 2 
RPE   retinal pigment epithelium 
RPE65  retinal pigment epithelium-specific protein, 65-KD 
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RPGR  retinitis pigmentosa GTPase regulator 
RPGRIP1  retinitis pigmentosa GTPase regulator interacting protein 1 
RT-PCR  reverse transcriptase polymerase chain reaction 
SAG   S-antigen; arrestin 
SD-OCT  spectral domain optical coherence tomography 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE spherical equivalent 
SGIP1 SH3 growth factor receptor-bound protein 2-like (endophilin) interacting 
protein 1 
SH3   SRC homology 3 domain 
SIFT   Sorting Intolerant From Tolerant 
SNP   single nucleotide polymorphism 
SNRNP200 small nuclear ribonucleoprotein, 200-KDa 
SPATA7  spermatogenesis associated protein 7 
SRC   v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
STGD  Stargardt disease 
STX3  syntaxin 3 
TaNGS  targeted NGS 
TBST  Tris-buffered saline with Tween 20 
TOPORS  topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase 
Tris   tris (hydroxymethyl) aminomethane 
TSPAN12  tetraspanin 12 
TTC8  tetratricopeptide repeat domain 8 
TULP1  tubby like protein 1 
Ube4b  ubiquitination factor E4B 
USH2A  Usher syndrome 2A (gene); usherin (protein) 
WDR19  WD repeat domain 19 
WGS  whole genome sequencing 
Wlds   wallerian degeneration, slow 
Xl   X-linked 
y   years 
ZNF   zinc finger 
ZFIN   Zebrafish International Resource Center 
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Historical perspective 
Congenital disorders have always been accompanying human populations. The earliest 
reports of such diseases come from ancient texts and images. For instance, around 3000 
BC, achondroplasia was depicted in paintings of ancient Egypt1. The reasons underlying 
these conditions in the pre-scientific era were explained in various ways. One example 
includes the sins of the parents, which is reflected in a quote from the New Testament: 
His disciples asked him, “Rabbi, who sinned, this man or his parents, that he was born 
blind?”2 
St. John, chapter 9, verse 2 
The common beliefs about congenital disorders in various ages of human culture are 
reflected by contemporary superstitions that are still present in many societies. Although 
concepts of heredity were already known, e.g. from the work of Abu al-Qasim al-Zahrawi 
describing haemophilia in the 11th century, this knowledge was not widespread in Europe. 
In medieval times and even in our age in some ethnic groups any disability, including 
blindness, was often explained by the deeds of a pregnant woman: a concept called 
“maternal impression”. For instance, microcephaly was thought to be the result of looking 
at a monkey and cleft lip/palate originated from looking at or eating a rabbit, which is 
reflected in its name, “hare-lip”. Some people believe in the lunar eclipse to be the reason 
for delivering a child with cleft lip/palate3. In many cultures, inborn disability is still thought 
to be a consequence of mocking a crippled person. Pregnant women may also be 
bewitched into bearing a sick child. Supernatural powers of men and women using magic, 
including “evil eye”, are still blamed for a wide variety of diseases, including congenital 
defects. Additionally, the kind of food ingested by expectant mothers is thought to be 
influencing the foetus. The consumption of “potato eyes” (sprouting sites) is believed to 
cause spina bifida. In the early eighties Jamaican women still believed that the ingestion of 
chilli peppers by an expectant mother can cause blindness in her child4. 
Congenital defects were not linked to heredity for a long period in human history, 
especially since inborn abnormalities do not always have a genetic background. In fact, 
before the era of common vaccinations, the dominant biological cause of congenital 
blindness was intrauterine infection by virus. The rubella virus, usually not harmful to 
pregnant women, can damage several tissues including photoreceptors and the optic 
nerve of the foetus. There are more instances of photoreceptor malformation or 
degradation due to various infections with different species, such as cytomegalovirus, 
herpes, syphilis or toxoplasmosis. For other congenital disorders, the non-biological 
environmental factors made this picture even more blurred, as medical community 
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believed that various substances, such as alcohol, may “poison” the germline. Multiple 
teratogenic agents nowadays are known to influence the phenotype of the foetus, without 
having any impact on heredity. 
In some cases, the connection between an inborn disease and inheritance is difficult even 
in our modern day world. For example, intellectual disability often affects only a single child 
in a family and is “reproductively lethal”, meaning there is little or no chance of producing 
offspring. The underlying defects are nonetheless frequently genetic, as the causative 
mutations may often arise de novo in the affected child5. 
Up to the 17th century, the ideas of inheritance were rather vague and disorganised. 
Linnaeus made an attempt to grasp the concepts of heredity by observing plants and 
animals6; however, these descriptions were far from what we perceive as modern science. 
He observed that if red and white tulips were crossed, the progeny would contain some 
red, some white, and for the greatest part two coloured flowers. It took more than two 
centuries before this knowledge was properly described and understood by Gregor 
Mendel, an Augustinian monk who was the first to formulate laws on genetic traits and 
patterns of inheritance. In the 19th century it was widely believed that the traits from both 
parents are blended and that offspring traits represent a random choice from the spectrum 
of the phenotypes between the two parents (such as in height). Gregor Mendel conducted 
his research on thousands of pea plants and made calculations necessary to devise the 
laws of heredity, which he presented in 18657. In this study, he described the concept of 
factors of inheritance, without mentioning any material carriers of the hereditary traits. The 
idea of particles of heredity, called the gemmules, was introduced later by Darwin8. In 
1904, Theodor Boveri demonstrated that chromosomes are the vectors of heredity9. The 
term “genetics” was introduced by Bateson in 1906 when laws of inheritance were fully 
embraced as fundamental work establishing the path for modern genetics10. Five years 
later, Johannsen described genotypes and phenotypes, stressing that a genotype was 
something constant, while the phenotype might be influenced by environmental factors11. 
He also invented the term “gene”, but it was not used in the meaning that we know today. 
By 1912, many diseases were described as hereditary (e.g. alkaptonuria)12 and the 
difference between autosomal recessive and autosomal dominant inheritance patterns was 
becoming clear. The investigation of normal traits that ran in families became popular, 
which converged with the popularisation of eugenics (from Greek “well-born”). This idea, 
conceived by Galton, imposes improving the genetic quality of the human population, 
promoting reproduction of people with good genetic traits and restricting the propagation of 
the undesired traits13. Sterilisation of individuals bearing undesired traits or diseases was 
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practiced in the United States since the early 1900s. Later, in the 1920s and 30s, it was 
implemented in other countries, including Belgium, Canada and Sweden. In Nazi 
Germany, it was used for propagation of the supposedly ideal Aryan race, which made 
eugenics lose its popularity. However, the eugenically rationalised sterilisation was still 
practiced in Sweden until 197514. 
With the discovery of the double helix structure of DNA in 195315 and first sequencing 
experiments in the 1970s, the genes were finally confirmed as actual units of heredity. The 
new technological advancements began with Sanger sequencing16 followed by the 
amplification of desired DNA fragments (polymerase chain reaction)17. These 
advancements led to the completion of a 15-year Human Genome Project in 200418. A 
truly revolutionary step was the invention of massive parallel sequencing (called next-
generation sequencing) in 200519-21, which made it possible to obtain the sequence of all 
protein-coding elements (the exons) within a week. Over 4000 genes responsible for 
monogenic disorders have been described until now. This number is continuously growing 
and has recently exceeded two hundred for inherited eye diseases22. 
Anatomy and function of the eye and the retina 
The eye is one of the most important sensory organs of the human body. The sensitivity to 
photons developed in various organisms throughout evolution. The importance of the sun 
for life on our planet cannot be overestimated. The sun rays are the basis of the food 
chain, which starts with plants, the primary producers of biomass from inorganic 
compounds. These organisms, although stationary, may display phototrophic movements, 
following the rays of the sun. Even in primitive single-cell organisms, phototaxis can be 
observed – the movement towards the light. Photon-sensing structures evolved beginning 
from an eyespot – a structure present in many unicellular organisms, which presumably 
has evolved independently multiple times. There are numerous types of eyes in animals. 
Humans possess a camera-type eye, which, interestingly, developed independently in 
vertebrates and octopuses. 
The human eye is an asymmetrical globe with a diameter of around 25 mm (Figure 1). This 
organ consists of three chambers: anterior (between the cornea and the iris), posterior 
(between the iris and the lens) and vitreous chamber (between the lens and the retina). It 
contains three main layers. The most external layer is the sclera, a hard opaque shell with 
soft cornea at the anterior part. Uvea or vascular tunic, can be divided into three areas: the 
iris – a coloured set of muscles with an aperture called the pupil, ciliary body, 
responsible for aqueous humour production and the choroid. The choroid, consisting of  
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Figure 1. The anatomy of the eye. Adapted from virtualmedicalcentre.com 
blood vessels, which supply oxygen and nutrients, is lining the whole posterior part of the 
eye. 
The choroid 
The choroid is divided into five layers: Bruch’s membrane, the choriocapillaris and the 
Sattle’s and Haller’s layers containing blood vessels of medium and large diameter and the 
suprachoroidea23. Inside the eye, two circulatory circuits can be distinguished: uveal, which 
supplies blood to the middle layers of the retina and the uvea, and retinal, on which the 
macula and the optic nerve are dependent. Due to melanin deposits, the choroid has a 
dark colour, which prevents uncontrolled light reflections. The choroid takes part in the 
outflow of the aqueous humour from the anterior chamber. It is also responsible for 
thermoregulation and enables adjustment of the position of the retina by changes in its 
thickness. The most important function of the choroid is providing the necessary growth 
factors during the development and providing nourishment to the retina via the blood 
vessels and the connection to the retinal pigment epithelium (RPE). 
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Retinal pigment epithelium 
The RPE is the pigmented cell layer underlying the retina; it is localised between the 
photoreceptors and the vasculature of the choroid. Its name refers to the dark melanin 
granules, which protect the retina against light toxicity. The RPE is a hexagonal single 
sheet of cells which contain pigment molecules and organelles necessary for transferring 
of photoreceptor outer segment discs into phagosomes. The basolateral membrane 
contacts with the specialised multilayered Bruch’s membrane (also called vitreous lamina). 
This membrane enables interaction of the RPE with blood in the vessels of the choroid. 
The RPE serves several purposes to support the function of the photoreceptor cells. Most 
importantly, RPE cells play a vital role in the phagocytosis of the photoreceptor discs. In 
addition, the RPE recycles the “bleached” chromophore (11-cis-retinal) molecules after 
they have been exposed to light in a process called the visual cycle. The RPE is also 
involved in the transfer of nourishing compounds from the choroid to the neural retina. 
The neural retina 
The neural retina is a photosensitive, multilayer structure (Figure 2). A photon coming 
through the eye reaches photoreceptors via several layers of neurons: ganglion cells, the 
inner plexiform layer containing their synapses, which connect to amacrine cells and 
bipolar cells, of which the nuclei are located in the inner nuclear layer. These neurons 
connect to rod and cone photoreceptors via synapses in the outer plexiform layer. This cell 
layer also harbours the horizontal cells. Photoreceptor nuclei are visible in the outer 
nuclear layer. Their multidisc, membranous outer segments are immersed in the RPE 
cells. The absorption of photons results in a cascade of biochemical reactions eventually 
leading to the alteration of the photoreceptor membrane potential. This enables sending 
out a signal to bipolar cells, which is transferred to ganglion cells transmitting the stimulus 
to the optic nerve. 
The horizontal and amacrine cells are involved in lateral interactions and bear 
responsibility for the luminance contrast sensitivity. There are various types of amacrine 
cells and although little is known about their function, they are believed to provide 
feedback to both bipolar and ganglion cells. Each photoreceptor contacts both bipolar and 
horizontal cells. There are several subtypes of horizontal cells, but their intriguing feature is 
that, like amacrine cells, they do not possess an axon. Their dendrites have pre-synaptic 
functions instead, which enable them to create connections with other neurons. 
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Figure 2. Retinal layers. Adapted from Kolb, H. Simple Anatomy of the Retina. In: Webvision: The Organization of 
the Retina and Visual System, http://www.ncbi.nlm.nih.gov/books/NBK11530/. 
Photoreceptors 
Photoreceptors are the cells in which the visual process occurs, leading to the 
transmission of an electrical signal via the optic nerve to the brain. They are specialised 
types of neurons, which consist of an outer segment, an inner segment, a cell body and a 
synapse (Figure 3). As mentioned before, the photoreceptor synapse connects to 
horizontal and bipolar cells to transmit the signal to the optic nerve. The photoreceptor 
cell’s organelles, including the nucleus, are located within the cell body. The inner 
segments are packed with mitochondria, as vision is very energy-consuming. The outer 
segment, taking part in the most important visual process, is a structure built of multiple 
stacked membrane discs filled with opsin, the molecule absorbing photons. The inner and 
outer segments are joined by a thin structure called the connecting cilium. The human 
retina contains approximately 125 million rods and 6 million cones. Rod and cone 
photoreceptors have different roles in the mechanism of sight. Being very sensitive to light 
(5-7 photons enough to trigger a response), rods permit night vision and, due to reacting to 
a single wavelength spectrum, they do not allow distinguishing between colours. In 
contrast, there are three distinct cone types responding to long (L, 564 nm, red), medium 
(M, 534 nm, green) and short (S, 420 nm, blue) wavelength light. They are responsible for 
visual acuity and colour vision; the centre of the retina, termed the fovea, is composed 
solely of cone photoreceptors. 
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The outer segments are formed close to the connecting cilium and slowly move towards 
the tip, where the oldest outer discs are discarded. This process, called disc shedding, is 
continuous and allows the full replacement of all discs in a period of approximately 12 
days. 
 
Figure 3. Photoreceptors. Adapted from Silverthorn, D.U. Sensory physiology. In: Human Physiology: an integrated 
approach. 
 
Most prevalent inherited retinal diseases (IRDs) 
Hereditary degenerative disorders of the retina display all patterns of Mendelian 
inheritance. Affecting approximately two million people worldwide, they present a full 
spectrum of outcomes, ranging from relatively mild sight deterioration (such as night 
blindness) to early-onset complete vision loss (Leber congenital amaurosis, LCA) (Figure 1 
in Chapter 1b). Legal blindness, as defined by the World Health Organisation, is vision in 
a person's best eye of less than 20/500 or a visual field of less than 10 degrees. IRDs are 
characterised by various degrees of rod and cone involvement, as well as the presence or 
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absence of additional, non-ocular symptoms, which makes them fall into two main 
categories: non-syndromic and syndromic retinal diseases. The proteins encoded by 
genes responsible for the most common disease types, along with their photoreceptor / 
RPE cellular localisation as well as the relevant biochemical pathway, are visualised in 
Figure 4. 
Non-syndromic IRDs 
The group of non-syndromic IRDs encompasses several diseases. The difference in the 
photoreceptor type that is initially or predominantly affected defines the disorders located 
at two ends of the spectrum depicted in Chapter 1b, Figure 1. 
The predominant rod photoreceptor involvement in complete congenital stationary night 
blindness (CSNB) determines its phenotype, i.e. nyctalopia (night blindness), which is 
present since birth. So far, three genes have been identified to be involved in its autosomal 
dominant form and ten genes are responsible for the autosomal recessive type of CSNB, 
both the complete and incomplete type. The most frequent form is X-linked CSNB, which is 
caused by mutations in NYX and CACNA1F22. 
Cone photoreceptors are the only type affected in achromatopsia (ACHM), hence, this 
disease causes complete loss of colour vision and severe impairment of visual acuity. The 
patients also display photophobia (excess sensitivity to light) and involuntary eye 
movements called nystagmus. Mutations in five genes are known to cause achromatopsia, 
which is inherited in a recessive fashion22. 
Progressive retinal dystrophies also cover a broad disease spectrum, leading to a different 
outcome based on types of photoreceptors that are affected. The most severe one is 
Leber congenital amaurosis (LCA), which involves early-onset blindness occurring in the 
first year of life. The hallmark of LCA are non-recordable or significantly reduced 
responses on electroretinography (ERG) before the age of 1 year. This disease presents 
with amaurotic (non-responsive) pupils and nystagmus. At present, 20 genes are known to 
be involved in the pathology of LCA, which is nearly always transmitted in a recessive 
manner. 
Rod-cone dystrophy, more commonly termed retinitis pigmentosa (RP), is another 
progressive retinal disorder with a variable age of onset. The first symptom is usually night 
blindness, observed in childhood to early adulthood. As rods in the periphery and mid-
periphery die during the course of the disease, patients experience visual field constriction 
leading to tunnel vision. Subsequent cone photoreceptor cell death may eventually lead to 
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complete vision loss. RP displays all inheritance patterns and thus far has been associated 
with mutations in no less than 60 genes. 
Cone- and cone-rod dystrophies (CD and CRD) start in childhood or early in adult life and 
can lead to complete blindness. Photophobia, reduced visual acuity and colour blindness, 
are typical for this disease group. In contrast to CRD, CD patients display no rod 
involvement and until late in life their electroretinograms show normal responses at 
scotopic (dim light) conditions. Fifteen genes have been found to be responsible for these 
phenotypes, which can display all inheritance patterns22. 
A subtype of retinal dystrophy involving mostly photoreceptors in the macula is called 
Stargardt disease (STGD). It is a form of juvenile macular dystrophy, which leads to legal 
blindness (more often than complete blindness) due to a gradual decrease in visual acuity. 
This disorder, in contrast to others, appears to be highly homogenous: only one gene, 
ABCA4, is involved in the autosomal recessive form24 and very rare dominantly inherited 
STGD type 3 is caused by mutations in the ELOVL4 gene25. Rare cases of “Stargardt-like” 
disease phenotypes have been reported with mutations in PRPH226,27 and PROM128. 
Another separate group are chorioretinal dystrophies, with choroideremia (CHM)29 as the 
best known example. It involves the choroid, the RPE and photoreceptors, thus 
representing a more generalised disease with a distinctive clinical picture. The outcome is, 
however, similar to other retinal degenerative disorders. Starting with night blindness due 
to rod photoreceptor degeneration, CHM involves progressive atrophy of the RPE and the 
choroid (eventually baring the sclera beneath), which leads to loss of sight by middle age. 
The disease is inherited in an X-linked fashion, caused by mutations in the REP-1 gene. 
Syndromic forms of IRD 
Ciliopathies 
There are numerous systemic disorders affecting multiple organs that also display retinal 
degeneration phenotypes. The most common group is associated with the malfunction, 
degeneration or malformation of the cilium. This organelle, which in most ciliated cells is an 
“antenna” of the cell, plays an important role in photoreceptors connecting the inner to the 
outer segment. Crucial visual proteins are transported along the cilium; therefore, any 
interruption in its structure and function may lead to photoreceptor death. Examples of 
syndromic ciliary disease that display retinal dystrophy are Bardet-Biedl, Joubert, Senior-
Løken, Usher, Sensenbrenner and Alström syndromes. Approximately one-third of non-
syndromic IRDs is also caused by ciliary defects30. 
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Neuronal ceroid lipofuscinoses (NCLs) 
Another group of syndromic retinopathies are neurodegenerative lysosomal storage 
diseases. Clinical characteristics include progressive psychomotor retardation, epileptic 
seizures and premature death. Presently, there are at least ten genes involved in NCLs 
with ocular involvement31. Variable age of onset allows the classification of these disorders 
into five subtypes, from infantile to adult forms. Recent findings suggest that genes 
responsible for NCLs may also be involved in some forms of non-syndromic retinal 
dystrophy32,33. 
Other syndromic IRDs 
Retinal degeneration may also be present as an additional symptom in a subset of patients 
suffering from several syndromes not associated with ciliary or lysosomal proteins, such as 
Alagille syndrome, Refsum disease or more rare multiorgan diseases, like mevalonic 
aciduria, methylmalonic acidaemia, Danon, Alport, Walker-Warburg, Smith-Lemli-Opitz or 
thiamine-responsive megaloblastic anaemia syndromes. The genes involved in these 
disorders play a role in various basic cellular processes ranging from basement membrane 
formation and peroxisome biogenesis to glycosylation and cholesterol biosynthesis. The 
mechanisms of retinal involvement in these syndromes in many cases are thus far not 
properly understood. 
Physiology and pathology of vision 
A variety of defective mechanisms has been identified to underlie retinal dystrophies, 
including defects in retinal development, splicing, ciliary transport, phototransduction and 
the visual cycle. The subcellular localisation and potential function of proteins involved in 
RP and LCA are depicted in Figure 4. 
Retinal development 
Many genes involved in IRDs have an important role during embryonic development of the 
eye. For instance, OTX2, mutated in LCA, is a member of homeodomain transcription 
factors involved in retinal and ocular development. Its broad spectrum of activities includes 
regulation of the choroid plexus and RPE patterning. Another example is CRX, which is the 
main differentiating factor in retinal maturation. CRX is a transcription factor enabling the 
switch of genetic programming typical for neurons to photoreceptor differentiation. It 
inhibits NEUROD2 and stimulates many other factors. It was found that the majority of 
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Figure 4. Schematic representation of three major processes in human rod photoreceptor cells and the 
RPE. Adapted from den Hollander et al., 2010. 
PC: photoreceptor cells; MC: Müller glia cells. Description of the processes is provided in the text. 
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photoreceptor proteins are regulated by CRX to a various degree. 
NRL also takes part in the developmental process of the neural retina. This transcription 
factor turns on the rod programming while suppressing the formation of cones. Knockout 
mice lacking this factor develop cone-dominated retinae. One of CRX’s downstream 
effectors is another transcription factor called NR2E3. This protein acts differentially in 
embryonic and adult retina. In developing retina it targets transcription factors, while in 
adults it targets various genes, activating rod-specific genes (e.g. GNB1) while repressing 
cone-specific genes (e.g. blue cone opsin)34. ZNF513, which was implicated in arRP, is a 
putative regulator of photoreceptor development and maintenance. All of the 
aforementioned proteins are involved in LCA and/or RP, with autosomal dominant and 
recessive inheritance patterns. 
Splicing factors 
Some of the factors involved in splicing are mutated mostly in autosomal dominant forms 
of IRD. Heterozygous mutations in PRPF3, PRPF6, PRPF8, PRPF31 or SNRNP200 were 
proven to hamper splicing, as approximately 10% of introns were incorrectly removed35. 
Some of the mutations show incomplete penetrance, such as in case of PRPF31. 
Recently, a CNOT3 mutation was identified as a trans-acting modifier of the RP phenotype 
by repressing PRPF31 transcription36. 
Although the splicing machinery is necessary in every cell of the organism, specific retina-
associated genes seem to be affected to a greater degree than ubiquitously expressed or 
tissue-specific genes. 
Cilia formation, maintenance and intraflagellar transport 
Since the outer and inner segments of photoreceptors are linked together by a structure 
called the connecting cilium, some proteins that play a role in the development and 
function of this organelle are crucial for visual function37. An ideal example is CEP290, 
whose mutations cause a wide spectrum of disorders without a clear genotype-phenotype 
correlation. CEP290 mutations have been linked to LCA, but also multiple syndromic IRDs, 
such as Joubert, Bardet-Biedl and Senior-Løken syndromes. Other genes encode proteins 
localised to the basal body (e.g. ARL2BP, C8orf37, FAM161A, RAB28 or RP2) or taking 
part in ciliary intraflagellar transport (IQCB1, lebercilin, RPGR and RPGRIP1). Other 
proteins, such as usherin, play a structural role in the cilium. A recently discovered protein, 
MAK, (discussed in Chapter 3 of this thesis) is involved in ciliary development and 
maintenance. Some proteins localise to the cilium, but their role is not yet clear, which for 
example is the case for TOPORS. 
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Phototransduction cascade 
For a full comprehension of the genetic causes underlying retinal diseases, an explanation 
of the molecular mechanisms of the visual process needs to be provided. The photon, 
entering the photoreceptor after passing all retinal layers, meets rhodopsin (RHO) 
containing the chromophore, 11-cis-retinal, which is a derivative of vitamin A. The energy 
of the photon is absorbed by this molecule enabling its photoisomerisation to all-trans-
retinal, which forces a conformational change of rhodopsin into metarhodopsin II. The 
instability of this compound causes it to split and subsequently opsin and all-trans-retinal 
are released. The latter then undergoes recycling, in a process called the visual cycle. 
Opsin interacts with transducin (containing 3 subunits: α, β and γ encoded by GNAT1, 
GNBT1 and GNGT1, respectively), which enables guanosine diphosphate (GDP) to be 
phosphorylated into guanosine triphosphate (GTP). In this active state, transducin 
displaces the inhibitory γ subunits of phosphodiesterase 6 (PDE6) complex (chaperoned 
by AIPL1), thus activating the α and β subunits. Cyclic guanosine monophosphate (cGMP) 
levels, which keep the cGMP-gated Na+ channels open, are then significantly reduced and 
subsequently the channels close. This leads to transient hyperpolarisation of the 
photoreceptor, which in turn results in closing of the Ca2+ voltage-gated channels. At the 
synapse, glutamate release is then reduced and the signal is sent via the optic nerve to the 
brain. 
The recycling of metarhodopsin II is mediated by rhodopsin kinase (GRK1). This enzyme 
is bound to recoverin, which is bound to Ca2+. A decrease in calcium levels results in 
dismantling of this complex and GRK1 is free to phosphorylate metarhodopsin II, which 
loses its affinity to transducin and is subsequently bound to arrestin. Arrestin enables the 
restoration of the “spent” opsin into its original state with the ability to bind 11-cis-retinal. 
Mutations in most of the genes encoding phototransduction proteins lead to retinal 
degeneration of various types. RHO is defective in ad and arRP, GNAT1 alterations cause 
arCSNB and phosphodiesterase subunits’ mutations are involved in arRP. Some genes, 
although not yet connected to human retinal diseases, were found mutated in natural and 
targeted animal mutants with retinal dystrophies (e.g. GNGT1). One such gene, PDE6D, 
was recently discovered to harbour mutations in Joubert syndrome patients38, indicating 
that proteins involved in phototransduction may also be associated with syndromic IRDs. 
Visual cycle 
As described above in the phototransduction process, all-trans-retinal must undergo 
restoration to its original, receptive state. This process starts with conversion of the 
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aldehyde form to all-trans-retinol, which is then transported by IRBP to the RPE. The 
enzyme LRAT converts it to the all-trans-retinyl ester, which is then further processed by 
RPE65 to 11-cis-retinol. This compound is then returned to the photoreceptor outer 
segment by IRBP, where it can re-associate to the opsin molecule. 
New 11-cis-retinal molecules can also be synthesised directly from vitamin A (11-trans-
retinol) by retinol dehydrogenase. The most extensively studied enzyme of this family is 
RDH12, although not all retinol dehydrogenases participating in the visual process have 
yet been identified. 
All of the aforementioned proteins taking part in the visual cycle are absolutely crucial for 
sight. Mutations in their corresponding genes were found to cause LCA. 
Other critical processes 
The involvement of phototransduction and visual cycle proteins in retinal degeneration is 
intuitive, as well as the transcription factors steering the expression of these genes. The 
necessity of proper ciliary transport to and from the photoreceptor outer segment is also 
understandable. Proteins crucial in retinal development may also be affected. However, 
there are many more processes disrupted by mutations in IRD genes, which are not 
straightforwardly explainable. Groups of genes associated with IRDs are involved in 
general processes, such as cellular structure (EMC1), lysosomal function (CLN3) or 
ubiquitination (KLHL7), as well as many specific pathways, e.g. N-linked glycosylation 
(DHDDS) or isoprenoid synthesis (MVK, Chapter 4a). In many cases the associated 
mechanisms of retinal degeneration, as well as sole retinal involvement, are not clear. 
Patient cohorts 
During the last two decades, various strategies proved to be successful in determining the 
genetic defect underlying retinal dystrophy. In this paragraph, the strategies applied to LCA 
and RP patient cohorts are discussed (Figure 5). 
Leber congenital amaurosis 
The cohort of LCA patients used in this thesis was of mixed ethnicity and initially included 
197 patients. Using various techniques, such as arrayed primer extension (APEX; Asper 
Biotech, Tartu, Estonia), homozygosity mapping39, candidate gene sequencing40-44 and 
gene identification studies (e.g. CEP29045, LCA546), 103 of them were solved. Subsequent 
exome sequencing in 8 LCA individuals identified genetic defects in four patients (IQCB142, 
KCNJ13, SPATA7 and GUCY2D). In the remaining 90 patients, the newly discovered 
NMNAT1 gene was tested for mutations (Chapter 5a). 
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Figure 5. IRD patient cohorts used in this thesis. 
The figure indicates the number of patients who received genetic diagnosis using various techniques (underlined). Gray 
boxes depict the number of genetically unsolved patients. ar/i – autosomal recessive or isolated. 
Retinitis pigmentosa 
In addition, 234 autosomal recessive or isolated RP patients, mostly of Dutch origin, were 
enrolled in this study. Twenty cases were found to harbour mutations in previously 
identified IRD-associated genes by either Sanger sequencing (ABCA4, CRB1, RPE65) or 
APEX44,47-51. Identity-by-descent mapping with genome-wide SNP arrays and subsequent 
Sanger sequencing of IRD-associated genes residing in homozygous regions yielded 
genetic diagnosis in 24 further probands52. In 13 families, homozygosity mapping led to the 
identification of mutations in a novel gene (EYS, IMPG2 and C2ORF71)53-55. In 100 
selected isolated and autosomal recessive cases, targeted next-generation sequencing 
(NGS) of 111 IRD-associated genes known at that time was performed56. 36 patients of 
this group were found to harbour either hemizygous (mutations in X-linked genes present 
in 2 isolated male cases), homozygous (6), compound heterozygous (21) or single 
heterozygous mutations (de novo in 2 patients and autosomal dominant RP after 
reassessment in two families) in the tested RD genes. 
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In the remaining group, candidate gene screening led to the discovery of FAM161A 
mutations in four patients and pathogenic variants in BBS157 and LCA558 in five and two 
individuals, respectively. One patient had a CYP4V2 alteration and was re-diagnosed as 
Bietti crystalline dystrophy (Astuti et al., unpublished data). 
In the remaining LCA and RP patients without genetic diagnosis, the studies described in 
this thesis were performed. Furthermore, 35 families of Indonesian origin were added to 
the RP cohort and 65 Danish families were included in the LCA cohort. 
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Aim of this thesis 
The main purpose of this thesis was to identify the genetic defects in patients with inherited 
retinal dystrophies, mainly RP and LCA. Homozygosity mapping or linkage analysis using 
genome-wide SNP microarrays were applied, and, in a later phase, exome sequencing 
was performed, occasionally supported by genome-wide SNP homozygosity mapping or 
haplotype analysis. In the general introduction, the patients cohorts used in this research 
are described. 
Chapter 1b summarises the contemporary methods that facilitate the discovery of genes 
mutated in inherited retinal diseases. 
Chapter 2a describes the study of molecular causes of IRDs in a cohort of Indonesian 
patients. In this study, homozygosity mapping was utilised and led to the identification of 
causative mutations in 50% of the analysed families. Additionally, an RP1 nonsense 
mutation, p.(R338*) was found to be involved in arRP in an Indonesian family, which is 
discussed in Chapter 2b. Most mutations in this gene cause the autosomal dominant form 
of RP, which led to speculations on potential pathophysiological mechanisms associated 
with dominant vs. recessive RP1 mutations. 
In Chapter 3 the discovery of the involvement of a new ciliary gene in arRP is discussed. 
A mutation in MAK was identified in a consanguineous Turkish arRP family after 
homozygosity mapping, exome sequencing and variant prioritisation according to the Crx-
binding score of the gene. Subsequently, five additional families were found to harbour 
MAK mutations. Knockout mice lacking this protein display abnormally long cilia and 
photoreceptor degeneration. 
Chapter 4a describes the detection of MVK mutations, which were previously found in the 
severe form of mevalonate kinase deficiency (MKD), in non-syndromic late-onset RP. After 
detailed re-examination the patients appeared to have had very mild MKD signs. However, 
these symptoms were never linked to RP. 
Chapter 4b, inspired by the discovery of MVK mutations in arRP, reviews the common 
theme of prenylation in proteins involved in IRDs. Several IRD proteins are either 
farnesylated or geranylgeranylated, which facilitates their membrane attachment and/or 
intracellular trafficking. Additionally, many proteins taking part in synthesis or processing of 
these residues, as well as chaperones and other interactors of prenylated proteins were 
previously found to be responsible for various IRDs. 
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Chapter 5a presents an analysis of NMNAT1 in an IRD cohort of mixed origin, which 
resulted in the identification of novel mutations in this gene. Subsequent work, presented 
in Chapter 5b, led to the conclusion that the NMNAT1 variant p.(E257K) is a hypomorphic 
allele, which is frequently not associated with ocular disease when present in a 
homozygous state. 
Chapter 6 contains the general discussion of findings presented in this thesis. Among 
others, the reasons for missing genetic defects in IRD patients are described. In a certain 
fraction of the remaining patients the cause may still lie in known genes, being impossible 
to detect with classical contemporary techniques. Another part of the missing genetic 
causes may be hypomorphic variants in genes responsible for non-syndromic IRDs. Novel 
genotype-phenotype correlations may also emerge with the combinations of null variants 
and relatively mild, frequent alleles in genes responsible for syndromic IRDs. 
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Abstract 
In view of their high degree of genetic heterogeneity, inherited retinal diseases (IRDs) pose 
a significant challenge for identifying novel genetic causes. Thus far, more than 200 genes 
have been found to be mutated in IRDs, which together contain causal variants in >80% of 
the cases. Accurate genetic diagnostics is particularly important for isolated cases, in 
which X-linked and de novo autosomal dominant variants are not uncommon. In addition, 
new gene- or mutation-specific therapies are emerging, underlining the importance of 
identifying causative mutations in each individual. Sanger sequencing of selected genes 
followed by cost-effective targeted next-generation sequencing (NGS) can identify defects 
in known IRD-associated genes in the majority of the cases. Exome NGS in combination 
with genetic linkage or homozygosity mapping studies can aid the identification of the 
remaining causal genes. As these are thought to be mutated in <1% of the cases, 
validation through functional modelling in, for example, zebrafish and/or replication through 
the genotyping of large patient cohorts is required. In the near future, whole genome NGS 
in combination with transcriptome NGS may reveal mutations that are currently hidden in 
the non-coding regions of the human genome. 
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Introduction 
Inherited retinal dystrophies are degenerative disorders of the retina characterised by 
photoreceptor cell death, which may lead to complete blindness. In general, they display 
significant clinical and genetic heterogeneity1,2. These disorders may be subdivided into 
two groups, either primarily affecting rod photoreceptor cells (e.g. retinitis pigmentosa, RP; 
congenital stationary night blindness, CSNB) or mainly affecting cone photoreceptors (e.g. 
cone dystrophy (CD), cone-rod dystrophy (CRD), achromatopsia (ACHM)). In the case of 
Leber congenital amaurosis (LCA), both photoreceptor types or the retinal pigment 
epithelium can be affected, resulting in severe visual impairment in the first year of life. The 
majority of retinal dystrophies show a progressive degeneration, but some are thought not 
to progress with age, such as CSNB and ACHM. Because some of these diseases have 
common characteristics (Figure 1), the differential diagnosis may be problematic. 
Additionally, with 200 genes known to be involved in various inherited retinal diseases 
(RetNet, https://sph.uth.edu/RetNet/sum-dis.htm#A-genes), the genetic diagnostics can be 
challenging. 
Figure 1. Photoreceptor involvement and progression with age showing clinical overlap between autosomal 
recessive retinal diseases. Adapted from den Hollander et al. (2010). 
Leber congenital amaurosis (LCA), as the most severe disorder, is rapidly progressing reaching blindness at an early age. 
Retinitis pigmentosa (RP), cone dystrophy (CD), cone-rod dystrophy (CRD) and Stargardt disease (STGD) have a broad 
spectrum of ages of onset and do not always lead to complete vision loss. Stationary disorders are on the edges of the 
graph, displaying sole rod or cone involvement. 
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Within this group of disorders, two major types can be distinguished: retinal dystrophies 
that are part of a syndrome and non-syndromic disorders affecting solely the retina. Most 
inherited retinal dystrophies are monogenic, displaying all patterns of Mendelian 
inheritance. However, there is growing evidence of additional contribution of alleles in 
other genes to the disease outcome in certain IRDs (see Chapter 4 in Retinal disorders, 
Section A: Genetics of inherited retinal degenerations, Cold Spring Harbor Perspectives in 
Medicine, © Cold Spring Harbor Press). 
In this review we outline the state-of-the-art genomic approaches to identify defects 
underlying non-syndromic IRDs that show a moderate or high degree of genetic 
heterogeneity, that is ACHM, CD, CRD, LCA and RP. We present examples of studies that 
illustrate the approaches we deem most effective at this moment, taking the associated 
costs into consideration. As the majority of IRD-associated genes have been identified, we 
discuss how mutations in known IRD genes can be excluded (e.g. by Sanger sequencing 
of frequently mutated genes or targeted NGS of sets of genes) before exome NGS is 
applied to identify defects in novel disease genes. Finally, we provide a future outlook on 
how the remaining genetic causes can be identified using whole genome NGS and 
transcriptomics. 
Genetic analysis of homogenous monogenic diseases 
Presently, 200 genes are known to be involved in the pathogenesis of IRDs. The most 
common retinal dystrophy, RP, is particularly heterogeneous, with 61 causative genes 
described so far. On the other side of the spectrum lie the diseases where most of the 
cases are explained by mutations in a single gene, such as ornithine amino transferase 
(OAT) in gyrate atrophy, CHM in choroideremia or ABCA4 in Stargardt disease. Further 
details of such diseases are provided in Chapter 2 (in Retinal disorders, Section A: 
Genetics of inherited retinal degenerations, Cold Spring Harbor Perspectives in Medicine, 
© Cold Spring Harbor Press). These homogeneous diseases are relatively undemanding 
in terms of genetic diagnostics. The preferred method of choice in these cases is Sanger 
sequencing, which is cost-effective for genes spanning no more than 50 amplicons. For 
autosomal recessive inheritance both alleles must be affected. If only one of the two alleles 
harbours a clear-cut mutation, looking for exonic deletions or duplications using the 
multiplex ligation probe amplification technique may be applied. For the genes expressed 
at detectable levels in peripheral blood lymphocytes, for instance in choroideremia, X-
linked congenital stationary night blindness or retinoschisis, RNA analysis may rather be 
considered. Reverse transcription and subsequent direct cDNA sequencing enables the 
discovery of splicing abnormalities such as the insertion of cryptic exons3 or the deletion of 
Genomic approaches for the discovery of genes mutated in IRDs 
49 
 
coding exons4. This technique is particularly valuable, since it also enables detection of 
mutation events that abolish transcription from one allele. This approach can be applied 
when a mutation is found in a heterozygous state in genomic DNA. In some of these 
cases, cDNA analysis may reveal the presence of only the mutated allele, indicating that 
the other allele either is not transcribed or is degraded via nonsense-mediated decay5. 
Unfortunately, many genes are not expressed at sufficient levels in peripheral blood 
lymphocytes and in these instances other approaches are necessary to uncover the 
causative alteration (see below). 
Genomic approaches for heterogeneous monogenic diseases 
Pre-screening for genes/variants responsible for a significant proportion of the cases 
For the majority of monogenic retinal dystrophies, mutations in multiple genes can be 
responsible for the phenotype. These genetically heterogeneous retinal dystrophies, such 
as CD, CRD, LCA and RP, present a challenge as mutations can be expected in any of 
20-61 genes. However, in some subtypes, one or only a few genes or mutations explain a 
significant proportion of cases, rendering a specific pre-screening for these genes or 
variants a cost-effective diagnostic method. In Figure 2, screening procedures for these 
types of retinal diseases are proposed. The majority of mutations responsible for ACHM 
are found in CNGB3 (50-87%), followed by CNGA3 (5-20%)6-8. Although autosomal 
dominant RP can be caused by mutations in 23 genes, alterations in rhodopsin (RHO) 
account for 20-30% of the cases9. RPGR is mutated in ~70% of X-linked RP families10-12, 
as well as in ~15% of isolated male RP cases13. The most common LCA-causing mutation 
in the Caucasian population (CEP290, c.2991+1655A>G), is responsible for ~15% of all 
cases3,14,15. In addition, the AIPL1 variant p.(W278*) in exon 6, the GUCY2D p.(R768W) 
variant in exon 12, as well as CRB1 variants in exons 7 and 9 together explain another 
20% of LCA alleles16-18. Sequence analysis of these four exons is therefore proposed by us 
as a second pre-screening step in LCA. Possibly, in specific populations, other genetic 
variants are so frequent that their pre-screening may be cost-effective. In such cases, a 
balance between Sanger sequencing costs and expected mutation yield should be 
assessed on an individual basis. 
Targeted NGS 
NGS encompasses many different massive parallel sequencing strategies. At least eight 
NGS methods are currently available and many others are under development. Older NGS 
sequencing strategies were originally designed to sequence entire genomes in a high- 
 
Expanding the genetic heterogeneity of RP and LCA 
50 
 
Figure 2: Genotyping strategy for genetic heterogeneous retinal dystrophies. 
ACHM: achromatopsia; ad: autosomal dominant; ar: autosomal recessive; CD: cone dystrophy; CRD: cone-rod dystrophy; 
ExNGS: exome next-generation sequencing; i: isolated; LCA: Leber congenital amaurosis; RP: retinitis pigmentosa; TaNGS: 
targeted next-generation sequencing. *In many Western countries, Sanger sequencing of the intronic CEP290 variant 
(c.2991+1655A>G) solves ~15% of the cases. Sequence analysis of AIPL1 exon 6 (p.W278*), CRB1 exons 7 and 9 and 
GUCY2D exon 12 (p.R768W) reveals at least one variant in another 20% of the cases. For ExNGS, if multiple affected cases 
are available, at least two should be analysed to minimise the number of putative causal variants. 
throughput manner, but have not been tailored to analyse smaller sets of genes. Many 
NGS methods have been shown to be reasonably sensitive, identifying genetic defects in 
40-50% of persons with autosomal recessive/isolated RP19-23. However, most of the 
techniques have two major shortcomings. First, analysis of protein-coding sequences of 
selected genes requires an enrichment step which invariably leads to underrepresentation 
or non-coverage of up to 15% of exons. In most cases this is due to high GC-content, in 
particular at 5’ ends of genes. Non-enrichment can also be due to the repetitive nature of 
targeted sequences, as in RPGR ORF15. Second, material costs for target enrichment 
and sequencing are substantial (~€ 1000/sample), which limits their use in routine 
diagnostics. 
Two of the targeted NGS approaches can be performed for less than € 200 per sample, 
assuming sequence analysis of a maximum of 100 IRD genes, parallel analysis of at least 
100 patient samples and use of the Illumina HiSeq 2000 or a comparable platform. With 
the first approach, fragment enrichment of protein coding exons or other relevant 
sequences is achieved by hybridisation, either in solution (Agilent SureSelect Target 
Enrichment System, NimbleGen SeqCap EZ) or on an array (NimbleGen)24. With the 
second approach, the enrichment utilises highly multiplexed PCR with molecular inversion 
probes designed to amplify the fragments of interest25-30. 
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A key advantage of targeted NGS is that it represents an unbiased approach. The analysis 
of the entire set of ~100 genes associated with non-syndromic CD, CRD, LCA and RP 
provides flexibility regarding the clinical diagnosis, which can be difficult at early and late 
stages of disease (see Figure 1). This is also important for isolated cases with RP, which is 
often caused by de novo mutations. Indeed, de novo mutations were identified in 4 of 28 
cases of isolated RP, with the mutations in both autosomal dominant and autosomal 
recessive genes19. 
Exome NGS 
When pre-screening of specific IRD genes or targeted NGS of a larger set of IRD genes 
does not reveal causative variants, exome NGS is currently the method of choice to reveal 
defects in “novel” IRD genes. 
The following two data sets illustrate typical yields of gene mutations for genetically 
heterogeneous diseases. Abu-Safieh et al. (2013) employed genome-wide homozygosity 
mapping and exome NGS to identify the underlying mutations in 78 unrelated 
consanguineous families with RP or allied dystrophies52. This yielded variants in previously 
identified IRD genes in 78% of the cases, variants in possible novel IRD genes in 8% of 
the cases and no result in 14% of the cases. Similar studies in 41 Pakistani families 
yielded causal variants in known IRD genes in 32 (78%) of the families (Khan and Ajmal., 
unpublished). 
As the majority of genes associated with genetically heterogeneous IRDs have mostly 
likely been identified, alterations are expected to be found in genes mutated at low 
frequency (1% or less). If multiple affected persons are available in a family, at least two 
affected individuals should be analysed in parallel. This is particularly important in the case 
of autosomal dominant diseases, as the number of novel heterozygous variants identified 
in each individual by exome sequencing (~500) can be daunting. By analysing affected 
persons that are remote relatives, the expected number of shared sequence variants 
decreases significantly. Below, we outline additional techniques and novel approaches to 
identify the culprit mutation(s). 
Genetic linkage studies and copy number variant detection 
Throughout the years, molecular diagnostics of genetically heterogeneous diseases like 
IRDs has been performed using different techniques. Genetic linkage studies have been 
employed to narrow down the critical genomic regions for all Mendelian inheritance types 
of IRDs and are still valuable in this era of high-throughput sequencing technologies. For 
example, two novel genes underlying autosomal dominant exudative vitreoretinopathy, 
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TSPAN12 and ZNF408, were identified by combining linkage mapping and targeted (to a 
40-Mb genomic region) or exome NGS, respectively31,32. Homozygosity mapping combined 
with exome sequencing identified several other novel IRD genes (for example MAK, 
DHDDS and RAB28)5,33-36. 
In the past, identity-by-descent mapping was the method of choice for narrowing down the 
critical regions in families with an autosomal recessive inheritance pattern. Half of the 
genes underlying autosomal recessive RP have been identified using this approach, both 
in consanguineous37-41 and in non-consanguineous families42,43. In brief, a microarray 
hybridisation technique is used to genotype single nucleotide polymorphisms (SNP) 
equally spread across the genome. Subsequently, runs of homozygosity shared between 
the affected individuals can be determined using freely available software for genome-wide 
SNP analysis such as PLINK44 or Homozygosity Mapper45. Theoretically, the IBD regions 
in an affected person whose parents are first-cousins on average span 33 Mb46 and in 
several studies the causal variant in >90% of the cases was found in the largest or second-
largest homozygous region47-49. In non-consanguineous families, however, the size of IBD 
regions can vary between ~1.0 Mb and 30 Mb. Because small homozygous regions in the 
genome are numerous and are less likely to contain the causative mutation, the initial cut-
off should be set to 2 Mb. If the gene responsible is not found in the two largest regions, 
the threshold may be further lowered. Exome data may also be used to determine the 
location, number and length of homozygous regions50. 
Homozygous mutations are frequently present in populations where consanguineous 
unions are culturally established, such as in Indonesia, Pakistan or Saudi Arabia48,51,52. In 
Western populations homozygous IBD regions within one family are smaller, because 
more generations have passed since the original founder. A significant proportion (~70%) 
of recessive inheritance in these populations is attributable to compound heterozygous 
alterations. Linkage analysis using SNP arrays may be more suitable for this type of data. 
Recently, a software tool, Haplobot, has been developed to extract stretches of common 
haplotypes between affected individuals within one family (Henkes and Collin, 
unpublished). Based on the same principle as PLINK44, it analyses common haplotypes 
within a given window with variable parameters (mismatches and no-calls between 
individuals per window and size threshold). After listing the common haplotype regions, the 
program automatically filters out variants from the exome data file that reside in unshared 
regions. Hence, it enables narrowing down the list of probable causative variants identified 
by exome NGS. This approach recently aided the identification of causative mutations in 
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MVK in an autosomal recessive RP family53. Exome data can also be filtered against 
existing linkage data for a given family, including previously obtained linkage loci. 
High-density SNP arrays also enable the detection of copy number variations, which may 
still explain an underrated part of the undiscovered heritability. At the moment, the highest 
probe density of 2.7 million is provided by CytoScan HD (Affymetrix); among those, 
700,000 SNPs have a high minor allele frequency, which is very informative for linkage 
and homozygosity mapping or for the detection of uniparental isodisomy54. Two million 
probes on the array are quantitatively assessed to detect deletions, duplications and 
amplifications larger than 20 kb. Changes smaller in size, e.g. encompassing several 
exons of a given gene, were previously analysed by multiplex ligation probe amplification. 
However, since this method requires custom-designed probes for every gene, quantitative 
assessment of exome NGS data may replace this strategy. In the near future, with 
sufficient read depth, it is expected that exome NGS will allow a reliable detection of homo- 
and heterozygous deletions and duplications. 
Mutations in genes causing syndromic and non-syndromic IRDs 
As illustrated by the abovementioned MVK case, novel genotype-phenotype correlations 
are constantly emerging. In the past, such associations were identified for many genes that 
were initially described as causative of syndromic forms of retinal dystrophies. Examples 
include OFD1, a Joubert syndrome gene recently found to be mutated in non-syndromic X-
linked RP55,56 and CEP290, a gene that was initially found to be mutated in Joubert 
syndrome and later turned out to be frequently involved in LCA3,57,58. IQCB1, a gene known 
for many years to be mutated in Senior-Løken syndrome, was found to be involved in 
LCA59,60 and finally the Bardet-Biedl Syndrome 1 (BBS1) gene was discovered to be 
involved in the pathogenesis of wide spectrum of syndromic and non-syndromic retinal 
dystrophies61,62. The recent implementation of whole-exome sequencing has facilitated the 
discovery of many of such novel associations. Mutations found in ALMS1, CNGA3 and 
MYO7A, involved in either syndromic or other non-syndromic forms of IRD, were 
discovered in LCA families63. In some cases, mutations reside in exons that are only 
present in retina-specific transcripts of a certain gene, e.g. BBS8 and OFD155,64. 
In many instances, autosomal recessive mutations show varying degrees of severity and 
the allelic combinations determine the final clinical outcome. For example, missense 
mutations in the Usher syndrome type 3A gene CLRN1 were found in non-syndromic RP65; 
the hypomorphic CEP290 c.2991+1655A>G variant was found predominantly in persons 
with LCA, but not in Joubert and Meckel-Gruber syndrome3; and the USH2A variant 
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p.(C759F) was found at higher frequency in persons with RP without hearing loss66,67. As a 
consequence, the panels for targeted NGS should ideally also contain genes involved in 
diseases that display retinal dystrophy as one of the symptoms of a multi-organ disorder, 
although this may double the analysis costs. However, in some instances, the exact same 
mutation can cause either a syndromic or a non-syndromic form of IRD and different 
models have been proposed to explain this phenomenon among which are modifier loci 
and digenic/oligogenic inheritance62,68. The novel approaches that are emerging to identify 
such modifier loci are described in Chapter 4 (In: Retinal disorders, Section A: Genetics of 
inherited retinal degenerations, Cold Spring Harbor Perspectives in Medicine, © Cold 
Spring Harbor Press). 
Whole genome sequencing and transcriptome analysis 
Whole genome sequencing 
For non-syndromic RP, recent publications describe the percentage of readily “solved” 
exome sequencing samples to be approximately 80%52. Because exome sequencing does 
not detect deep intronic variants, which may cause aberrant splicing events, or variants in 
regulatory sequences that may cause a decrease or imbalance in transcript levels, next 
generation sequencing of the whole genome may be the next method to analyse 
“unsolved” samples. With the costs of whole genome sequencing constantly decreasing, 
this method is now becoming available for a broader group of laboratories. However, the 
analysis of whole genome data is still very difficult. First, a very large number of variants 
(~3 million in each individual) is obtained and the filtering of potentially causative variants 
may prove challenging. Second, the effects of regulatory and intronic mutations are not 
certain, even with the use of contemporary prediction software. An additional cDNA 
analysis can provide crucial evidence regarding the functional significance of a variant at 
the RNA level. In the near future, a combination of whole genome sequencing and 
transcriptome sequencing may effectively decrease the number of candidate variants that 
require follow-up. 
Transcriptome analysis of induced pluripotent stem cells 
The term “transcriptome” refers to all mRNA transcripts that are synthesised in a particular 
cell type or tissue. Whole-transcriptome sequencing provides the most complete analysis 
possible at the cDNA level (see Chapter 5 in Retinal disorders, Section A: Genetics of 
inherited retinal degenerations, Cold Spring Harbor Perspectives in Medicine, © Cold 
Spring Harbor Press). Many described alterations can be detected by examining their 
consequences at the mRNA level: small insertions and deletions in exons, exon 
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inversions, erroneous splicing events, transcript-level variations (e.g. a mutation is 
heterozygous in the genomic DNA, but the transcript is not produced from the second 
allele), exonic and intronic splice site enhancer/silencer changes as well as nonsense-
mediated exon skipping69. Some of these variants are detectable only as a mutation result 
at the transcript level; the genomic DNA alterations are not visible and require additional 
Sanger sequencing. In the case of regulatory sequences, identification of these mutations 
may be problematic. 
An additional challenge regarding cDNA analysis in IRDs is the low level of gene 
transcription. Many genes involved in IRDs are expressed solely or at least predominantly, 
in the retina and have very low expression levels in peripheral blood leukocytes or 
fibroblasts. Recently, an interesting option arose to overcome this difficulty. 
Transcriptomes may now be derived from photoreceptor-like cells that have been 
differentiated from induced pluripotent stem cells derived from somatic cells of affected 
persons. mRNA libraries derived from such cells will not exactly match transcription levels 
or patterns in the retina, but they do provide the best use of cells currently available (see 
Chapter 6 in Retinal disorders, Section A: Genetics of inherited retinal degenerations, Cold 
Spring Harbor Perspectives in Medicine, © Cold Spring Harbor Press). Furthermore, 
transcriptome analysis requires a reference sequence created for the appropriate tissue. 
This sequence, targeted to human retina and other ocular tissues, was assembled by 
several different groups70-72; the latter (Farkas et al.)72 is available online 
(http://oculargenomics.meei.harvard.edu/index.php/ret-trans/110-human-retinal-
transcriptome). Shortly, the transcript library from photoreceptor-like cells derived from 
induced pluripotent stem cells will also become available. However, because transcriptome 
analysis is a novel tool, confirmation and comparison from other laboratories will be 
necessary to ensure high quality of this analysis. 
Disease variant interpretation 
Allele frequency analysis in control cohorts 
With the increasing possibilities of mutation detection via NGS methods, there is an 
unprecedented need for additional measures to assess the pathogenicity of the variants. 
Typically, exome NGS for a single patient using the SOLiD technique yields around 30,000 
variations. Because the reference sequence was obtained via Sanger sequencing by the 
Human Genome Project73 and Celera Genomics74, which involved a small number of 
anonymous donors, it is not always accurate. Some nucleotides present in the reference 
are in fact rare variants or sequencing artefacts and therefore these loci will appear as 
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“mutated” in almost every analysed sample. An improved reference genome, based on 
novel genomic sequences involving a large number of studied individuals and, as a result, 
more reliable frequencies, is being assembled. Before it becomes available, the only 
method of eliminating these variants from exome data is filtering against variant 
frequencies. Depending on the software used for analysis, SNP frequency from the dbSNP 
database may be available (http://www.ncbi.nlm.nih.gov/projects/SNP/). The newest build 
of this database (138) also contains the Exome Variant Server data from data from the 
NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/), 1000 genomes 
(www.1000genomes.org) and the HapMap project (http://hapmap.ncbi.nlm.nih.gov/). It is 
crucial to also incorporate in-house exome variant frequency data in order to eliminate 
population-specific frequent variants or systematic equipment errors, which may not be 
present in the dbSNP database. After eliminating the polymorphic alterations and common 
false positives, further frequency filtering depends on prevalence of the disease. Keeping 
in mind that most novel genes will be mutated rarely in IRDs, the allele frequency cut-off 
for autosomal recessive IRDs may be set to 0.5%. All variants below this threshold have a 
higher probability of being causative; however, there are exceptions to this rule. For 
instance, a disease may be caused by a null allele combined with a SNP or a mild allele, 
such as ABCA4 c.2588G>C, which occurs heterozygously in 3% of healthy individuals in 
the Netherlands75. Obviously, establishing such associations may be challenging. Due to 
the extremely high heterogeneity of IRDs, it is estimated that one in five individuals bears a 
null allele in an autosomal recessive IRD-associated gene with proven causality76. In 
general, recessive IRDs mainly involve mutations that result in a loss of function. In 
contrast, a dominant inheritance pattern can be caused by null or regulatory mutations 
(haploinsufficiency) or by missense mutations that cause a gain of function or exert a 
dominant-negative effect on the wild-type protein. Due to incomplete penetrance, which is 
occasionally observed in dominant IRDs or recessive hypomorphic alleles, the frequency 
threshold may need to be set as high as 1%. 
Variant prioritisation 
In the analysis of autosomal recessive diseases, null alleles should receive utmost priority. 
Insertion/deletion variants, nonsense variants and canonical splice site variants, which 
may lead to the introduction of a premature termination codon, should be examined first. 
Subsequently, missense alleles and in-frame deletions/insertions should be analysed. 
Last, intronic sequence changes and synonymous variants should be given attention. 
There are several in silico prediction programs and tools that may be helpful in the analysis 
and prioritisation of the variants. For missense mutations, one such tool is PhyloP, which is 
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a nucleotide conservation score derived from 46 vertebrate species (available for all 
genomic positions at http://genome.ucsc.edu/cgi-bin/hgTables). Most causative mutations 
have been shown to have a high PhyloP score (>2.5)21. Therefore, filtering out variants 
with lower PhyloP scores may facilitate identification of the causative mutation. A 
complementary value in assessing mutation pathogenicity is the Grantham score, which is 
a measure of physico-chemical differences between amino acids that takes features such 
as size, charge and polarity into consideration77. The higher the value, the more different 
the properties of the amino acids are and the more likely it is that the missense change will 
affect protein structure or function. In addition, pathogenicity prediction software, such as 
Sorting Intolerant From Tolerant (SIFT)78, PolyPhen279 and Mutation Assessor (MASS)80 
take various features such as evolutionary conservation and Grantham scores into account 
and predict a variant to be benign or pathogenic. One should bear in mind, however, that 
false negative results may arise from such an analysis and a “neutral” score does not 
necessarily mean that the alteration is not causative. 
Extreme caution must be exercised in pathogenicity evaluation. As stated above, rare 
clear-cut null recessive mutations within autosomal recessive IRD-associated genes may 
be present heterozygously in ~1 in 5 individuals76. Coding sequence length of a given gene 
also plays a major role in the number of discovered missense alterations. In RP1L1 and 
HMCN1 the rate of such variants reaches 4% and many of these changes are indicated as 
deleterious by prediction software81. 
Canonical splice site mutations (affecting donor and acceptor nucleotides -1, -2, +1 and 
+2) are usually considered clear splice site abolishing mutations and are expected to 
significantly diminish the percentage of the normal transcript. The flanking regions of splice 
sites, including non-canonical sequences, may be evaluated with splice site prediction 
programs, such as NNSPLICE, Human Splicing Finder, Gene Splicer, SpliceSiteFinder-like 
or MaxEntScan or AlaMut, which is a software package containing all of the above. 
 For the purpose of identifying mutations abrogating exonic splice enhancers  
and silencers, SKIPPY, an online analysis tool, may be applied82 
(http://research.nhgri.nih.gov/skippy/input.shtml). Intronic splice enhancers and silencers 
are more complicated in their nature and a program enabling their analysis has not yet 
been devised, although it is known that these modifiers are enriched near alternatively 
spliced exons83. 
Candidate genes obtained by exome sequencing data may be further prioritised using 
existing databases of animal model phenotypes, such as Mouse Genome Informatics 
(MGI, http://www.informatics.jax.org/searches/allele_form.shtml) or Zebrafish International 
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Resource Center (ZFIN, http://zfin.org/). Other helpful tools involve binding data for retina-
specific transcription factors necessary for photoreceptor development and maintenance 
(e.g. CRX, NRL)84,85. Such data have already facilitated the identification of two retinal 
dystrophy genes, namely MAK and FAM161A5,86. Because many IRD-associated genes 
are involved in the development and maintenance of the photoreceptor connecting cilium, 
the database containing ciliary proteins (http://www.sfu.ca/~leroux/ciliome_database.htm) 
may be used to prioritise candidate IRD-associated genes from exome data. 
Allele-specific control and large patient cohort analyses 
Mutations that are classified as likely responsible for a phenotype must undergo further 
scrutiny. A population-specific polymorphism that is not present in available SNP 
databases can be excluded using ethnically matched control panel analysis. This may be 
achieved even by indirect allele assessment methods such as the amplification-refractory 
mutation system (ARMS) or, in case of some amplicons, restriction fragment length 
polymorphism (RFLP) analysis. Alternatively, especially when working with large patient 
numbers, Taqman/Kaspar assays can be used. 
To exclude the possibility that rare variants represent benign polymorphisms, DNA 
samples of ethnically-matched healthy individuals must be analysed. Assuming a variant 
allele frequency of 1%, to achieve 80% power of significance at least 210 chromosomes 
must be analysed; for 95% power 340 chromosomes should be analysed87. However, one 
should bear in mind that some relatively common alleles may still exert a negative effect 
on the protein75. Subsequently, allele-specific analysis can be performed on a large cohort 
of IRD patients with no identified disease cause. This may reveal other patients with the 
same mutation, either in homozygous or heterozygous state. In the latter case, Sanger 
sequencing of the remaining exons may enable the identification of the second hit in the 
same gene. For the same purpose, if genome-wide SNP genotyping data are available 
and a homozygous stretch encompasses the respective gene, one can directly sequence 
all of its exons in other individuals with the same phenotype and overlapping homozygous 
regions. Both of these methods, however, require significant numbers of patient samples. 
As such, it is essential to have access to large patient cohorts, which unequivocally 
addresses the need for multi-centre collaborations, especially for rare diseases. 
Functional assessment of mutation pathogenicity 
Although null alleles, such as frameshift deletions/insertions, canonical splice site 
alterations and nonsense mutations, are usually considered pathogenic, this is not always 
the case. A mechanism discovered two decades ago, nonsense-mediated exon skipping, 
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may restore the reading frame. Briefly, a nonsense codon introduced within an exon (with 
the exception of a premature termination codon in the last exon) causes the spliceosome 
machinery to exclude this exon from the mRNA transcript. Provided that the nucleotide 
number of the excised exon is divisible by three, the reading frame is preserved. If the 
portion of the protein encoded by the exon in question does not significantly influence its 
structure and it is not crucial for the protein function, such an allele may be relatively mild. 
This mechanism was found for CEP290, in which a protein-truncating mutation in exon 7 
(c.451C>T, p.(R151*)) resulted in the skipping of exon 7 or exons 7 and 8 and an in-frame 
deletion49. Persons carrying this CEP290 variant showed a relatively mild retinal dystrophy. 
Therefore, transcript analysis is highly advised, even for variants that are expected to 
result in null alleles. 
Recent advances in morpholino-induced gene knock-down enabled the accurate and 
relatively fast evaluation of missense variants in genes that have zebrafish orthologues. In 
particular, genes acting in cilia were positively evaluated: the rescue of the morpholino-
induced phenotype was obtained using human wild-type RNA88. Since around 70% of 
human genes have zebrafish counterparts89, this assay is an important tool in functional 
assessment of potentially pathogenic mutations. (Further details are described in Chapter 
6 in Retinal disorders, Section A: Genetics of inherited retinal degenerations, Cold Spring 
Harbor Perspectives in Medicine, © Cold Spring Harbor Press). If available, functional 
analysis is best performed in a mammalian model, such as knock-out mice or appropriate 
murine cell lines. Other experiments to consider, which are relatively simple, are 
subcellular localisation studies. Immunostaining of the desired protein in appropriate cell 
type (e.g. ciliated cell when studying a ciliary protein) may give a clue about the 
pathogenicity of the variant. Such studies may also be performed in induced pluripotent 
stem cells differentiated into photoreceptor-like cells. 
Concluding remarks 
Over the recent years, we have witnessed a dramatic change in the methods of gene 
identification. Contemporary techniques enable faster detection of genetic defects, even in 
large patient cohorts. Nevertheless, pathogenicity evaluation of the identified variants 
remains a challenging endeavour. The abundance of known pathogenic mutations in the 
heterozygous state, observed also in healthy individuals, confers further difficulty in 
identifying the causative alleles. Adding to the complexity, variants in other genes may 
contribute to the phenotype. With rapidly decreasing costs of the newest next-generation 
sequencing techniques, exome sequencing is already becoming a standard in diagnostics 
of retinal dystrophies. Transcriptome analysis of photoreceptor cells derived from induced 
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pluripotent stem cells and whole-genome sequencing may soon become the next 
advancements widely used in this field. Many of the IRD-associated genes that have been 
identified to date and those that remain to be identified, are mutated in only a small 
proportion of affected individuals. Therefore, there is an emerging need for worldwide 
networks of patients that can contribute to studies aiming at future therapeutic trials. 
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Abstract 
Purpose: Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous retinal 
disorder. Despite tremendous knowledge about the genes involved in RP, little is known 
about the genetic causes of RP in Indonesia. Here, we aim to identify the molecular 
genetic causes underlying RP in a small cohort of Indonesian patients, using genome-wide 
homozygosity mapping. 
Methods: DNA samples from affected and healthy individuals from 14 Indonesian families 
segregating autosomal recessive, X-linked or isolated RP, were collected. Homozygosity 
mapping was conducted using Illumina 6k or Affymetrix 5.0 single nucleotide 
polymorphism (SNP) arrays. Known autosomal recessive RP (arRP) genes residing in 
homozygous regions and X-linked RP genes were sequenced for mutations. 
Results: In 10 out of the 14 families, homozygous regions were identified that contained 
genes known to be involved in the pathogenesis of RP. Sequence analysis of these genes 
revealed seven novel homozygous mutations in ATP-binding cassette, sub-family A, 
member 4 (ABCA4), crumbs homolog 1 (CRB1), eyes shut homolog (Drosophila) (EYS), c-
mer proto-oncogene tyrosine kinase (MERTK), nuclear receptor subfamily 2, group E, 
member 3 (NR2E3) and phosphodiesterase 6A, cGMP-specific, rod, alpha (PDE6A), all 
segregating in the respective families. No mutations were identified in the X-linked genes 
retinitis pigmentosa GTPase regulator (RPGR) and retinitis pigmentosa 2 (X-linked 
recessive; RP2). 
Conclusions: Homozygosity mapping is a powerful tool to identify the genetic defects 
underlying RP in the Indonesian population. Compared to studies involving patients from 
other populations, the same genes appear to be implicated in the aetiology of recessive 
RP in Indonesia, although all mutations that were discovered are novel and as such may 
be unique for this population. 
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Introduction 
Retinitis pigmentosa (RP), a group of clinically diverse progressive retinal disorders, is a 
major cause of inherited blindness, affecting 1.5 million people worldwide. RP is initially 
characterised by night blindness, followed by a gradual loss of peripheral vision and 
eventually leading to legal blindness1. Generally, the manifestation of the first symptom 
occurs in childhood or early adulthood. The main clinical characteristics of RP are bone 
spiculed pigmentations, attenuation of retinal vessels, a waxy pallor appearance of the 
optic disc and absent or severely reduced a-waves on electroretinography. 
Genetically, RP is also very diverse, with over 50 different causative genes identified to 
date and being inherited in an autosomal dominant (30-40%), an autosomal recessive or 
isolated (50-60%), an X-linked (5-20%) or, very rarely, in a mitochondrial or digenic 
manner2. Due to the relatively high rate of marriages within specific ethnic groups, 
autosomal recessive inheritance was reported to be even more frequent in Indonesia3. A 
significant fraction of the causative arRP genes has been identified using homozygosity 
mapping in large, often consanguineous pedigrees. Recently, we have also applied high-
resolution homozygosity mapping to identify the genetic defect underlying autosomal 
recessive RP (arRP) in non-consanguineous populations4-7. Despite a tremendous 
knowledge on the genetic causes of RP, little is known about the genes involved in RP in 
the Indonesian population. A study published earlier this year involved the analysis of RHO 
in families with an autosomal dominant mode of inheritance8. Here, we describe the 
molecular genetic analysis of 14 Indonesian families segregating arRP and show that 
homozygosity mapping is a powerful tool to identify causative mutations in this population. 
Materials and methods 
Subjects 
Fourteen Indonesian families segregating RP, thirteen living on Java and one on Sulawesi 
islands, were enrolled in the study (total number of 55 individuals, 32 affected, 23 
unaffected). All families appeared to be autosomal recessive, except for W09-0049, which 
was more suggestive of X-linked recessive pattern. This type of inheritance is also 
possible in families W09-0048 and W09-0050 (Figure 1). Affected individuals were 
diagnosed at the Kariadi Hospital, the William Booth Hospital or the Panti Wilasa Citarum 
in Semarang Central Java, Indonesia and examined by direct ophthalmoscopy and visual 
acuity tests using a Snellen chart. The presumed mode of inheritance was determined by 
anamnesis and pedigree analysis. Informed consent was obtained from all participating 
individuals or, in case of underage participants, from their parents. This study adhered to 
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the tenets of the Declaration of Helsinki. In addition, 149 ethnically matched and unrelated 
control individuals participated in this study. 
 
Figure 1. Overview of the pedigree structure of the Indonesian families participating in this study. 
Affected individuals are indicated with filled symbols, whereas unaffected relatives are indicated by open symbols. Symbols 
with a slash depict deceased individuals. Probands are indicated with arrows and individuals that were genotyped on 
genome-wide SNP arrays are marked with asterisks. Upon the identification of mutations in the probands (gene and mutation 
indicated below the pedigree), segregation analysis was performed in all available relatives, the results of which are indicated 
with M (mutated allele) or + (wild-type allele). 
 
Molecular genetics of RP in Indonesia 
75 
 
Clinical characterisation 
Clinical characterisation that included fundoscopy and visual acuity measurements 
revealed that the majority of affected individuals had poor vision and showed typical 
hallmarks of RP on fundoscopy, e.g. bone-spicule pigmentation, attenuated retinal vessels 
and/or a pale appearance of the optic disc (Table 1). Only in family W09-0036, the visual 
acuity is not dramatically decreased. 
Linkage analysis and homozygosity mapping 
Genomic DNA of participating individuals was isolated from peripheral blood using a 
standard salting out procedure9. Affected individuals were selected for genome-wide SNP 
analysis. For three consanguineous families (W09-0041, W09-0042 and W09-0046), the 
“low-resolution” Illumina 6k SNP array (Illumina Inc., San Diego, CA, USA) that contains 
6,020 SNPs was used, whereas the patients from the remaining eleven families were 
genotyped on a high-resolution Affymetrix 5.0 array (Affymetrix, Santa Clara, CA, USA) 
that contains 500,000 SNPs. For the three consanguineous families that were analysed on 
the Illumina array, multi-point parametric linkage analysis was performed using the 
GeneHunter 2.1r5 program in the easyLINKAGE v5.052beta software package10. For the 
other families, homozygous regions were calculated using PLINK software11, with a cut-off 
of 3 Mb and allowing 2 heterozygous SNP calls per window of 50 SNPs. 
Mutation analysis 
Exons and intron-exon boundaries of all known arRP genes residing in homozygous 
regions and X-linked RP genes RPGR and RP2 were sequenced in the corresponding 
probands using the Big Dye Terminator Cycle Sequencing Kit v3.1 on a 3130 automated 
sequencer (Applied Biosystems, Foster City, CA, USA). Upon identification of an unknown 
variant, available family members and/or ethnically matched control individuals were 
analysed using direct sequencing, the amplification refractory mutation system (ARMS) or 
restriction fragment length polymorphism (RFLP) analysis. Primer sequences and PCR 
conditions are available upon request. The analysis of mutations was conducted with 
AlaMut 1.5 software (Interactive Biosoftware, Rouen, France). Splice site scores were 
calculated using an internal AlaMut module that combines the scores of GeneSplicer, 
MaxEntScan, SpliceSiteFinder-like and NNSPLICE. For the missense changes that were 
identified, the evolutionary conservation of the substituted amino acids was assessed by 
aligning the corresponding protein sequences of several species, using the Align  
program in VectorNTI Advance 11.0 software (Invitrogen, Carlsbad, CA, USA). The 
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AA: attenuated arterioles; BSP: bone spicule pigmentation; CF: counting fingers; F: female. HM: hand motion; LP+: light 
perception; LP-; no light perception; M: male; OD: oculus dexter, right eye; OS: oculus sinister, left eye; n.d.: not determined; 
POD: pale optic disc 
Table 1. Clinical and demographical characteristics of affected individuals 
Family 
code 
Patient Gender 
Age of 
onset (y) 
Current 
age (y) 
Visual acuity Fundus 
appearance OD OS 
W09-0036 
II:6 M 21 46 20/40 20/40 AA, BSP 
II:4 F 25 50 20/40 20/40 AA, BSP 
II:3 M 25 51 20/40 20/40 AA, BSP 
W09-0037 
II:2 F 14 32 HM HM AA, BSP 
II:3 F 14 29 HM HM AA, BSP 
W09-0038 
II:3 M 17 30 HM CF AA, BSP 
II:2 F 18 32 HM HM AA, BSP 
W09-0039 III:1 F 20 46 LP+ LP+ AA, BSP, POD 
W09-0040 
III:3 M 15 45 LP- LP+ AA, BSP, POD 
IV:1 F 8 10 HM HM n.d. 
II:6 M 14 71 HM LP- n.d. (cataract) 
III:5 M 13 59 HM LP- AA, BSP, POD 
W09-0041 
IV:4 M 14 44 20/200 20/200 BSP 
IV:5 F 13 41 20/100 20/70 BSP 
IV:1 F 15 49 20/200 20/200 BSP 
IV:7 M 15 35 20/40 20/40 BSP 
IV:2 M 13 64 HM HM AA, BSP, POD 
W09-0042 
IV:2 F 5 64 HM HM AA, BSP, POD 
IV:3 M 6 62 HM HM AA, BSP, POD 
W09-0044 II:1 F 12 59 LP+ LP+ AA, BSP, POD 
W09-0045 
II:2 M 11 55 LP+ LP+ AA, BSP, POD 
II:9 F 11 37 20/240 20/240 BSP 
II:10 F 12 35 20/240 20/240 BSP 
II:4 M 13 48 HM HM BSP 
II:7 M 12 39 HM HM BSP 
W09-0046 
IV:7 M 14 46 20/400 20/400 BSP 
IV:8 M 15 40 20/400 20/400 BSP 
IV:5 M 14 47 HM HM BSP 
W09-0047 
II:1 F 15 39 HM HM BSP 
II:2 M 12 33 CF CF BSP 
W09-0048 II:1 M 12 59 LP- LP- AA, BSP, POD 
W09-0049 III:1 M 15 68 LP- LP- AA, BSP, POD 
W09-0050 IV:3 M 15 48 LP+ LP+ AA, BSP, POD 
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pathogenicity of these mutations was evaluated using SIFT12 and PolyPhen-213 prediction 
programs. In addition, Grantham scores, that define the physico-chemical difference 
between amino acids14 and PhyloP scores that are a measure of evolutionary  
nucleotide conservation (PhyloP44wayAll; http://genome.ucsc.edu/cgi-bin/hgTables), were 
determined. 
Results 
Linkage analysis and homozygosity mapping in arRP families 
To determine the location of the genetic defect in the 14 presumed arRP families, affected 
individuals were genotyped using whole-genome SNP arrays (Figure 1). In three 
consanguineous families with multiple affected individuals (W09-0041, W09-0042 and 
W09-0046), the Illumina HumanLinkage-12 SNP array was used. Multi-point linkage 
analysis was performed to detect genomic regions that might contain the genetic defect. In 
family W09-0041, only a single peak with a maximum multi-point LOD-score of 3.00 was 
identified, on chromosome 15 (Figure 2A). In families W09-0042 and W09-0046, multiple 
peaks potentially harbouring the genetic defect were identified, with multi-point LOD-
scores of 1.80 (Figures 2B and C). As expected in patients born from consanguineous 
marriages, all regions with the highest LOD-scores in the three families represented 
continuous stretches of homozygous SNP calls (Table 2), with identical haplotypes shared 
between affected siblings. In the remaining eleven arRP families, high-resolution SNP 
genotyping was performed using Affymetrix 5.0 arrays. Homozygous regions were 
calculated and considered to be significant if they span more than 3 Mb of genomic DNA. 
For the families with multiple affected siblings, only those regions that were homozygous in 
all affected individuals were considered to potentially harbour the causative gene. In four 
families, no regions that were homozygous in all affected siblings were identified, whereas 
in a few others, many of those regions were present. In the non-consanguineous families, 
the number of homozygous segments per family varied from 0 to 5, with a maximum length 
of 20.2 Mb. 
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Figure 2. Overview of linkage plots for the three consanguineous Indonesian families. 
Linkage results for three consanguineous Indonesian families, W09-0041 (A), W09-0042 (B) and W09-0046 (C) that were 
analysed with Illumina 6k arrays. The peaks that correspond to the regions harbouring the genes in which mutations were 
identified are indicated with arrows. 
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Mutation analysis of arRP genes in homozygous region 
In the majority of the families, one or more homozygous regions contained one of the 31 
known arRP genes. Sequence analysis of these genes in the corresponding families 
revealed 7 novel mutations that are likely causative for RP in the respective families (Table 
2). The pathogenicity of the missense and splice site mutations were evaluated using a 
detailed in silico analysis (Table 3). In family W09-0038, the largest homozygous region 
contained the MERTK gene. Exon 15 failed to amplify in the affected individuals, but not in 
the unaffected family members, suggesting a genomic deletion (Figure 4A). Detailed 
analysis revealed the occurrence of a complex rearrangement that included a 1732-bp 
deletion containing exon 15 of MERTK (Figure 4B). The absence of exon 15 from the 
MERTK mRNA is predicted to result in a frameshift and premature stop codon, which may 
lead to truncation of the MERTK protein (p.(G654Afs*41)) or trigger nonsense-mediated 
mRNA decay. The affected individuals of family W09-0045 displayed three shared 
homozygous regions, of which the second largest contained MERTK. Sequence analysis 
revealed a homozygous mutation (c.2487-2A>G), that affects the consensus splice site of 
exon 19 and most likely results in aberrant splicing and premature termination of the 
MERTK protein, including the highly conserved tyrosine kinase domain (Table 3). 
 
Figure 3. Sequence comparison of amino acids mutated in Indonesian RP families 
Shown are the mutated and flanking amino acids, from orthologous and homologous protein sequences, for A) CRB1 B) 
NR2E3 and C) EYS. The arrows indicate the position of the mutated amino acid residue in the alignment. Residues that are 
conserved in all protein sequences are depicted in white on a black background, whereas residues that are conserved in 
more than 50% of the analysed sequences are indicated in black on a grey background. 
  
 
 
Table 2. Homozygous regions and mutations identified in this study 
 
Family 
No. of 
affected 
individuals 
No. of affected 
individuals on 
SNP array 
SNP array 
# homozygous 
regions > 3Mb 
Rank Start position 
Size 
[Mb] 
arRP gene in the 
region 
Mutation (DNA) 
Predicted effect 
(protein) 
W09-0036 3 3 Affy 5.0 0       
W09-0037 2 2 Affy 5.0 1 1 chr1: 43.472.727-47.007.137 3.5    
W09-0038 2 2 Affy 5.0 3 1 chr2: 94.722.526-114.958.239 20.2 MERTK complex rearrangement p.(G654Afs*41) 
     2 chr2: 74.821.929-86.961.722 12.1    
     3 chr12: 46.563.980-50.101.308 3.5    
W09-0039 1 1 Affy 5.0 0       
W09-0040 5 3 Affy 5.0 0       
W09-0041 4 3 Illumina 6k 1 1 chr15: 55.310.834-76.576.278 21.3 NR2E3 c.1025T>G p.(V342G) 
W09-0042 2 2 Illumina 6k 5 1 chr 1 : 88.202.625-114.480.309 26.3 ABCA4 c.302+4A>C Altered splicing 
     2 chr 13 : 97.294.596-113.158.661 15.9    
     3 chr 9 : 7.717.818-18.877.591 11.2    
     4 chr 19 : 795.02-10.879.403 10.1    
     5 chr 17 : 68.734.433-74.980.093 6.2 PRCD   
W09-0044 1 1 Affy 5.0 0       
W09-0045 4 3 Affy 5.0 3 1 chr7: 25.394.592-32.791.157 7.4    
     2 chr2: 109.814.503-114.973.711 5.2 MERTK c.2487-2A>G Altered splicing 
     3 chr1: 49.055.999-52.858.628 3.8    
W09-0046 3 2 Illumina 6k 3 1 chr 5 : 154.427.149-164.983.908 10.6    
     2 chr 6 : 74.26.927-76.965.256 69.5 TULP1, EYS c.9082G>T p.(D3028Y) 
     3 chr16 : 37.354-4.720.263 4.7    
W09-0047 2 2 Affy 5.0 2 1 chr5: 139.038.773-163.355.069 24.3 PDE6A c.1675C>A p.(Y558*) 
W09-0048 1 1 Affy 5.0 2 1 chr1: 188.030.378-207.318.912 19.3 CRB1 c.3914C>T p.(P1305L) 
     2 chr12: 82.720.660-101.627.801 18.9    
W09-0049 2 1 Affy 5.0 5 1 chr9: 14.485.574-27.392.109 12.9    
     2 chr12: 95.081.092-104.387.559 9.3    
     3 chr2: 113.783.799-121.286.558 7.5    
     4 chr2: 60.823.051-64.299.067 3.5 FAM161A   
     5 chr1: 48.779.373-52.133.652 3.4    
W09-0050 2 1 Affy 5.0 21 1 chr1: 71.823.794-120.992.603 49.2 ABCA4, RPE65   
     2 chr1: 196.164.119-224.123.536 28.0 USH2A   
     3 chr5: 106.422.150-131.638.131 25.2    
     4 chr13: 30.509.319-52.819.567 22.3    
     5 chr4: 173.631.572-191.167.888 17.5    
     6 chr4: 121.482.239-136.825.720 15.3    
     7 chr1: 148.152.207-161.819.282 13.7    
     8 chr16: 55.072-12.523.392 12.5    
     9 chr17: 6.888-9.800.824 9.8 PRCD   
     10 chr12: 61.88-8.589.738 8.5    
Overview of the homozygous regions per family and the mutations identified in this study. All genes within the regions have been screened for mutations and all mutations 
that have been identified are novel. For family W09–0050, only the 10 largest homozygous regions are depicted. 
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In family W09-0041, four affected siblings shared only one large homozygous region, on 
chromosome 15, harbouring the NR2E3 gene. Mutation analysis of NR2E3 identified a 
homozygous mutation substituting a glycine for a valine residue (c.1025T>G; p.(V342G)). 
The PolyPhen program predicts it to be probably damaging and SIFT indicates that in this 
position only a valine or isoleucine is tolerated (Table 3). Furthermore, the mutation was 
homozygously present in five affected family members and it was absent or 
heterozygously present in three unaffected siblings. Finally, this variant was not detected 
in 298 ethnically matched control alleles. NR2E3 encodes a transcription factor that 
belongs to the family of nuclear hormone receptors, with a DNA binding domain (DBD) at 
the N-terminus and a ligand-binding domain (LBD) located more C-terminally15. The vast 
majority of NR2E3 mutations that cause retinal dystrophy affect amino acid residues 
located in these two domains16. The LBD of NR2E3 is structurally similar to that of other 
nuclear hormone receptor family members and consists of twelve structurally conserved α-
helices17,18. The valine residue at position 342 is highly conserved, both in the NR2E3 
proteins of other species and in the LBD of other nuclear hormone receptors, being either 
a valine or a similar isoleucine residue in all other protein sequences (Figure 3B). This high 
degree of conservation suggests that a relatively large, non-polar amino acid must be 
present at this position to preserve the structure and/or function of the LBD of these 
proteins. The glycine residue that is present in the mutant NR2E3 protein is very small and 
might interrupt the structure and render the protein inactive or partially active. The 
pathogenic character of this variant is supported by the fact that this alteration has not 
been found in alleles of healthy, ethnically matched individuals. 
In family W09-0042, the largest homozygous region contains the ABCA4 gene, which has 
been associated with Stargardt disease19, cone-rod dystrophy, and, to a lesser extent, with 
arRP20. Sequence analysis revealed a nucleotide variant in the splice donor site of exon 3 
(c.302+4A>C), homozygously present in the two affected siblings and absent or 
heterozygously present in their non-affected relatives. In addition, the variant was also not 
detected in 298 ethnically matched control chromosomes. In silico prediction of the 
strength of the splice donor site showed a decrease due to the alteration (e.g. 40% 
decrease in GeneSplicer, 24% in MaxEntScan, 12.3% SpliceSiteFinder-like and 0.04% 
decrease in NNSPLICE, respectively), indicating that this variant might alter ABCA4 
splicing (Table 3). However, due to the unavailability of patient RNA or lymphoblastoid cell 
lines, altered ABCA4 splicing could not be confirmed in vivo. Hence, the pathogenicity of 
this variant remains uncertain. 
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In family W09-0046, three regions that are homozygously shared by two affected siblings 
were detected. The second largest region contained two known arRP genes, namely 
TULP1 and EYS. Sequence analysis of TULP1 did not reveal any pathogenic variants, 
whereas a missense variant was detected in EYS that segregated with arRP in the family 
(c.9082G>T; p.(D3028Y)). This alteration affects an aspartic acid residue localised in the 
most C-terminal of five laminin A G-like domains of the human EYS protein. The aspartic 
acid residue at this position is also present in homologous positions of other EYS LG 
domains and is evolutionarily conserved in EYS proteins of other species (Figure 3C). Both 
SIFT and PolyPhen predict this change to be damaging, which is further supported by high 
Grantham and PhyloP scores (Table 3). Intriguingly, a similar mutation (p.(D2767Y)), 
located at the homologous position in the fourth laminin A-G like domain of EYS, was 
recently found in a Pakistani family segregating arRP21. This suggests that the aspartic 
acid residue located at that position within the laminin A G-like domain is crucial for proper 
functioning of EYS and that the p.(D3028Y) mutation is indeed pathogenic in family W09-
0046. 
 
Figure 4. Molecular genetic analysis of MERTK in family W09-0038 
A) Upper panel: PCR analysis of exon 15 of MERTK. Exon 15 was not amplified in the two affected individuals of family 
W09-0038. All relatives and their position in the pedigree are indicated above the electropherogram. Lower panel: after 
identification of the breakpoints of the complex rearrangement, PCR primers were designed to amplify a product spanning 
the deletion. A PCR product indicating the presence of a rearrangement is observed in all individuals demonstrating that the 
unaffected family members are carriers. 
B) Schematic representation of the complex rearrangement in MERTK. A deletion of a genomic region containing exon 15 is 
accompanied by a duplication and an inversion event. 
In two affected siblings from family W09-0047, only a single homozygous region was 
detected that harboured the PDE6A gene. A nonsense mutation (c.1675C>A; p.(Y558*)) 
was found to segregate with RP in this family, that is predicted to either result in premature 
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termination of the alpha subunit of the phosphodiesterase enzyme or to cause nonsense-
mediated decay of the PDE6A mRNA. 
Table 3. Pathogenicity predictions for missense and splice site mutations 
List of missense and splice site mutations identified in this study and predictions of their consequences with the 
use of freely available software. Splicing prediction shows the percent decrease in comparison to the original 
splice site scores. 
The largest homozygous region detected in the affected individual 50068 from family W09-
0048 contained the CRB1 gene and sequence analysis revealed a transition of cytosine to 
thymine, resulting in the substitution of a leucine for a proline residue (c.3914C>T; 
p.(P1305L)). This alteration was not detected in 149 ethnically matched control individuals 
and is predicted to be probably damaging by PolyPhen, although the SIFT software 
predicts it to be tolerated (Table 3). The proline residue that is substituted resides in one of 
the EGF-like calcium binding domains of CRB1 and neighbours one of the six core 
cysteine residues that are essential for the formation of disulphide bridges and proper 
structure of these domains22. The fact that the proline residue is highly conserved 
throughout vertebrate evolution and even in fruit fly (Figure 2A), suggests that this 
mutation is causative for arRP in family. 
Amino acid change prediction 
Family 
code 
Gene 
affected 
Mutation 
(DNA) 
Mutation 
consequence 
SIFT PolyPhen 
Grantham 
score 
Phylo
P 
W09-0048 CRB1 c.3914C>T p.(P1305L) tolerated 
probably 
damaging 
98 4.3 
W09-0046 EYS c.9082G>T p.(D3028Y) 
not 
tolerated 
probably 
damaging 
160 3.6 
W09-0041 NR2E3 c.1025T>G p.(V342G) 
not 
tolerated 
probably 
damaging 
109 0.6 
          
Splicing prediction 
Family 
code 
Gene 
affected 
Mutation 
(DNA) 
Mutation 
consequence 
Gene 
Splicer 
MaxEntScan NNSPLICE 
Splice
Site 
Finder
-like 
W09-0042 ABCA4 c.302+4A>C altered splicing 40% 24% 0.04% 12.3% 
W09-0045 MERTK c.2487-2A>G altered splicing 100% 100% 100% 100% 
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In two of the families (W09-0049 and W09-0050) genes residing in the largest 
homozygous regions (FAM161A, ABCA4, RPE65, USH2A and PRCD) were excluded. 
Four families (W09-0036, W09-0039, W09-0040 and W09-0044) had no significant 
homozygous regions. 
For the families with plausible X-linked inheritance we performed screening of the two 
known X-linked RP genes: RP2 and RPGR were sequenced, but no mutations were 
identified. 
Discussion 
In this study, we analysed the molecular genetic causes of RP in fourteen Indonesian 
families with an apparent recessive mode of inheritance, although especially in the simplex 
families, de novo mutations or an X-linked inheritance cannot be ruled out. 
In all 14 families, genome-wide homozygosity mapping was performed to find genomic 
regions potentially harbouring the causative genetic defect. In 10 of the 14 families, 
significant homozygous regions were detected in the affected individuals, ranging from 3.4 
to 69.5 Mb in size (Table 2). On average, European populations, which are mostly outbred, 
display a total of about 93 Mb of genomic runs of homozygosity (ROH) longer than 0.5 Mb, 
corresponding to ~3.5% of the genome23. Unfortunately, no such studies were conducted 
within the Indonesian population. In our small cohort, these average ROH in 16 individuals 
from 9 families without reported consanguinity (see Figure 1) comprised 146 Mb (~5,5%) 
of genomic DNA, which suggests a slightly higher level of inbreeding in this population. 
Consanguineous unions within the Indonesian culture are not uncommon. Moreover, 
Indonesia consists of a large archipelago of islands, 922 of which are inhabited, which 
further increases the possibility of marrying distant relatives. Hence, our data support the 
hypothesis that the Indonesian population is highly suited for a homozygosity mapping 
approach to determine genetic defects underlying recessive diseases. 
In 9 families, the homozygous regions contained one or more of the 31 known arRP 
genes. Sequence analysis of all these genes in the corresponding probands revealed 
potentially pathogenic mutations in seven families. A homozygous nonsense mutation in 
PDE6A, a canonical splice mutation in MERTK and a complex rearrangement in MERTK 
are three mutations that are undoubtedly pathogenic in the respective families. The 
causality of the novel three missense and one splice donor mutation is not obvious. The 
pathogenic effect of missense alterations may be difficult to interpret in the absence of 
suitable functional assays or animal models. However, due to the high degree of 
conservation of the mutated amino acid residues, their location within predicted functional 
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domains of the encoded proteins and the absence of these alleles in ethnically matched 
control individuals, the missense variants in CRB1, EYS and NR2E3 are considered to be 
the probable pathogenic mutation in the respective families. The splice alteration in ABCA4 
(c.302+4A>C) was also not detected in Indonesian controls and the strength of the splice 
donor site was predicted to be decreased by several splice site strength prediction 
programs. The fourth nucleotide of an intron in primates is an adenine in 71% of the cases, 
a guanine in 12% and a cytosine in only 8%24. Therefore, the strength of the splice donor 
site in ABCA4 may be reduced due to the A-to-C transition at that position. However, RT-
PCR analysis on patient-derived RNA is necessary to confirm pathogenicity of this variant 
in the respective family. 
The identification of genetic events underlying RP was previously clinically useful only in 
genetic counselling. However nowadays, with the successful development of gene therapy 
for retinal dystrophies, such as for Leber congenital amaurosis due to RPE65 mutations25-
27, molecular diagnosis is becoming of increasing importance to enrol patients in future 
clinical trials. Since RP is a progressive disease, early diagnosis is essential and the 
identification of causative alteration will be crucial in the near future to plan gene- or even 
mutation-tailored therapy. Homozygosity mapping has been demonstrated to be a powerful 
tool to detect recessive mutations underlying RP in Indonesian population. Based upon the 
criteria of the percentage of homozygous regions in an individual genome, which is about 
50% higher than in outbred European populations, SNP array analysis appears to be the 
most practical approach. Since we have identified the probable causative genetic defect in 
seven out of 14 arRP families using homozygosity mapping and excluded RPGR and RP2 
in families suggestive of X-linked inheritance, some of the other families might harbour a 
homozygous mutation in a novel arRP gene, in any of their homozygous regions. 
However, many of the genetically unsolved families are non-consanguineous and do not 
display large homozygous regions. Therefore, the majority of these families is likely to 
carry compound heterozygous mutations, either in one of the known arRP genes or in yet 
to be identified genes. Only next-generation sequencing approaches, either on predefined 
genomic regions28 or unbiased exome sequencing29,30 will allow a cost- and time-efficient 
analysis to discover the genetic causes underlying RP in the remaining families. 
Due to the extreme heterogeneity of arRP, it is not easy to predict the percentage of arRP 
cases that can be explained by mutations in the known arRP genes, although current 
estimates are around 50%. Being aware of the relatively small size of our cohort, but 
taking into consideration that some of the 14 tested arRP families may carry compound 
heterozygous mutations in known arRP genes or homozygous mutations in these genes in 
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homozygous regions smaller than 3 Mb, we can conclude that the known arRP genes 
appear to explain at least 50% of the underlying genetic defects. This conclusion will be 
strengthened upon the analysis of more families, both in the Indonesian and in other 
populations. 
Taken together, the results described in this study have helped to clarify the molecular 
genetic causes underlying recessive RP in Indonesia and as such will be beneficial in 
terms of genetic counselling, disease diagnosis and/or prognosis and in the future might 
even help to select patients eligible for genetic therapies to cease the progression of this 
disabling disease. 
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Abstract 
Purpose: The purpose of this study was to identify the underlying molecular genetic defect 
in an Indonesian family with three affected individuals who had received a diagnosis of 
retinitis pigmentosa (RP). 
Methods: Clinical evaluation of the family members included measuring visual acuity and 
fundoscopy and assessing visual field and colour vision. Genomic DNA of the three 
affected individuals was analysed with Illumina 700K single nucleotide polymorphism 
(SNP) arrays and homozygous regions were identified using PLINK software. Mutation 
analysis was performed by sequence analysis of the retinitis pigmentosa 1 (RP1) gene that 
resided in one of the homozygous regions. The frequency of the identified mutation in the 
Indonesian population was determined with TaqI restriction fragment length polymorphism 
analysis. 
Results: A novel homozygous nonsense mutation in exon 4 of the RP1 gene, c.1012C>T 
(p.(R338*)), was identified in the proband and her two affected sisters. Unaffected family 
members either carried two wild-type alleles or were heterozygous carriers of the mutation. 
The mutation was not present in 184 Indonesian control samples. 
Conclusions: Most of the previously reported RP1 mutations are inherited in an autosomal 
dominant mode and appear to cluster in exon 4. Here, we identified a novel homozygous 
p.(R338*) mutation in exon 4 of RP1 and speculate on the mutational mechanisms of 
different RP1 mutations underlying dominant and recessive RP. 
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Introduction 
Retinitis pigmentosa (RP, OMIM #268000) represents a clinically heterogeneous group of 
progressive inherited retinal disorders that primarily affect rod photoreceptor cells, followed 
by secondary cone photoreceptor cell degeneration1-3. RP is the most frequent cause of 
inherited blindness, affecting approximately 1 in 3,500 to 1 in 5,000 people worldwide. This 
disease is initially characterised by night blindness followed by visual field constriction that 
can ultimately lead to legal blindness at a later stage4. 
In addition to the clinical diversity of RP, the disease is genetically heterogeneous. RP can 
be inherited in an autosomal dominant (adRP, 30 to 40%), autosomal recessive (arRP, 
50% to 60%, with sporadic cases accounting for about 45% of all RP4) or X-linked (xlRP, 
5% to 20%)1,4 and rarely in a digenic manner3,5. At present, of 55 genes known to be 
mutated in individuals with RP, most display allelic heterogeneity and some have been 
implicated in both dominant and recessive modes of inheritance e.g., bestrophin 1 
(BEST1), neural retina leucine zipper (NRL), nuclear receptor subfamily 2, group E, 
member 3 (NR2E3), rhodopsin (RHO), retinitis pigmentosa 1 (RP1) and retinal pigment 
epithelium-specific protein 65 kDa (RPE65); RetNet (Retinal Information Network; provided 
in the public domain by the University of Texas Houston Health Science Center, Houston, 
TX). 
Mutations in the retinitis pigmentosa 1 gene (RP1, OMIM #603937) are thought to account 
for approximately 5.5% of adRP cases and only 1% of arRP cases, depending on the type 
and the position of the mutations6. To date, more than 50 disease-causing mutations in the 
RP1 gene have been identified. They are predominantly frameshift or nonsense mutations 
in individuals with dominant RP, clustered in a region spanning codons 500–1053 in exon 
46-24. Only a few reported cases of recessive RP1 mutations in exon 4 have been 
reported6,20,25-29, the majority of which is located very close to the 3’ end of exon 4. Here, 
we report an early truncating mutation in the 5’ part of exon 4 (c.1012C>T; p.(R338*)), 
which we found was homozygously present in an Indonesian family segregating arRP. A 
heterozygous carrier of this nonsense mutation did not display any clinical abnormalities 
characteristic of RP. Therefore, our findings suggest that this particular null allele of RP1 
causes recessive rather than dominant RP. 
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Methods 
Subjects 
An Indonesian family of Javanese origin with three affected individuals and two available 
unaffected relatives was included in this study (Figure 1). Affected family members were 
diagnosed by an ophthalmologist at the Dr. Kariadi Hospital in Semarang, Central Java, 
Indonesia. This study was approved by the ethical review boards of the centres involved. 
Informed consent adhering to the tenets of the Declaration of Helsinki was obtained from 
all participating affected individuals and unaffected family members. In addition, 184 
ethnically matched and unrelated control individuals took part in this 
study.
 
Figure 1. Pedigree structure and mutation analysis of the family 
A) In the family pedigree, affected individuals are indicated with filled symbols whereas unaffected relatives are indicated with 
open symbols. Genotypes are indicated below the pedigree symbols. M represents the c.1012C>T (p.(R338*)) substitution 
and + represents the wild-type allele. 
B) Shown are sequence chromatograms of RP1 corresponding to the three affected individuals (II:4, II:6, II:7), the proband’s 
father (I:1) and one unaffected sibling (II:2). The substituted nucleotides are indicated by arrows. 
Clinical characterisation 
The three affected individuals (II:4, II:6 and II:7) and two unaffected relatives (I:1 and II:2) 
underwent a detailed ophthalmologic examination that included evaluation of visual acuity 
measurement, fundoscopy and fundus photography after pupillary dilation. Colour vision 
was tested using Ishihara plates. The size and extent of the visual field defects were 
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assessed with a Humphrey Visual Field Analyzer (Carl Zeiss Meditec, Dublin, CA, USA). 
Fundus photographs were taken using a Visucam Pro NM (Carl Zeiss Meditec). 
Homozygosity mapping 
EDTA blood samples were obtained from all participants. Total genomic DNA was 
extracted from peripheral leukocytes using a standard salting out procedure30. DNA 
aliquots of each individual were stored at -20°C. Affected individuals were genotyped on 
Infinium Human OmniExpress 700K arrays (Illumina Inc., San Diego, CA, USA) containing 
approximately 700,000 single nucleotide polymorphisms (SNPs). Array experiments were 
performed according to the protocol provided by the manufacturer. Homozygous regions 
were determined using PLINK software31, with parameters manually set at a cut-off of 1 Mb 
and allowing two heterozygous SNPs and ten missing SNPs per window of 50 SNPs. 
Homozygous regions were ranked based on the size of the regions. The SNP positions 
were derived from the UCSC Human Genome Browser build NCBI36/hg18, March 2006. 
Mutation analysis 
Primers for RP1 were designed using Primer3 software32 and are listed in Table 1. All 
coding exons and exon-intron boundaries of the RP1 gene (NM_006269) were amplified 
with touch-down polymerase chain reaction (PCR) from 50 ng of genomic DNA. PCR 
reactions were performed in a volume of 25 µl containing 50 ng genomic DNA, 0.2 µM of 
each primer, 2 mM MgCl2, 1 mM deoxyribonucleotide triphosphates, PCR buffer provided 
by the manufacturer and 0.5 U Taq polymerase (Invitrogen, Breda, The Netherlands). 
PCR products were purified on NucleoSpin Plasmid QuickPure columns (Macherey-Nagel 
GmbH & Co, Duren, Germany) and analysed either in the sense or antisense direction 
using dye termination chemistry (BigDye Terminator Cycle Sequencing Kit version 3.1, on 
a 3130 DNA automated sequencer; Applied Biosystems, Foster City, CA, USA). 
Segregation analysis of the RP1 mutation identified in the family was performed with 
sequence analysis. The frequency of this mutation in 184 unrelated and unaffected 
ethnically matched Indonesian controls was assessed by digesting PCR products with 
TaqI (New England Biolabs, Ipswich, MA, USA), the recognition site of which is abolished 
by the alteration in RP1. 
Results and discussion 
All three affected individuals (II:4, II:6 and II:7) presented with night blindness that started 
at an early age. They displayed gradual constriction of their visual field and low visual 
acuity. Fundus examination revealed typical RP including the bone spicule-like pigment
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Table 1. Primer sequences for the amplification of the RP1 gene 
Primer Sequence 
Product size  
(base pairs) 
RP1 exon1 F CCATGTATTCGCTATGGTGC 
421 
RP1 exon1 R TGTCCAGGTCTACAGGCTGC 
RP1 exon2 F GGCAGGCACAGCATCAC 
434 
RP1 exon2 R CACCATTCATATCCCACACG 
RP1 exon3 F TTCAAGCCTAGGAGGTTGTTG 
357 
RP1 exon3 R ATTGAAGCATGGATTTTGCC 
RP1 exon4_1 F GATATTTCTAACTTCTCTGCCTTCC 
595 
RP1 exon4_1 R CCCTGGATGATATCTGTGTCC 
RP1 exon4_2 F ATCAAGAGGGCAGTTTGGC 
592 
RP1 exon4_2 R TTGAAGTTCTTGATACCAGTTTTG 
RP1 exon4_3 F TCACATAATAATGGTTTGCCATC 
599 
RP1 exon4_3 R TTTCTATGGAAATTCTTGGAAATC 
RP1 exon4_4 F TCCCCTTAAAGGAGGGATAC 
580 
RP1 exon4_4 R AATTGAATGATGAGCAATAGCC 
RP1 exon4_5 F GAATGGCAAAGAAGAGTTTAGTTTC 
739 
RP1 exon4_5 R ACTGAAGCTTGCAATTGGTG 
RP1 exon4_6 F GCTTATTTGGTTCCCCTGC 
678 
RP1 exon4_6 R AGAGCAACCTCCATCCAAAG 
RP1 exon4_7 F ACTTGAAAGCTGCTGTTGCC 
659 
RP1 exon4_7 R GCTTAAATTACTGACATTTTGATGTG 
RP1 exon4_8 F CAATGTCTGCAATACCATTGAC 
658 
RP1 exon4_8 R TCCTTCATTGGTCTCCTTTTC 
RP1 exon4_9 F TTAATCCAAGAAGAGGTAGAGGC 
616 
RP1 exon4_9 R CCTGGAATTCCTGCAACATAG 
RP1 exon4_10 F TGGAATTTCAGTGTTCCAGG 
592 
RP1 exon4_10 R TGATGACTACCCTTCTCCTCTG 
RP1 exon4_11 F CATGGTAGTGACTCAGAACCTTTTC 
590 
RP1 exon4_11 R CCTTCTTCCTCTAACCCCAAG 
RP1 exon4_12 F GATAATGCCATTGGTGATATATTTG 
600 
RP1 exon4_12 R CGTATTCGTCACATGTGCTTC 
 
A nonsense mutation in RP1 causes arRP 
97 
 
Figure 2. Fundus photographs of affected individuals 
Fundus photographs of the right eye from affected individual II:4 (A), affected individual II:6 (B), affected individual II:7 (C) 
and the unaffected father I:1 (D) who carries the mutation heterozygously. The ages at the time of investigation of individuals 
II:4, II:6 and II:7 were 36, 28 and 26, respectively. Fundus examination of the affected individuals revealed typical features of 
retinitis pigmentosa, bone spicule-like pigmentations were found in the mid periphery of retina (indicated with arrows) and 
retinal vessels were attenuated (arrowheads). 
deposits in the mid-peripheral retina and narrowing of the retinal vessels (Figure 2). The 
unaffected sibling (II:2) did not experience night blindness or any other symptoms of RP. 
Apart from slightly decreased visual acuity, which is probably age-related, the proband’s 
father (I:1) did not display any ophthalmological symptoms either. The clinical data for all 
participating individuals are summarised in Table 2. 
Genome-wide SNP array analysis revealed four homozygous regions larger than 1 Mb that 
were shared among the three affected siblings (Table 3). Whereas no obvious candidate 
genes resided in the three largest homozygous regions, the fourth largest homozygous 
region (1.3 Mb, on chromosome 8q12.1) encompassed RP1. 
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Sequence analysis of RP1 revealed a novel homozygous substitution (c.1012C>T) in the 
proximal portion of exon 4, replacing an arginine residue at position 338 with a stop codon 
(p.(R338*)). Sequence chromatograms and segregation analysis of the RP1 mutation are 
shown in Figure 1. This nonsense alteration was not present in the unaffected sibling and 
was identified heterozygously in the unaffected father, who did not show any symptoms of 
RP. To rule out the possibility that the second allele (inherited from the mother) harbours a 
deletion of RP1 responsible for the loss of heterozygosity, we employed copy number 
analysis of our genome-wide SNP data and did not find any abnormalities in this genomic 
region. The mutation was not detected in 184 ethnically matched and unrelated Indonesian 
control subjects. 
Table 2. Clinical characteristics of participating family members 
Person 
Current 
age (y) 
Gender 
Age of 
onset (y) 
Visual acuity 
Fundus appearance 
OD OS 
II:4 37 F 8 LP+ LP+ AA, BSP, POD 
II:6 29 F 9 1/300 1/300 AA, BSP, POD 
II:7 27 F 11 1/300 2/60 AA, BSP 
I:1 64 M NA 20/40 20/25 Normal 
II:2 42 M NA 20/15 20/20 Normal 
 
Clinical characteristics of affected family members carrying two RP1 variants and non-affected family members 
carrying one RP1 variant or two wild-type alleles. AA: attenuated arterioles; BSP: bone spicule pigmentation; F: 
female; LP+: light perception; M: male; NA: not affected; OD: oculus dexter, right eye; OS: oculus sinister, left 
eye; POD: pale optic disc. 
The RP1 gene consists of four exons and gives rise to a transcript of approximately 7.1 kb 
encoding a protein of 2,156 amino acids. The RP1 protein is localised in the region of the 
connecting cilium and axoneme of photoreceptor sensory cilia7. RP1 is a photoreceptor-
specific microtubule-associated protein that regulates the length and stability of the 
photoreceptor axoneme mediated by the two putative doublecortin domains at the N-
terminus of RP133. The doublecortin domain is essential for the correct localisation and 
proper stacking of outer segment discs34-36. Moreover, a region of the RP1 protein between 
codons 486 and 635 bears some homology to the Drosophila melanogaster bifocal protein 
that is required for normal photoreceptor morphogenesis in the fruit fly7. 
The many mutations in exon 4 of RP1, which cause autosomal dominant RP, all tend to 
cluster in a “hot spot” region between amino acid residues 500 and 1053 (Figure 3)6-24. 
Since these mutations are expected to be insensitive to nonsense-mediated decay due to  
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Table 3. Overview of homozygous regions shared between the three affected individuals. 
Shown are all homozygous regions shared by three affected siblings and larger than 1 Mb. Flanking SNPs and 
their physical positions correspond to the hg18 NCBI genome assembly. The fourth largest homozygous region 
harbours RP1. 
the absence of a downstream intron, they result in the production of truncated proteins33. 
Previously, mutant RP1 mRNA was found to be present in a human lymphoblast cell line 
carrying the p.(R677*) variant, providing evidence that this mRNA indeed escapes the 
nonsense-mediated mRNA decay process35. The resulting truncated proteins lack 
important functional domains, but are still able to interact with wild-type RP1 and/or 
microtubule-associated proteins. This hypothesis is supported by a previous study which 
showed that in Rp1-myc mice, that expressed only the 661 N-terminal amino acids of RP1, 
truncated proteins are produced and localise correctly to the axonemes of photoreceptor 
cells36. Due to the retained ability to interact with microtubule-associated proteins and/or 
wild-type RP1, these mutated proteins are thought to abolish the function of the normal 
RP1 molecules in a dominant-negative fashion. 
For RP1 mutations that cause recessive RP, the story is more complex. These mutations 
can be clustered in four different groups (Figure 3). First, protein-truncating mutations that 
reside in exon 2 or exon 3 are expected to undergo nonsense-mediated decay and 
therefore can be considered true loss-of-function alleles26,28,29. The second group consists  
of missense mutations that appear not to cluster25,28. These changes cause autosomal 
recessive RP because the produced proteins retain residual function and therefore are not 
pathogenic when present in the heterozygous state. The third group includes protein-
truncating mutations near the 3’ end of the gene6,20,26,27. Most likely, the resulting proteins 
display only a minor loss of their C-terminal portion, preserving the majority of functional 
domains and also have residual activity. Therefore, these variants are also pathogenic only 
when present homozygously. Finally, the most interesting group of mutations 
encompasses the few nonsense changes located in the proximal part of exon 420,26 and  
 
Chr 
Start 
position 
(hg 18) 
End 
position 
(hg 18) 
SNP 1 SNP 2 
Size 
(Mb) 
Rank 
Known 
arRP gene 
in the 
region 
Mutation 
(DNA) 
Mutation 
(protein) 
16 77.098.649 80.083.138 rs8056971 rs12445748 3 1    
8 50.357.738 52.191.973 rs17664823 rs10090890 2 2    
16 65.737.699 67.289.958 rs11643507 rs1886699 1.5 3    
8 55.432.038 56.765.392 rs7827900 rs7011147 1.3 4 RP1 c.1012C>T p.(R338*) 
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includes the mutation identified in this study. Since the mRNAs deriving from these alleles 
are expected to escape nonsense-mediated mRNA decay, truncated RP1 proteins are 
likely to be produced. However, unlike the adRP-causing proteins, the truncated RP1 
proteins apparently lack some domains that are crucial for the interactions with wild-type 
RP1 or microtubule-associated proteins and therefore no dominant-negative effect 
emerges. This is supported by the absence of clinical symptoms in the father, who carried 
the p.(R338*) mutation heterozygously. 
Taken together, the results of our study indicate that early protein-truncating mutations in 
RP1, including p.(R338*), cause autosomal recessive RP, supporting the idea that 
haploinsufficiency is probably not causative for autosomal dominant RP. A better 
understanding of the pathophysiology of RP1 mutations may ultimately lead to an 
improved prognosis and provide new tools for therapeutic interventions. 
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Abstract 
A fundamental challenge in analysing exome-sequence data is distinguishing pathogenic 
mutations from background polymorphisms. To address this problem in the context of a 
genetically heterogeneous disease, retinitis pigmentosa (RP), we devised a candidate-
gene prioritisation strategy called cis-regulatory mapping that utilises ChIP-seq data for the 
photoreceptor transcription factor CRX to rank candidate genes. Exome sequencing 
combined with this approach identified a homozygous nonsense mutation in male germ 
cell-associated kinase (MAK) in the single affected member of a consanguineous Turkish 
family with RP. MAK encodes a cilium-associated mitogen-activated protein kinase whose 
function is conserved from the ciliated alga, Chlamydomonas reinhardtii, to humans. 
Mutations in MAK orthologues in mice and other model organisms result in abnormally 
long cilia and, in mice, rapid photoreceptor degeneration. Subsequent sequence analyses 
of additional individuals with RP identified five probands with missense mutations in MAK. 
Two of these mutations alter amino acids that are conserved in all known kinases and an 
in vitro kinase assay indicates that these mutations result in a loss of kinase activity. Thus, 
kinase activity appears to be critical for MAK function in humans. This study highlights a 
previously underappreciated role for CRX as a direct transcriptional regulator of ciliary 
genes in photoreceptors. In addition, it demonstrates the effectiveness of CRX-based cis-
regulatory mapping in prioritising candidate genes from exome data and suggests that this 
strategy should be generally applicable to a range of retinal diseases. 
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Introduction 
Next-generation sequencing is currently revolutionising Mendelian disease analysis1. It is 
now possible to identify causative mutations in Mendelian disorders via whole genome 
exon (exome) sequencing of affected individuals2-5. Yet, given that every human genome 
contains thousands of codon-altering sequence variants, the fundamental challenge in 
analysing exome data is identifying the causal mutation amidst a sea of benign 
polymorphisms1. A first step in sifting through exome-sequence variants is removing those 
that represent known polymorphisms in the human population. If a disease is thought to be 
genetically homogeneous, the candidate list can then be further reduced by intersecting 
exome-sequencing data from multiple affected individuals and different families. In 
diseases that are genetically heterogeneous, however, this latter filter cannot be applied 
and thus there is a need for additional approaches to candidate-gene prioritisation. 
Retinal degenerations (RDs) represent a genetically heterogeneous group of inherited 
diseases that affect millions of people worldwide6-8. Identifying the disease-causing 
mutation in these individuals is a prerequisite for proper genetic counselling and for the 
selection of subjects for novel gene-specific therapies. Mutations in over 200 genes have 
been implicated in RDs and this makes it one of the most genetically heterogeneous 
families of disease (see RetNet under Links to databases). Despite this growing 
knowledge base, sequencing of genes known to be mutated in RDs locates the causative 
mutation in only about half of all individuals with RDs7. Thus, there is a pressing need for 
new approaches that will accelerate the discovery of additional genes involved in this 
disease. 
Here, we present a general approach to prioritising retinal-disease gene candidates; we 
call this approach “cis-regulatory mapping”. The strategy is based on the findings of a 
recent study in which we used chromatin immunoprecipitation followed by massively 
parallel sequencing (ChIP-seq) to identify binding sites for the transcription factor CRX 
(OMIM #602225) across the mouse genome9. CRX is a key photoreceptor transcription 
factor required for the expression of many rod and cone genes, including the majority of 
genes known to be mutated in RDs10-13. CRX directly regulates photoreceptor genes by 
binding to ~10,000 cis-regulatory regions referred to as CRX-bound regions (CBRs)9. 
Because the majority of genes involved in RDs are preferentially expressed in 
photoreceptors9,11,14, we reasoned that clustering of CBRs could be used to pinpoint genes 
with mutations causing RDs within lists of candidate genes. 
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We applied the combined strategy of exome sequencing and prioritisation of candidate 
genes by CBR clustering to a Turkish subject with retinitis pigmentosa (RP) who is the only 
affected member of a consanguineous family. This analysis resulted in the identification of 
a homozygous nonsense mutation in male germ cell-associated kinase (MAK; OMIM 
#154235). We subsequently screened Dutch and Israeli subjects with RP and found five 
additional missense mutations affecting critical residues of this protein. MAK encodes a 
highly conserved mitogen-activated protein (MAP) kinase that regulates ciliary length in a 
wide range of species15-17. In addition, it has recently been shown that Mak mutations in 
mice cause rapid photoreceptor degeneration17. This study demonstrates the utility of 
CRX-based cis-regulatory mapping as an approach for prioritising candidate genes from 
whole-exome data in individuals with RDs. 
Subjects and methods 
cis-regulatory mapping 
CRX ChIP-seq data were generated from 8-week-old mouse retinae as previously 
described9. We used the UCSC Genome Browser liftover tool to map mouse CBRs onto 
the human genome18. CBRs were then assigned to individual genes as previously 
described9. CBRs were assigned to a total of 21,515 and 21,912 RefSeq genes in humans 
and mice, respectively (Supplementary table 1). This same procedure was repeated for 
CRX ChIP-seq data generated from 8-week-old Nrl-/- mouse retinae9. Lists of candidate 
genes derived from defined genomic regions or exome-sequencing datasets were 
numerically ranked according to their raw read counts as given in Supplementary table 1. 
Families and DNA extraction 
The tenets of the Declaration of Helsinki were followed and informed consent was obtained 
prior to donation of a blood sample from all individuals who participated in this study. Blood 
samples for DNA analysis were obtained from affected and unaffected family members. 
Genomic DNA was extracted from peripheral blood samples with the FlexiGene DNA kit 
(Qiagen, Venlo, the Netherlands) or with a standard salting-out procedure19. The ethical 
review boards of Radboud University Nijmegen Medical Centre, Hacettepe University and 
Hadassah-Hebrew University Medical Center approved this study. 
Clinical evaluation 
Ophthalmic examinations, including electroretinography (ERG) according to International 
Society for Clinical Electrophysiology of Vision (ISCEV) standards and fundus 
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photography, were performed for all affected individuals. Goldmann perimetry was 
performed in seven of the eight affected individuals. 
Exome sequencing and analysis 
Five micrograms of high-quality genomic DNA from subject RP-2011 was prepared for 
sequencing with an Illumina Paired- End Sample Preparation kit (Illumina Inc., San Diego, 
CA, USA) according to manufacturer’s instructions. Coding exons were captured from the 
resultant sample with the Agilent SureSelect Human All Exon kit (Agilent Technologies, 
Santa Clara, CA, USA) according to manufacturer’s instructions. Cluster generation was 
performed with the Paired-End Cluster Generation kit (v2) and the Illumina Cluster Station. 
A paired-end, 75 bp run was performed on an Illumina Genome Analyzer IIx. Images were 
analysed with the standard Illumina Pipeline (version 1.4) and a total of 4.5 billion bases of 
sequence were obtained. Sequences were aligned with the human genome reference 
sequence (build hg18) and variant calls were made and annotated according to the dbSNP 
database (build 129). A total of 52 putative homozygous nucleotide changes not present in 
the dbSNP database were identified in 38 genes (Supplementary table 2). These genes 
were ranked according to CRX-binding scores and the top five candidate genes were 
further evaluated by direct sequence analysis. 
Homozygosity mapping and mutation analysis 
Whole-genome SNP analysis was performed on subject RP-2011, her parents and her 
siblings with the Affymetrix GeneChip Mapping 250k array set (Affymetrix, Santa Clara, 
CA, USA). Homozygous regions were calculated with Affymetrix GTYPE software and the 
VIGENOS (Visual Genome Studio) Program (Hemosoft Inc., Ankara, Turkey). In addition, 
whole-genome SNP analysis was performed on 334 subjects of Dutch, Italian, Israeli and 
Palestinian origin with the Illumina 6k or the Affymetrix 10k, 250k, 5.0 or 6.0 SNP arrays 
(SNP analysis of Dutch subjects was reported previously20). Homozygous regions were 
calculated with Partek software (Partek Incorporated, St. Louis, MO, USA) or PLINK 
software21. Primers for PCR amplification of the 15 exons and exon-intron boundaries of 
MAK (including the retina-enriched alternative exon 13) were designed with Primer 3 
software (Supplementary table 3). PCR was performed with 50 ng of genomic DNA in 25 
ml reactions for 35 cycles. PCR fragments were purified with 96-well PCR filter plates 
(Millipore, Billerica, MA, USA) and mutation analysis was performed by direct sequencing 
of purified PCR products. 
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Animal studies 
Adult CD1 mice were housed at Washington University in St. Louis (St. Louis, MO, USA), 
in an air-conditioned environment on a 12 hr light-dark cycle at 22⁰C and had free access 
to water and food. All animal studies were conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals and the Animal Welfare Act and were approved by 
the Washington University in St. Louis institutional animal care and use committee 
(approval number 20110089). 
CBR-reporter fusion constructs 
Three CBRs identified around the MAK locus were obtained by PCR from human genomic 
DNA with the primer pairs indicated in Supplementary table 3. The resultant PCR products 
were cloned into the Rho-basal DsRed reporter vector with the restriction enzyme sites 
underlined in the primer (Supplementary table 3)13. Retinal electroporation and explant 
cultures were performed exactly as described previously13. 
MAK expression constructs 
Human retinal cDNA was generated from total human retinal RNA with SuperScript II 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) per the manufacturer’s instructions. 
The retinal isoform of MAK was generated by PCR with primers shown in Supplementary 
table 3. A Kozak consensus site (upper case letters in Supplementary table 3) was added 
to the 50 primer. The resultant PCR product was digested with SacII and NotI, (underlined 
in primers in Supplementary table 3) and cloned into an intermediate cloning vector. We 
determined by sequencing that the clone was free of mutations and contained the retina-
enriched exon 13. MAK mutations were generated by site directed mutagenesis with the 
Quik-Change II kit (Stratagene, Cedar Creek, TX, USA) according to the manufacturer’s 
instructions. Wild-type and mutant forms of the MAK expression construct were then 
cloned in frame with the C-terminal Myc/his tag in pcDNA3.1(þ)Myc/his A vector 
(Invitrogen). 
In vitro kinase assay 
MAK-WT-Myc/his, MAK-mut-Myc/his or empty vector was transfected into HEK293 (PlatE) 
cells with TransIT-LT1 transfection reagent (Mirus Bio LLC, Madison, WI, USA). Forty-
eight hours after transfection the cells were washed twice with cold PBS and lysed on plate 
in modified RIPA buffer (150 mM NaCl, 50 mM Tris (pH 7.4), 1% NP-40, 0.25% sodium 
deoxycholate, 1 mM EDTA). Expression of MAK was confirmed via immunoblot analysis 
with 40 mg of total protein from the immunoprecipitation input lysate. Proteins were run on 
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a 4-12% Bis-Tris gel (Invitrogen) and transferred to a Protran nitrocellulose membrane 
(Sigma, St. Louis, MO, USA). The membranes were blocked for 1 hour at room 
temperature with 5% nonfat dry milk in TBST (Tris-buffered saline with 0.1% Tween 20), 
incubated with 1:500 dilution of mouse monoclonal c-Myc (9E10) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) in TBST with 5% nonfat dry milk followed by 1:5000 
dilution of ImmunoPure Goat anti-Mouse HRP (Thermo Scientific Pierce Protein Research 
Products, Rockford, IL, USA) and signal was detected on Classic Blue autoradiography 
film (Molecular Technologies, St. Louis, MO, USA) via chemiluminescence with Immun-
Star WesternC (Bio-Rad Hercules, CA, USA) following the manufacturer’s instructions. 
For the kinase assay, cleared lysate was rotated with anti-c-Myc Agarose beads (Sigma, 
St. Louis, MO, USA) for 3 hrs at 4⁰C. Beads were washed 4 times with RIPA buffer and 
then twice in kinase equilibration buffer (20 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM 
DTT). Beads were resuspended in 20 ml of kinase assay buffer (20 mM HEPES (pH 7.5), 
10 mM MgCl2, 1 mM DTT, 10 mM MnCl2, 2 mg/ml leupeptin, 10 mM ATP, 2 mg myelin 
basic protein (Active Motif, Carlsbad, CA, USA) and 2 µCi ATP-g 32P) and incubated for 30 
min at 30⁰C. Reactions were terminated with 53 SDS PAGE buffer and run on a 15% SDS-
PAGE gel. The dried gels were exposed to a Phosphorimager screen overnight and 
scanned with a Typhoon Phosphorimager (GE Healthcare, Piscataway, NJ, USA). 
Quantitation of scans was performed with ImageJ software. 
Analysis of MAK isoforms 
We used Trizol (Invitrogen) or Paxgene Blood RNA kit (Qiagen) to isolate RNA from fresh 
human retina and testis according to the manufacturer’s instructions. We used SuperScript 
II reverse transcriptase (Invitrogen) or iScript cDNA Synthesis kit (BioRad) to generate 
cDNA per the manufacturer’s instructions and PCR primers that span the 75 bp alternative 
exon to amplify MAK transcripts from retinal and testis cDNA (Supplementary table 3). 
Bioinformatic analysis of ciliary-gene regulation by CRX 
A list of 200 phylogenetically conserved ciliary genes with RefSeq identifiers was obtained 
from Supplementary table 8 of a recent study of the mouse photoreceptor sensory cilium 
complex22 and was compared with the genes listed in Supplementary table 1 of the 
present study. All ciliary genes that had assigned CBRs in either the wild-type or Nrl-/- 
datasets were defined as CBR-associated. 
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Results 
CRX-based cis-regulatory mapping of retinal-disease genes 
The majority of genes known to be involved in RDs show photoreceptor-enriched 
expression9,11,14; thus we hypothesised that the genome-wide pattern of binding of CRX, a 
global transcriptional regulator of photoreceptor genes, could be used to pinpoint novel 
genes that, when mutated, cause RDs. We previously discovered that CBRs cluster 
around known photoreceptor genes in the mouse9. To determine whether this is also true 
in humans, we used the UCSC Genome Browser liftover tool to map 10,212 mouse CBRs 
onto the human genome. We found that ~80% (8,214/10,212) of mouse CBRs mapped 
successfully to the human genome. We assigned CBRs to individual genes across the 
human genome on the basis of proximity and found that they tightly cluster around 
photoreceptor genes (Supplementary table 1). 
Next, we determined whether these assignments could be used to identify retinal-disease 
genes within defined genomic intervals. As a test case, we attempted to rediscover 
rhodopsin (RHO; OMIM #180380) because mutations in this gene are known to cause 
RP23,24. We analysed a 51 gene region around RHO (including 25 on either side of RHO; 
Figure 1A).  
Figure 1. cis-regulatory mapping at the RHO locus 
(A) The genomic interval including 25 genes on either side of the human RHO locus (pink oval) spans 4.8 Mb. 
(B) There are eight CBRs in the immediate vicinity of the RHO locus that were assigned to nearby genes as indicated by the 
arrows. The number of raw sequence reads corresponding to each of the CBRs is shown. 
(C) The 51 genes shown in (A) were ranked according to the number of raw sequence reads assigned to them. The RHO 
locus (green arrow), which was assigned a total of 579 raw sequence reads, ranked number one out of all 51 genes in this 
interval. Only the ten highest ranking genes are shown. Portions of the images in (A) and (B) are adapted from the UCSC 
Genome Browser25. 
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The CBR assignments in the immediate vicinity of RHO are shown in Figure 1B. The 
number of raw sequence reads at a given CBR reflects the extent of CRX binding at that 
CBR. Thus, by tallying the number of raw sequence reads assigned to each of the 51 
genes in this region, we can derive a ranked list of genes that reflects how heavily they are 
bound by CRX. With this approach, RHO is ranked as the number one retinal-disease 
gene candidate within this genomic region (Figure 1C). 
Next, we attempted to use this approach to rediscover the 33 additional genes known to be 
mutated in autosomal-recessive RP. As was done with RHO, we created ranked lists of 
candidate genes for a 51 gene region around each locus. We found that in 62% of cases 
(21/34, including RHO), the gene known to be mutated in autosomal-recessive RP ranked 
among the top three candidates (Supplementary figure 1A). 
 
Supplementary figure 1. Candidate gene prioritisation at 34 autosomal recessive retinitis pigmentosa loci. 
(A) The genomic intervals around each of 34 previously characterised autosomal recessive RP loci were analysed as was 
shown for RHO. 
(B) Twelve of the genes analysed had no assigned CBRs and were therefore unranked. Six of those 12 are either RPE-
specific or are expressed in RPE and Müller glia (highlighted in blue). 
In addition, more than one-third (12/34) of the genes mutated in RP were ranked as the 
number one candidate within their corresponding region. An additional gene (DHDDS; 
OMIM #608172) was ranked fifth in its interval. Overall, the cis-regulatory mapping 
approach successfully prioritised the gene known to be mutated in RP in nearly two-thirds 
of cases. 
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In 12 cases, CRX-based cis-regulatory mapping failed to rank the known gene highly. The 
reason for this becomes apparent upon inspection of the expression pattern of these 
genes. Half of the genes (6/12) are expressed in retinal pigment epithelium (RPE) and not 
in photoreceptors (Supplementary figure 1B). Thus, these genes would not be predicted to 
be regulatory targets of CRX in the mouse. Another gene that was not assigned any CBRs 
was EYS (OMIM #612424). In this case, the approach failed because the mouse genome 
does not contain an orthologue of EYS and thus no CBRs were found in its vicinity. 
This same approach can also be extended to other categories of retinal disease. We found 
comparable rates of success upon reanalysing known loci implicated in autosomal-
dominant RP, autosomal-recessive Leber congenital amaurosis and autosomal-dominant 
cone-rod dystrophy (data not shown). In contrast, this approach was less successful at 
predicting the genes mutated in achromatopsia, which tend to be cone-specific26. Given 
that the Crx ChIP-seq dataset we used derives from wild-type retinae and most of the raw 
sequence reads therefore derive from rods9, this failure is understandable. To address this 
issue, we performed cis-regulatory mapping by using Crx ChIP-seq data derived from Nrl-/- 
retinae that represent an enriched source of cones9,27-29 (Supplementary table 1). When we 
applied this approach to the known achromatopsia (ACHM) loci, we found that three of the 
four genes known to be mutated in autosomal-recessive ACHM were predicted as the 
number one candidate within a 51 gene interval (data not shown). 
Mutations in the ciliary gene MAK cause autosomal-recessive RP 
To determine whether CRX-based cis-regulatory mapping could help to identify causative 
genes within exome datasets, we analysed exome-sequence data from an individual with 
RP after first excluding mutations in genes known to be implicated in this disease. This 
Turkish individual, whose parents were first cousins, is the only affected member of her 
family (IV:1 in Figure 2A). We identified sequence variants in the subject’s exome data and 
removed all variants found in the dbSNP database (build 129), which left a total of 38 
genes with putative homozygous or compound heterozygous mutations (Supplementary 
table 2). We then ranked these 38 genes by using CRX-based cis-regulatory mapping 
(Figure 2B and Supplementary table 2). The top five candidate mutations were tested by 
Sanger sequencing, which confirmed homozygous variants in SGIP1 (OMIM #611540), 
MAK and FRYL in the subject. The variants identified in USH2A (OMIM #608400) and 
CTBP2 (OMIM #602619) were not confirmed. The exons containing the variants in SGIP1, 
MAK and FRYL were then sequenced in the subject’s parents and siblings. The variant in 
SGIP1 did not segregate with the disease and was therefore excluded from the analysis. 
The variants in FRYL and MAK both segregated with the disease phenotype. 
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Homozygosity mapping performed on the subject identified nine regions of identity-by-
descent totalling ~48 Mb of genomic DNA (data not shown). FRYL and MAK fall within the 
first and fourth largest identical-by-descent regions, respectively. The amino acid change 
in FRYL (RefSeq NM-015030.1; c.2668C>T (p.(P890S)) is predicted to be non-pathogenic 
by two prediction programs (SIFT: tolerated, score 0.28; Polyphen2: benign, score 0.015). 
Given that the mutation in MAK (RefSeq NM-001242957.1; c.718C>T (p.(Q240*)) resulted 
in a premature stop codon predicted to truncate more than half of the protein, we focused 
our subsequent analysis on this candidate. Both of the subject’s parents and her four 
healthy siblings were all heterozygous carriers of the mutation, which was not identified in 
130 healthy Turkish control individuals (Figure 2A). Three CBRs were identified around the 
MAK locus: MAK-CBR1, which partly overlapped the first non-coding exon of MAK and 
MAK-CBR2 and 3, which are located within the first intron (Figure 2C). We tested the cis-
regulatory activity of these three human CBRs by electroporating individual CBR-reporter 
fusion constructs into newborn mouse retinae. Whereas MAK-CBR1 and 2 did not drive 
any expression by themselves (data not shown), MAK-CBR3 drove strong, photoreceptor-
specific expression within the retina (Figure 2D). These findings suggest that MAK-CBR3 
represents a bona fide cis-regulatory region for MAK and that CRX is a direct 
transcriptional regulator of this gene. Previous studies have shown that about half of CBRs 
demonstrate autonomous photoreceptor- specific cis-regulatory activity in this assay13. In 
addition, many of the non-functioning CBRs can act as potent enhancers or repressors 
when placed next to an adjacent CBR9. We therefore tested MAK-CBR1 and 2 for 
enhancer activity by cloning them upstream of a Rho promoter shown previously to drive 
rod-specific expression9. This assay revealed a strong enhancement of reporter 
transcription relative to the Rho promoter alone, indicating that MAK-CBR1 and 2 do 
indeed possess potent enhancer activity (data not shown). 
Next, we screened for MAK mutations in additional individuals with RP. Whole-genome 
SNP analysis of 334 isolated or autosomal-recessive RP subjects of Dutch, Italian, Israeli 
and Palestinian origins revealed 11 RP probands with a large homozygous region 
encompassing MAK (Supplementary table 4). Mutation analysis of MAK revealed 
homozygous missense mutations in three of these probands: c.37G>A (p.(G13S)) in 
subject 027775 (II:3 in Supplementary figure 2), c.388A>C (p.(D130H)) in subject 009539 
(II:5 in Supplementary figure 2) and c.497G>A (p.(R166H)) in subject MOL0708-1 (II:4 in 
Supplementary figure 2) (Table 1). The p.(R166H) mutation segregates with the disease in 
the family of subject MOL0708-1 (which is of oriental Jewish origin): two affected siblings 
are homozygous for the mutation, whereas one unaffected sibling is heterozygous and two 
unaffected siblings do not carry the mutation (Supplementary figure 2). The p.(R166H) 
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Figure 2. cis-regulatory mapping identifies MAK as a cause of retinitis pigmentosa 
(A) The family tree of the Turkish subject with RP. 
(B) The 38 genes with putative homozygous mutations in the exome-sequence dataset were ranked according to their 
number of raw sequence reads. MAK (green arrow) ranked fourth. Only the ten highest ranking genes are shown. 
(C) CBRs in the vicinity of the MAK locus. 
(D) A PCR product encompassing MAK-CBR3 was cloned into a DsRed reporter vector and co-electroporated along with a 
ubiquitously expressing CAG-eGFP loading control into explanted P0 mouse retinae. The retinae were grown for 8 days and 
then imaged in both red and green channels in flat-mount and as cross-sections. MAK-CBR3 drives strong, photoreceptor-
specific expression restricted to the outer nuclear layer. The following abbreviations are used: ONL, outer nuclear layer; INL, 
inner nuclear layer; GCL, ganglion cell layer. 
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Supplementary figure 2. Additional pedigrees with MAK mutations. 
mutation was identified in the heterozygous state in one out of 217 oriental Jewish 
controls. The p.(G13S) and p.(D130H) mutations were not identified in 163 Dutch control 
individuals. In addition, we screened 93 Dutch isolated or autosomal-recessive RP 
subjects for mutations in all coding exons and splice junctions of MAK by direct 
sequencing. In the majority of these individuals, mutations in genes previously implicated 
in RP had already been excluded. This analysis identified compound heterozygous 
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missense mutations in subject 038230 (II:3 in Supplementary figure 2): c.79G>C 
(p.(G27R)) and c.542T>C (p.(I181T) (Table 1). Segregation analysis within this family 
revealed that the sister of this individual carries both of the mutations. The disease status 
of this individual must be determined through clinical tests. Heterozygous changes were 
detected in two RP subjects: c.79G>A (p.(G27R)) was detected in subject 012115 (II:1 in 
Supplementary figure 2) and c.974C>T (p.(P325L)) in subject 050135 (data not shown). 
Although no second pathogenic allele was found in individual 012115 on the genomic DNA 
level, RNA analysis of peripheral blood revealed the presence of a hemizygous c.79G>A 
(p.(G27R)) mutation, indicating the lack of an RNA product from the second allele. The 
p.(P325L) variant in subject 050135 was not detected in the subject’s affected sibling, 
suggesting that it is not pathogenic, when assuming an autosomal-recessive mode of 
inheritance. None of the missense variants (p.(G27R), p.(I181T) and p.(P325L)) were 
detected in 163 Dutch control individuals. 
The clinical findings for individuals carrying MAK mutations are presented in Table 1. The 
age at diagnosis in three of eight subjects was in the third decade of life and in the 
remaining five subjects in the fourth through sixth decades of life. In retrospect, however, 
retinal dysfunction had been present at an earlier age in at least one subject (038230). 
Visual acuity was relatively preserved in the subjects and six of the eight subjects 
displayed 20/40 or better in at least one eye. The visual field appears to be more heavily 
affected: half of the subjects experienced tunnel vision of 25 degrees or less. Interestingly, 
two subjects demonstrated sectorial RP. Consanguinity was present in at least three of the 
index subjects. Overall, individuals with MAK mutations appear to have a disease course 
that is somewhat less rapid and severe than what has been observed in a number of other 
genetic forms of RP. 
MAK encodes a highly-conserved regulator of ciliary length that contains a MAP kinase 
domain in its N-terminal half (Figure 3A). Mutations in the MAK orthologues of 
Chlamydomonas reinhardtii, Leishmania mexicana, Caenorhabditis elegans and mice 
result in formation of abnormally long cilia15-17,30. Mak mutations in mice also cause rapid 
degeneration of photoreceptors17. All six of the putatively pathogenic mutations in MAK 
that we identified fall within the conserved kinase domain (Figure 3A). The most severe 
mutation (p.(Q240*)) creates a premature stop codon within the C-terminal portion of the 
domain that is predicted to remove kinase subdomain XI31. All missense mutations 
(p.(G13S), p.(G27R)), p.(N130S), p.(R166H) and p.(I181T)) are predicted to be pathogenic 
with various pathogenicity prediction programs (Supplementary table 5). In addition, two 
  
 
 
Table 1. Clinical characteristics of patients with MAK mutations. 
Patient 
number 
Country of 
origin 
Gender 
Age at 
diagnosis 
(y) 
Age at 
examination 
(y) 
Initial 
symptom 
Visual acuity 
(refraction in dioptres) 
Full field ERG 
Fundoscopic 
findings 
Perimetry 
Additional 
findings 
Diagnosis MAK mutation 
OD OS 
RP-
2011 
Turkey F ~20 31 
Night 
blindness 
20/25 
No refraction 
20/25 
No refraction 
Minimal responses 
for both rods and 
cones 
Diffuse pigmentation 
throughout fundus 
Constricted visual 
fields of 25 
degrees 
Clear lens; normal 
aspect of central 
OCT; 
consanguinity  
RP 
c.718C>T; 
(p.(Q240*)) hmz 
009539 Netherlands F 37 57 
Night 
blindness 
20/125 
(S-2.5D SE) 
20/40 
(S-1.5 SE) 
No responses 
Bone spicules and 
attenuated vessels; Bull’s 
eye-like pattern 
Central islands of 
10 degrees with 
small nasal 
patches  
2 older brothers 
also affected; 
consanguinity; 
lens opacities 
RP 
c.388A>C 
(p.(N130H)) hmz 
027775 Netherlands M 23* 23 
Visual field 
defects 
20/25 
(S-2.25 SE) 
20/25 
(S-3 SE) 
Severely reduced 
rod responses, 
mildly reduced cone 
responses  
No bone spicules; RPE 
alterations and possibly 
early stage atrophy; 
Attenuated vessels; optic 
disc pallor 
Severely 
constricted visual 
field, 20 degrees 
BE 
None RP 
c.37G>A (p.(G13S)) 
hmz 
038230 Netherlands F 43** 43 
Night 
blindness 
20/20 
(S-7 SE) 
20/20 
(S-7 D SE) 
Significantly 
reduced rod 
responses and 
mildly reduced cone 
responses (at 43 
yrs) 
Mild pallor optic disc, 
moderately attenuated 
vessels; preserved 
macular region; RPE 
atrophy and bone-spicules 
in the nasal quadrants 
n.a. None Sectorial RP 
c.79G>C (p.(G27R))/ 
c.542T>C (p.(I181T)) 
012115 Netherlands F 51 59 
Night 
blindness 
20/32 
No refraction 
20/100 
No refraction 
NA 
Attenuated vessels; bone 
spicule pigmentation 
Mild constriction 
and arcuate 
scotomas 
Subcapsular 
posterior cataract 
OS>OD 
RP 
c.79G>A (p.(G27R))/ 
r.0 
MOL 
708-1 
Israel F 32 36-49 
Night 
blindness 
20/32 – 20/40 
(-2.75 SE) 
20/25-20/32 
(S-2.5 SE) 
Severely reduced 
rod responses, 
moderately reduced 
cone responses 
Posterior poles within 
normal limits; mild changes 
in nasal retina 
Localised visual 
field loss: BE 
midperipheral 
temporal 
scotomas 
Consanguinity 2:2 Sectorial RP 
c.497G>A 
(p.(R166H)) hmz 
MOL 
708-2 
Israel M 25 66 
Night 
blindness 
20/63 
(S+0.75 SE) 
20/50 
(S-2.75 SE) 
n.a. n.a. n.a. n.a. RP 
c.497G>A 
(p.(R166H)) hmz 
MOL 
708-4 
Israel F 30 57 
Night 
blindness 
20/50 
aphakic 
20/32 
aphakic 
Severely reduced 
cone and rod 
responses 
Mild pigmentary changes 
around arcades 
Midperipheral 
scotomas, 
temporal more 
than nasal 
Congenital 
cataract 
RP 
c.497G>A 
(p.(R166H)) hmz 
ERG: electroretinogram; n.a.: not available; SE: spherical equivalent; OS: oculus sinister, left eye; OD: oculus dexter, right eye; BE: both eyes; hmz: homozygous; * severe 
tunnel vision was present at age 23; ** night blindness since childhood 
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missense mutations (p.(G13S) and p.(D130H)) affect amino acids that are universally 
conserved across all known kinases31. These amino acids correspond to glycine 52 and 
asparagine 171 in cAMP-dependent protein kinase that serves as a paradigm for kinase 
structure/function relations31-33. Glycine 52 forms part of a critical glycine-rich loop required 
for binding ATP33. Asparagine 171, in contrast, acts as a stabiliser within the catalytic loop 
of the protein33. The other three mutations we identified (p.(G27R)), p.(R166H) and 
p.(I181T)) all affect highly-conserved residues within the kinase domain. These results 
strongly suggest that kinase activity is critical for the normal function of the MAK gene 
product in photoreceptors. 
In order to evaluate the effects of these mutations on MAK kinase activity directly, we 
employed an in vitro kinase assay. An expression construct was engineered that contained 
the full-length wild-type human MAK coding sequence derived from retinal cDNA. In 
addition, two variant constructs were engineered that carried the human mutations that 
affect universally conserved amino acids (p.(G13S) and p.(D130H)). We found that the 
wild-type MAK protein resulted in increased phosphorylation of myelin basic protein 
relative to background (Figure 3B). In contrast, the kinase activity observed with the two 
mutant forms of MAK was essentially the same as that seen with the empty vector (Figure 
3B). These results confirm that these two disease-causing mutations result in a loss of 
kinase activity in vitro. 
PCR amplification of the full-length MAK coding sequence from human retina resulted in 
the identification of a photoreceptor-enriched alternative exon (number 13) that was 
previously reported in mice17 (Figure 4A). This exon corresponds to a block of phylogenetic 
conservation encoding 25 amino acids (Figure 4A). Given the relatively restricted pattern 
of expression of MAK in testis and retina17, we determined the extent to which the two 
transcript isoforms (with and without the alternative exon) are expressed in these two 
tissues in humans. We found that the longer isoform (including the alternative exon) is the 
predominant species in the retina and there is only a barely detectable level of expression 
of the shorter isoform (Figure 4B). In contrast, in testis, the short isoform predominates, 
whereas the longer form is detectable at lower levels. A similar pattern of retinal- and 
testis-predominance of the long and short isoforms, respectively, was also observed in 
mice (data not shown). 
 
 
 
Exome sequencing and cis-regulatory mapping identify mutations in MAK in RP 
123 
 
 
 
Figure 3. Analysis of additional MAK mutations 
(A) Schematic of the MAK protein shows the location of six identified disease-associated mutations. Cross-species 
comparison of two regions of MAK indicates that all the identified missense mutations affect highly-conserved residues. 
(B) In vitro kinase assay showing that two mutations in MAK, p.(G13S) and p.(D130H), result in a loss of kinase activity. Note 
that there is a modest background level of phosphorylation of myelin basic protein (MBP) even in the epty vector control 
condition. The graph at the bottom shows results for two biological replicates of the kinase assay. The amount of phospho-
MBP is normalised to the amount of kinase expressed. Error bars represent standard deviation. 
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Figure 4. The predominant retinal transcript isoform of MAK includes an alternative exon 
(A) Pattern of phylogenetic conservation within the alternative exon of MAK. The images are adapted from the UCSC 
Genome Browser25. 
(B) PCR results assessing the presence of the alternative exon in cDNA derived from the human retina and testis. 
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CRX is a global transcriptional regulator of ciliary genes in photoreceptors 
The binding of CRX around the MAK locus suggests a previously underappreciated role for 
CRX in regulating the expression of cilium-related genes in photoreceptors. To explore this 
idea further, we bioinformatically analysed a large set of ciliary genes for direct binding by 
CRX by using our CRX ChIP-seq dataset. A prior analysis of the proteome of the mouse 
photoreceptor sensory cilium complex (i.e., the outer segment) revealed the presence of 
more than a thousand different proteins in this structure22. Among these were more than 
200 genes encoding phylogenetically conserved ciliary proteins. We analysed 200 of these 
genes and found that ~60% (119/200) had CBRs associated with them (data not shown). 
This figure represents a marked enrichment for CRX binding around ciliary genes 
compared to binding around all genes in the genome (P = 1.07 x 10-24, hypergeometric 
distribution). CRX binding was also detected in the proximal promoter region of RFX1 
(OMIM #600006), a key transcriptional regulator of ciliary genes (data not shown)34. Taken 
together, these data suggest that CRX might directly regulate many cilium-related genes 
including a critical transcriptional regulator of these genes. 
Discussion 
This study introduces a bioinformatic strategy called cis-regulatory mapping for prioritising 
candidate genes within lists derived from either genetic mapping or exome sequencing of 
individuals with retinal degeneration. We used this approach to identify a homozygous 
mutation in MAK in a Turkish individual with RP. Further studies revealed additional 
mutations in MAK in RP subjects from several geographical regions. MAK encodes a 
cilium-associated MAP kinase that is selectively expressed in retina and testis. Two 
disease-causing mutations in MAK result in a loss of kinase activity in vitro and suggest a 
critical role for kinase activity in photoreceptor survival in humans. In addition, a retina-
enriched transcript isoform of MAK was identified that contains an alternative 13th exon. 
Because all identified MAK mutations are shared by both retinal- and testis-enriched 
isoforms, it is possible that mutations in this gene could affect spermatogenesis. Overall, 
the cis-regulatory mapping approach should be widely applicable to the prioritisation of 
retinal-disease gene candidates and the generation of ChIP-seq datasets for other retinal 
disease relevant cell types such as RPE should allow the further extension of this strategy. 
Unlike other approaches for candidate-gene prioritisation, cis-regulatory mapping does not 
depend on knowledge of gene expression pattern (i.e., whether a candidate gene is 
enriched in retina) or the extent of gene annotation. In individuals with dominant retinal 
disease, the list of candidate mutations in exome data is longer compared to that in 
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recessive disease because a single heterozygous mutation is sufficient to cause disease. 
CRX-based cis-regulatory mapping should therefore be particularly useful in such 
individuals. Overall, CRX-based cis-regulatory mapping appears to be a sensitive and 
versatile tool for prioritising retinal-disease genes in many rod- and cone-based diseases. 
The ability of CRX ChIP-seq data to facilitate candidate gene prioritisation in retinal 
disease was recently demonstrated in another study that pinpointed mutations in 
FAM161A (OMIM #613596) as a cause of RP35. In addition, preliminary analyses suggest 
that CRX-based cis-regulatory mapping is effective at prioritising retinal disease candidate 
genes in mice (data not shown). In order to facilitate the application of this approach to 
mouse models of retinal disease, we have included cis-regulatory mapping datasets for 
mice in Supplementary table 1. 
The cis-regulatory mapping approach introduced here should, in principle, be applicable to 
disease gene prioritisation in any differentiated cell type. Crx is a terminal selector gene 
that co-ordinately regulates a host of different genes required for the differentiation of 
photoreceptors10,13,14,36. Such key regulators are known to be present in many cell types. If 
the identity of a key regulatory transcription factor is known, the creation of a cis-regulatory 
map with ChIP-seq should therefore permit the application of this strategy to other families 
of diseases affecting specific cell types. For example, CRX-based cis-regulatory mapping 
failed to identify mutations in genes expressed in RPE and this suggests that additional 
ChIP-seq datasets for regulators of RPE gene expression such as OTX2 or MITF might 
facilitate the identification of such disease genes. Similar considerations apply to a range 
of other disease-relevant cell types throughout the body. 
Despite the fact that the CRX ChIP-seq data used in this study were generated in mice, 
they proved effective at pinpointing photoreceptor genes in humans. This finding suggests 
that the high degree of phylogenetic conservation observed at many CRX ChIP-seq peaks 
is indicative of functional conservation at the level of transcriptional control of gene 
expression. This result stands in contrast to a recent report that found that there is 
relatively poor cross-species correlation between ChIP-seq peaks for certain liver 
transcription factors37. It is therefore possible that individual transcription factors differ with 
respect to the evolutionary rate of turnover of their target binding sites. In the case of CRX, 
this rate appears to be relatively slow. 
Mak knockout mice displayed normal retinogenesis, with progressive retinal degeneration 
of both rods and cones beginning around 1 month of age17. This time course of disease 
progression appears to be somewhat accelerated relative to the human subjects who had 
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MAK mutations and whose symptoms first developed relatively late in life. Whereas the 
visual field defects were a prominent feature in the human subjects, loss of visual acuity 
was generally mild. Sectorial RP was present in two of the subjects with MAK mutations 
and represents a relatively uncommon subtype of RP in which a specific region of the 
retina appears to be more heavily or even uniquely affected. Determining the extent of this 
phenotype will require the identification of a larger number of individuals with MAK 
mutations. 
All of the MAK mutations identified in the present study fall within exons shared by both 
retinal- and testis-enriched transcript isoforms, raising the possibility that these mutations 
could have an effect on spermatogenesis. However, there were no reports of infertility in 
the two male subjects we identified. This finding is consistent with the phenotype of the 
Mak knockout mouse, which is fertile and has only mild defects in sperm motility38. 
Nevertheless, given the expression pattern of MAK, analysis of sperm function in subjects 
carrying mutations in this gene might be warranted. In conclusion, this study introduces a 
bioinformatic strategy for prioritising retinal-disease gene candidates based on the 
genome-wide pattern of binding of the photoreceptor transcription factor CRX. This 
approach successfully identified RP-causing mutations in a ciliary gene, MAK and should 
be widely applicable to retinal-disease gene candidate prioritisation in a range of retinal 
diseases. 
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Supplementary table 2. Prioritisation of 38 candidate disease genes from exome sequence data based 
on CRX binding (first worksheet). 
gene 
symbol 
contig 
reference 
position 
reference 
nucleotide 
variant 
#1 
counts 
of 
variant 
#1 
read 
cover-
age 
frequency 
of variant 
#1 
amino 
acid 
change 
overlapping annotations 
AGAP4 
chr10 
contig 
45,641,533 G A 13 13 100 R-> C 
SureSel_Exon: 
entg|AGAP4:ccds|CCDS7215.1, 
Exon: NM_133446, CDS: 
NM_133446, mRNA: BC171820, 
mRNA: BC062366, mRNA: 
BC171833, mRNA: AF411132, 
mRNA: BC048341 
AGAP5 
chr10 
contig 
75,112,549 C T 76 76 100 E -> K 
Exon: NM_001144000, CDS: 
NM_001144000, mRNA: BC127746, 
mRNA: BC020053 
CDC27 
chr17 
contig 
42,576,317 A C 28 36 77.778 I -> M 
SureSel_Exon: 
entg|CDC27:ccds|CCDS11509.1, 
Exon: NM_001256, Exon: 
NM_001114091, CDS: 
NM_001114091, CDS: NM_001256, 
mRNA: DQ896027, mRNA: 
AB384784, mRNA: DQ892780, 
mRNA: AK296881, mRNA: 
BC011656, mRNA: U00001, mRNA: 
S78234 
CDH5 
chr16 
contig 
64,992,277 G A 12 17 70.588 R -> H 
SureSel_Exon: 
entg|CDH5:ccds|CCDS10804.1, 
Exon: NM_001795, CDS: 
NM_001795, mRNA: AK300461, 
mRNA: X59796, mRNA: AK300322, 
mRNA: U84722, mRNA: AB385138, 
mRNA: AB209908, mRNA: X79981, 
mRNA: AK300299, mRNA: 
AB035304, mRNA: BC096365, 
mRNA: BC096363, mRNA: BC09 
CTBP2 
chr10 
contig 
126,673,180 C A 28 35 80 D -> Y 
SureSel_Exon: 
entg|CTBP2:ccds|CCDS7643.1, 
Exon: NM_022802, Exon: 
NM_001083914, Exon: NM_001329, 
CDS: NM_001329, CDS: 
NM_022802, CDS: NM_001083914, 
mRNA: AB462993, mRNA: 
BT007012, mRNA: CU691519, 
mRNA: CU691518, mRNA: 
BC002486, mRNA: BC047018, 
mRNA: AK2903 
CTBP2 
chr10 
contig 
126,681,969 C G 41 47 87.234 E -> D 
SureSel_Exon: 
entg|CTBP2:ccds|CCDS7643.1, 
Exon: NM_022802, Exon: 
NM_001083914, Exon: NM_001329, 
CDS: NM_001329, CDS: 
NM_022802, CDS: NM_001083914, 
mRNA: AB462993, mRNA: 
BT007012, mRNA: CU691518, 
mRNA: BC002486, mRNA: 
BC047018, mRNA: AK290390, 
mRNA: AF0165 
DNAJC21 
chr5 
contig 
34,985,435 G T 11 11 100 A -> S 
Exon: NM_194283, CDS: 
NM_194283, mRNA: AK127749, 
mRNA: BC141523 
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FAM66D 
chr8 
contig 
12,032,471 G A 10 10 100 A -> V 
SureSel_Exon: 
entg|FAM66D:ccds|CCDS43713.1, 
Exon: NM_201402, CDS: 
NM_201402, mRNA: AY509884, 
mRNA: BC157073, mRNA: 
BC156290 
FAM66D 
chr8 
contig 
12,032,949 C T 9 11 81.818 E -> K 
SureSel_Exon: 
entg|FAM66D:ccds|CCDS43713.1, 
Exon: NM_201402, CDS: 
NM_201402, mRNA: AY509884, 
mRNA: BC157073, mRNA: 
BC156290 
FAM66D 
chr8 
contig 
12,033,495 G A 12 14 85.714 L -> F 
SureSel_Exon: 
entg|FAM66D:ccds|CCDS43713.1, 
Exon: NM_201402, CDS: 
NM_201402, mRNA: AY509884, 
mRNA: BC157073, mRNA: 
BC156290 
FAM66D 
chr8 
contig 
12,033,559 C G 19 26 73.077 K -> N 
SureSel_Exon: 
entg|FAM66D:ccds|CCDS43713.1, 
Exon: NM_201402, CDS: 
NM_201402, mRNA: AY509884, 
mRNA: BC157073, mRNA: 
BC156290 
FAM75A3 
chr9 
contig 
40,695,193 G C 19 27 70.37 E -> D 
Exon: NM_001083124, CDS: 
NM_001083124, mRNA: BC040528, 
mRNA: BC018886, mRNA: 
AL080148 
FRYL 
chr4 
contig 
48,272,857 G A 26 26 100 P -> S 
SureSel_Exon: 
entg|FRYL:ccds|CCDS43227.1, 
Exon: NM_015030, CDS: 
NM_015030, mRNA: BC050336, 
mRNA: CR627228 
GABRA4 
chr4 
contig 
46,625,351 C T 140 144 97.222 R -> H 
SureSel_Exon: 
entg|GABRA4:ccds|CCDS3473.1, 
Exon: NM_000809, CDS: 
NM_000809, mRNA: AK090780, 
mRNA: CU690039, mRNA: 
BC035055, mRNA: DQ891679, 
mRNA: DQ894864, mRNA: 
EU176605, mRNA: U30461 
HLA-
DRB1 
chr6 
contig 
32,660,017 C T 15 19 78.947 V -> M 
Exon: NM_002124, CDS: 
NM_002124, mRNA: CR610561, 
mRNA: AK291499, mRNA: M17378, 
mRNA: AJ536121, mRNA: M17381, 
mRNA: M59803, mRNA: M20504, 
mRNA: L02545, mRNA: EU375850, 
mRNA: U56640, mRNA: X03069, 
mRNA: U95818, mRNA: AF010142, 
mRNA: BC108922, mRNA: 
AF291675 
HPS4 
chr22 
contig 
25,202,985 T C 79 79 100 I -> V 
SureSel_Exon: 
entg|HPS4:ccds|CCDS13835.1, 
Exon: NM_022081, Exon: 
NM_152841, CDS: NM_022081, 
CDS: NM_152841, mRNA: 
BC035614, mRNA: BC028625, 
mRNA: AL713795, mRNA: 
BC050285, mRNA: AK290211, 
mRNA: CU012967, mRNA: 
AY043416, mRNA: CU013255, 
mRNA: AL365512, mRNA 
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KIAA1683 
chr19 
contig 
18,238,791 T C 11 15 73.333 M -> V 
SureSel_Exon: 
entg|KIAA1683:ccds|CCDS32958.1, 
Exon: NM_025249, Exon: 
NM_001145304, Exon: 
NM_001145305, CDS: 
NM_001145304, CDS: 
NM_001145305, CDS: NM_025249, 
mRNA: AM392555, mRNA: 
AK302431, mRNA: BC127099, 
mRNA: BC112932, mRNA: 
AB465189, mRNA: AK057466, 
mRNA 
LOC81691 
chr16 
contig 
20,759,259 C G 38 41 92.683 Q -> E 
SureSel_Exon: 
entg|LOC81691:ccds|CCDS10591.1, 
Exon: NM_001144924, Exon: 
NM_030941, CDS: NM_001144924, 
CDS: NM_030941, mRNA: 
BC068503, mRNA: AK057254, 
mRNA: CR621882, mRNA: 
AF332193, mRNA: AB463203, 
mRNA: AK314458, mRNA: 
AL162035, mRNA: BC007646, 
mRNA: AL1 
MAGEC1 
chrX 
contig 
140,821,655 T C 21 21 100 S -> P 
SureSel_Exon: 
entg|MAGEC1:ccds|CCDS35417.1, 
Exon: NM_005462, CDS: 
NM_005462, mRNA: AF056334, 
mRNA: BC153867, mRNA: 
BC025969, mRNA: AY952890 
MAK 
chr6 
contig 
10,910,224 G A 38 39 97.436 Q -> * 
SureSel_Exon: 
entg|MAK:ccds|CCDS4516.1, Exon: 
NM_005906, CDS: NM_005906, 
mRNA: AK310329, mRNA: 
AK097831, mRNA: AB527975, 
mRNA: AK314408, mRNA: 
BC039825, mRNA: AF505623, 
mRNA: CU691770, mRNA: 
CU691771, mRNA: BC033002 
OR10G4 
chr11 
contig 
123,391,517 C T 121 122 99.18 A -> V 
SureSel_Exon: 
entg|OR10G4:ccds|CCDS31702.1, 
Exon: NM_001004462, CDS: 
NM_001004462 
OR10V1 
chr11 
contig 
59,237,524 A T 19 20 95 F -> Y 
SureSel_Exon: 
entg|OR10V1:ccds|CCDS31565.1, 
Exon: NM_001005324, CDS: 
NM_001005324, mRNA: BX538158, 
mRNA: AB529286 
OR2T35 
chr1 
contig 
246,868,215 C T 35 35 100 G -> D 
SureSel_Exon: 
entg|OR2T35:ccds|CCDS31123.1, 
Exon: NM_001001827, CDS: 
NM_001001827, mRNA: AB528813, 
mRNA: BC156815 
OR2T35 
chr1 
contig 
246,868,233 G A 20 20 100 A -> V 
SureSel_Exon: 
entg|OR2T35:ccds|CCDS31123.1, 
Exon: NM_001001827, CDS: 
NM_001001827, mRNA: AB528813, 
mRNA: BC156815 
OR2T35 
chr1 
contig 
246,868,234 C T 21 21 100 A -> T 
SureSel_Exon: 
entg|OR2T35:ccds|CCDS31123.1, 
Exon: NM_001001827, CDS: 
NM_001001827, mRNA: AB528813, 
mRNA: BC156815 
OR4C16 
chr11 
contig 
55,096,894 G A 86 88 97.727 V -> I 
SureSel_Exon: 
entg|OR4C16:ccds|CCDS31502.1, 
Exon: NM_001004701, CDS: 
NM_001004701 
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OR4C46 
chr11 
contig 
51,372,216 A G 50 54 92.593 H -> R 
SureSel_Exon: 
entg|OR4C46:ccds|CCDS31498.1, 
Exon: NM_001004703, CDS: 
NM_001004703 
OR4C46 
chr11 
contig 
51,372,488 C T 111 114 97.368 L -> F 
SureSel_Exon: 
entg|OR4C46:ccds|CCDS31498.1, 
Exon: NM_001004703, CDS: 
NM_001004703 
OR4P4 
chr11 
contig 
55,162,598 C G 113 116 97.414 Y -> * 
SureSel_Exon: 
entg|OR4P4:ccds|CCDS31504.1, 
Exon: NM_001004124, CDS: 
NM_001004124 
OR5D14 
chr11 
contig 
55,319,912 A T 68 73 93.151 Q -> L 
SureSel_Exon: 
entg|OR5D14:ccds|CCDS31508.1, 
Exon: NM_001004735, CDS: 
NM_001004735, mRNA: AB463969, 
mRNA: BC153005, mRNA: 
BC148380 
OR5P2 
chr11 
contig 
7,774,428 C G 39 41 95.122 C -> S 
SureSel_Exon: 
entg|OR5P2:ccds|CCDS7782.1, 
Exon: NM_153444, CDS: 
NM_153444, mRNA: BC101710, 
mRNA: BC113557, mRNA: 
AF220494, mRNA: AF173006 
OR5P2 
chr11 
contig 
7,774,432 C T 41 44 93.182 V -> I 
SureSel_Exon: 
entg|OR5P2:ccds|CCDS7782.1, 
Exon: NM_153444, CDS: 
NM_153444, mRNA: BC101710, 
mRNA: BC113557, mRNA: 
AF220494, mRNA: AF173006 
PARG 
chr10 
contig 
50,895,513 C T 23 25 92 R -> H 
SureSel_Exon: 
entg|PARG:ccds|CCDS41522.1, 
Exon: NM_001077686, CDS: 
NM_001077686, mRNA: BC171820, 
mRNA: BC051717, mRNA: 
AF411132, mRNA: BC171833, 
mRNA: BC062366, mRNA: 
BC048341 
POM121C 
chr7 
contig 
74,891,435 G A 81 87 93.103 S -> L 
Exon: NM_001099415, CDS: 
NM_001099415, mRNA: AK293781, 
mRNA: BC082993 
PPP2R1B 
chr11 
contig 
111,119,453 G A 94 102 92.157 R -> * 
SureSel_Exon: 
entg|PPP2R1B:ccds|CCDS8348.1, 
Exon: NM_181699, Exon: 
NM_002716, CDS: NM_002716, 
CDS: NM_181699, mRNA: 
BC027596, mRNA: EU176538, 
mRNA: AF163473, mRNA: 
AK292275, mRNA: AK301705, 
mRNA: AK294716, mRNA: 
DQ890606, mRNA: AF087438, 
mRNA: M65254, mRNA 
RBM46 
chr4 
contig 
155,938,639 T G 83 85 97.647 I -> M 
SureSel_Exon: 
entg|RBM46:ccds|CCDS3790.1, 
Exon: NM_144979, CDS: 
NM_144979, mRNA: CU688522, 
mRNA: AK302720, mRNA: 
AK125877, mRNA: BC028588 
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SFRS15 
chr21 
contig 
31,990,808 C A 10 10 100 V -> L 
SureSel_Exon: 
entg|SFRS15:ccds|CCDS33537.1, 
Exon: NM_020706, Exon: 
NM_001145444, Exon: 
NM_001145445, CDS: 
NM_001145444, CDS: 
NM_001145445, CDS: NM_020706, 
mRNA: BC064990, mRNA: 
BC014921, mRNA: AL117417, 
mRNA: AL834304, mRNA: 
AF023142, mRNA: AB032998, 
mRNA 
SGIP1 
chr1 
contig 
66,910,224 T G 34 37 91.892 V -> G 
SureSel_Exon: 
entg|SGIP1:ccds|CCDS30744.1, 
Exon: NM_032291, CDS: 
NM_032291, mRNA: AK299941, 
mRNA: AL136561, mRNA: 
EU831934, mRNA: AM392887, 
mRNA: AK298970, mRNA: 
BX640813, mRNA: AK090697, 
mRNA: AX746580, mRNA: 
CR749541, mRNA: AB384389, 
mRNA: EU832029, mRNA 
SLC37A1 
chr21 
contig 
42,859,027 A T 22 31 70.968 S -> C 
SureSel_Exon: 
entg|SLC37A1:ccds|CCDS13689.1, 
Exon: NM_018964, CDS: 
NM_018964, mRNA: AK025993, 
mRNA: BC152997, mRNA: 
BC148368, mRNA: AF311320, 
mRNA: AB527213, mRNA: 
AJ269529 
SLC45A2 
chr5 
contig 
34,020,317 G T 18 18 100 F -> L 
SureSel_Exon: 
entg|SLC45A2:ccds|CCDS3901.1, 
Exon: NM_001012509, Exon: 
NM_016180, CDS: NM_016180, 
CDS: NM_001012509, mRNA: 
BC003597, mRNA: CU687878, 
mRNA: AF172849, mRNA: 
CU678524, mRNA: CU678525, 
mRNA: BC064405 
TEKT4 
chr2 
contig 
94,901,247 C G 10 14 71.429 R -> G 
SureSel_Exon: 
entg|TEKT4:ccds|CCDS2005.1, 
Exon: NM_144705, CDS: 
NM_144705, mRNA: AK296678, 
mRNA: BC042429, mRNA: 
BC021716, mRNA: AK097438, 
mRNA: CU692394 
TEKT4 
chr2 
contig 
94,901,271 A G 18 22 81.818 T -> A 
SureSel_Exon: 
entg|TEKT4:ccds|CCDS2005.1, 
Exon: NM_144705, CDS: 
NM_144705, mRNA: AK296678, 
mRNA: BC042429, mRNA: 
BC021716, mRNA: AK097438, 
mRNA: CU692394 
TEKT4 
chr2 
contig 
94,901,295 C G 16 21 76.19 R -> G 
SureSel_Exon: 
entg|TEKT4:ccds|CCDS2005.1, 
Exon: NM_144705, CDS: 
NM_144705, mRNA: AK296678, 
mRNA: BC042429, mRNA: 
BC021716, mRNA: AK097438, 
mRNA: CU692394 
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TEKT4 
chr2 
contig 
94,901,320 C G 20 22 90.909 T -> R 
SureSel_Exon: 
entg|TEKT4:ccds|CCDS2005.1, 
Exon: NM_144705, CDS: 
NM_144705, mRNA: AK296678, 
mRNA: BC042429, mRNA: 
BC021716, mRNA: AK097438, 
mRNA: CU692394 
TEKT4 
chr2 
contig 
94,901,376 A G 17 23 73.913 M -> V 
SureSel_Exon: 
entg|TEKT4:ccds|CCDS2005.1, 
Exon: NM_144705, CDS: 
NM_144705, mRNA: AK296678, 
mRNA: BC042429, mRNA: 
BC021716, mRNA: AK097438, 
mRNA: CU692394 
TNCR6A 
chr16 
contig 
24,712,455 A T 15 15 100 Q -> H 
SureSel_Exon: 
entg|TNRC6A:ccds|CCDS10624.2, 
Exon: NM_014494, CDS: 
NM_014494, mRNA: BC172409, 
mRNA: AK299905, mRNA: 
AL833757, mRNA: AY035864, 
mRNA: AJ492221, mRNA: 
AB040893 
UQCRC1 
chr3 
contig 
48,613,455 T C 8 11 72.727 N -> S 
SureSel_Exon: 
entg|UQCRC1:ccds|CCDS2774.1, 
Exon: NM_003365, CDS: 
NM_003365, mRNA: AK300694, 
mRNA: CR601929, mRNA: 
CR624684, mRNA: CR608620, 
mRNA: CR615622, mRNA: 
AK129903, mRNA: CR622944, 
mRNA: CR620730, mRNA: 
CR619930, mRNA: CR612327, 
mRNA: CR597640, mRNA 
USH2A 
chr1 
contig 
214,026,776 A C 11 15 73.333 C -> G 
SureSel_Exon: 
entg|USH2A:ccds|CCDS31025.1, 
Exon: NM_206933, CDS: 
NM_206933, mRNA: AY481573 
ZNF595 
chr4 
contig 
76,022 C A 12 12 100 Y -> * 
Exon: NM_182524, CDS: 
NM_182524, mRNA: AK301848, 
mRNA: CU690298, mRNA: 
AK056302, mRNA: BC036110, 
mRNA: BC043151, mRNA: 
BX537887, mRNA: EU832005, 
mRNA: AK300505, mRNA: 
EU831911 
ZNF595 
chr4 
contig 
76,023 A T 13 13 100 R -> Trp 
Exon: NM_182524, CDS: 
NM_182524, mRNA: AK301848, 
mRNA: CU690298, mRNA: 
AK056302, mRNA: BC036110, 
mRNA: BC043151, mRNA: 
BX537887, mRNA: EU832005, 
mRNA: AK300505, mRNA: 
EU831911 
ZNF595 
chr4 
contig 
76,024 G A 13 13 100 R -> K 
Exon: NM_182524, CDS: 
NM_182524, mRNA: AK301848, 
mRNA: CU690298, mRNA: 
AK056302, mRNA: BC036110, 
mRNA: BC043151, mRNA: 
BX537887, mRNA: EU832005, 
mRNA: AK300505, mRNA: 
EU831911 
ZNF717 
chr3 
contig 
75,870,713 C T 9 12 75 V -> I 
Exon: NM_001128223, CDS: 
NM_001128223 
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Supplementary table 2. Prioritisation of 38 candidate disease genes from exome sequence data based 
on CRX binding (second worksheet). 
gene 
symbol 
chromosome start end 
number of wild-type 
sequence reads 
assigned to gene 
number of Nrl-/- 
sequence reads 
assigned to gene 
gene falls within 
regions of 
homozygosity 
SGIP1 chr1 66999824 67210767 287 188 NO 
CTBP2 chr10 126676418 126849624 222 210 YES 
USH2A chr1 215796235 216596738 188 130 NO 
MAK chr6 10762956 10831110 138 100 YES 
FRYL chr4 48499379 48782316 126 56 YES 
HPS4 chr22 26847446 26879820 31 21 NO 
CDH5 chr16 66400524 66438688 27 54 NO 
CDC27 chr17 45195312 45266665 13 0 NO 
OR2T35 chr1 248801587 248802559 0 0 NO 
AGAP4 chr10 46321050 46342921 0 0 NO 
AGAP5 chr10 75434033 75457554 0 0 NO 
PARG chr10 51026326 51371331 0 0 NO 
OR10G4 chr11 123886281 123887215 0 0 NO 
OR10V1 chr11 59480388 59481318 0 0 NO 
OR4C16 chr11 55339604 55340534 0 0 NO 
OR4C46 chr11 51515281 51516209 0 0 NO 
OR4P4 chr11 55405833 55406771 0 0 NO 
OR5D14 chr11 55563031 55563975 0 0 NO 
OR5P2 chr11 7817520 7818489 0 0 NO 
PPP2R1B chr11 111597631 111637169 0 0 NO 
LOC81691 chr16 20817766 20860989 0 0 NO 
TNRC6A chr16 24741048 24837545 0 20 NO 
KIAA1683 chr19 18367905 18385319 0 0 NO 
TEKT4 chr2 95537231 95542568 0 0 NO 
SFRS15 chr21 33043312 33104431 0 0 NO 
SLC37A1 chr21 43919741 44001549 0 0 NO 
UQCRC1 chr3 48636431 48647098 0 0 NO 
ZNF717 chr3 75786029 75834255 0 0 NO 
GABRA4 chr4 46920918 46995580 0 0 YES 
RBM46 chr4 155702426 155749964 0 0 NO 
ZNF595 chr4 53227 88099 0 0 NO 
DNAJC21 chr5 34929697 34959068 0 11 YES 
SLC45A2 chr5 33944721 33984780 0 0 YES 
HLA-DRB1 chr6 32546548 32557562 0 0 NO 
POM121C chr7 75046065 75115568 0 0 NO 
FAM66D chr8 11973290 12008698 0 0 NO 
FAM75A3 chr9 40700290 40706536 0 0 NO 
MAGEC1 chrX 140991641 140997185 0 0 NO 
The first worksheet, “52 homozygous sequence variants”, lists 52 novel sequence variants identified in the 
exome of Turkish patient RP-2011 (IV:1 in Figure 2A). These variants were not found in the dbSNP database 
and represented at least 70% of the sequence reads at the given chromosomal position. These 52 variants fall 
within 38 different genes. The second worksheet, “Ranking of 38 candidate genes”, shows a ranked list of the 
38 candidate disease genes based on CRX binding. 
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Supplementary table 3. Oligonucleotides used in this study. 
PCR primers spanning alternative exon 12 for analysing MAK isoforms 
forward reverse 
TGAATCCCAAGAAGGTGTCC CGTTGCATTGAGAGGTGCTA 
PCR primers for obtaining MAK-CBRs 
MAK-CBR1: 
TCCCCGgatatcGGAATTGGCGGGGATTTC GCTCGAGggtaccGGACCCTCCTCCCTCCAGT 
MAK-CBR2: 
TCCCCGgatatcCGCTCAGGTGAAAGTGGAAT GCTCGAGggtaccTTGGCTTCCCTCTTTGAGAA 
MAK-CBR3: 
TCCCCGgatatcCGTTGCTTTTTAAAGAGTTTGG GCTCGAGggtaccGTTCTCCAGTTCACGCACAA 
PCR primers for obtaining the retinal isoform of human MAK for expression constructs 
tccccgccgcggGCCGCCACCatgaaccgatacacaaccatg ggtaccggcggccgcctaccggtggcctccatac 
PCR primers for screening of the MAK gene 
MAK-exon1 
GGAATTGGCGGGGATTTC CAAGAGGTCTGGGAGACACC 
MAK-exon2 
AAGTTGCCAGTACAATTTTTG GAGGACAGGAAAATAAAGAGC 
MAK-exon3 
CAAAGTGAACCAGTAGTGGAG AGTGAATTTTCAAATGTGAGG 
MAK-exon4 
CCAGGAGAAATGGAAAATTAC AATTTACCTTTTGGAGCAATC 
MAK-exon5 
GGGAATATAAACCTTCTTTGG ATTTGTATGCACAATCTGGAC 
MAK-exon6 
AGGGGGTTCATTTATATTTTG CGTAGGAAAATTTCACCATAG 
MAK-exon7 
GTAGAATGCTACTGCCCATC TCAGATATCTAGGCAAAAGTTG 
MAK-exon8 
GTGGTCTGGTATTTCATTTTC AAACATCCCTGATATTACAAAAC 
MAK-exon9 
TTTATGTGCAATACATTTAGGTG GGGTCTTTAACAAAGAAAAATC 
MAK-exon10 
AGAATGGGGACTGTTAGTGTC TCTTCTTTTAGGGTCTACATGC 
MAK-exon11 
GTATACGGGAGCTTTTCTAGC AGACACTTGAACCTGACCTATC 
MAK-exon12 
TTTATTTCCATTCTCCTGTCC CATGTATCTTGGTTGGAAGAG 
MAK-exon13 
CATTTTTAAGGGCTCTTTCTG TCCTGATCTGACTTCTCAAAG 
MAK-exon14 
AGCTCAGTGCCTAAAACATAG CTGACTAAAAGTCTTCGCTTG 
MAK-exon15 
TAAATTCAGATTTTCCCCATC TTTGCATATTTCTTCCAGAAC 
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Supplementary table 4. Number of RP probands genotyped with SNP microarrays and number of 
subjects homozygous at the MAK locus. 
Country of origin 
Total number of RP 
probands 
Probands with 
homozygous region at 
the MAK locus 
Probands with MAK mutation 
Netherlands 186 2 2 
Israel 74 6 1 
Spain 44 2 0 
Italy 30 1 0 
 
Supplementary table 5. Analysis of identified MAK mutations with prediction programs 
MAK 
mutation 
genomic DNA 
(hg18) 
SIFT PolyPhen2 
MutPred 
probability 
of 
deleterious 
mutation 
MutPred Hypotheses PhyloP 
       
p.(G13S) g.10938831C>T Deleterious 
Probably 
damaging 
0.862 
Gain of glycosylation at 
G13 
(P = 0.0217) 
3.37 
p.(G27R) g.10938789C>G Deleterious 
Probably 
damaging 
0.74 
Gain of MoRF binding 
(P = 0.0169); 
Gain of solvent 
accessibility 
(P = 0.0306) 
3.30 
p.(N130H) g.10917132T>G Deleterious 
Probably 
damaging 
0.953 
Loss of catalytic 
residue at N130 
(P = 0.0236) 
4.89 
p.(R166H) g.10912105C>T Deleterious 
Probably 
damaging 
0.926 
Loss of MoRF binding 
(P = 0.0432) 
5.56 
p.(I181T) g.10912060A>G Deleterious 
Probably 
damaging 
0.845 
Loss of stability 
(P = 0.0025) 
5.28 
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Chapter 4a 
Mutations in the mevalonate kinase 
(MVK) gene cause non-syndromic 
retinitis pigmentosa 
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Abstract 
Objective: Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous disorder, 
characterised by night blindness, peripheral vision loss and in many cases leading to 
blindness. Despite extensive knowledge about genes involved in the pathogenesis of RP, 
the genetic cause remains elusive in many patients. In this study, we aimed to identify 
novel genes that are involved in the aetiology of RP. 
Design: We present a case series with mutations in the mevalonate kinase (MVK) gene. 
Participants: A total of 769 non-syndromic RP patients and 174 Dutch control individuals 
participated in this study. 
Methods: Exome sequencing analysis was performed in a proband of Dutch origin who 
was initially diagnosed with non-syndromic autosomal recessive RP. Mutations in MVK 
were identified and subsequently tested for segregation within the patient’s family and 
screened in a large cohort of genetically unsolved RP patients. Patients with mutations 
underwent extensive clinical re-examination. 
Main outcome measures: Digital fundus photography, spectral-domain optical coherence 
tomography (OCT) and fundus autofluorescence analysis were performed in patients with 
MVK mutations. Mevalonate kinase enzyme activity was analysed in cultured 
lymphoblastoid cells and mevalonic acid levels were measured in urine samples. 
Results: Exome variant filtering and prioritisation led to the identification of compound 
heterozygous mutations in MVK (p.(I268T) and p.(A334T)) in the proband and her affected 
brother. Screening of our non-syndromic RP patient cohort revealed an additional 
individual who was homozygous for the p.(A334T) alteration. Clinical re-evaluation of all 
three patients showed a classic form of RP with variable extraocular symptoms, such as 
history of recurrent childhood febrile crises in two patients, mild ataxia in one and renal 
failure in one. All three affected individuals showed a significantly decreased mevalonate 
kinase activity and highly elevated levels of urinary mevalonic acid. 
Conclusions: Although the MVK activity in cells and mevalonic acid concentrations in urine 
are strongly aberrant and comparable to patients with systemic mevalonate kinase 
deficiency (MKD), only mild clinical symptoms related to this syndrome were observed in 
our patients. Herewith, we add another phenotype to the spectrum of diverging disorders 
associated with mutations in MVK. 
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Introduction 
Retinitis pigmentosa (RP)1 is a clinically and genetically multifarious subset of progressive 
retinal dystrophies. RP is a major cause of inherited blindness and affects approximately 1 
in 4000 people globally2. The initial symptom of RP is nyctalopia (night blindness), with 
subsequent gradual impairment of peripheral vision frequently followed by complete loss of 
sight at a later stage. At least 50 different genes have been associated with non-syndromic 
RP, displaying all Mendelian modes of inheritance (RetNet)3. 
Retinitis pigmentosa also may occur as part of a multisystem disorder, as in Usher, Bardet-
Biedl, Bassen-Kornzweig, Refsum, Alström or Senior-Løken syndromes. Among them, 
mevalonate kinase deficiency (MKD) is a rare syndrome, with approximately 300 cases 
reported worldwide. Two major types of MKD can be distinguished. Mevalonic aciduria 
(MEVA)4 is the most severe phenotype, characterised by psychomotor retardation, 
progressive cerebellar ataxia, dysmorphic features, recurrent febrile crises and failure to 
thrive. The life expectancy of these patients is seriously reduced and many patients do not 
reach adulthood5. Febrile episodes frequently coincide with hepatosplenomegaly, 
lymphadenopathy, abdominal symptoms, arthralgia and skin rashes. Patients with the 
second clinical type, hyper-immunoglobulin D and periodic fever syndrome (HIDS)6, 
usually experience solely febrile attacks7. However, a subgroup also displays mental 
retardation, ataxia and epilepsy8. Ocular symptoms, such as RP, may occur in both 
subtypes of MKD, although they are more frequently observed in MEVA8-10. In the 1990s, 
MEVA and subsequently HIDS were determined to be caused by mutations in the MVK 
gene that encodes mevalonate kinase11-13. This enzyme plays a key role in the isoprenoid 
pathway. Overlapping clinical features of HIDS and MEVA, together with recurrent 
mutations in the same gene, suggest a phenotypic continuum rather than two separate 
entities8,14. In this study, we identified compound heterozygous mutations in MVK in 
individuals from two families who were initially diagnosed with non-syndromic autosomal 
recessive RP. 
Methods 
Subjects 
In total, 194 Dutch, 23 Indonesian, 52 Pakistani, 360 Spanish and 140 Italian RP probands 
took part in this study. In addition, affected and non-affected relatives of the probands, as 
well as 174 unrelated healthy individuals of Dutch origin, were included. The research 
described in this article was conducted after obtaining permission of the appropriate 
institutional review boards. Written informed consent adhering to the tenets of the 
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Declaration of Helsinki was obtained from all patients and their relatives participating in this 
study. DNA was extracted from peripheral blood using a standard salting-out procedure. 
Ophthalmic examination in the three patients with MVK mutations included best-corrected 
visual acuity (Early Treatment Diabetic Retinopathy Study charts; Precision Vision Inc., La 
Salle, IL, USA), biomicroscopy, ophthalmoscopy and fundus photography. Additional tests 
were colour vision testing (Panel D-15 Saturated and Desaturated version), Goldmann 
kinetic perimetry and electroretinography according to the protocol of the International 
Society for Clinical Electrophysiology of Vision15. Spectral-domain optical coherence 
tomography (OCT) and fundus autofluorescence (Spectralis HRA+OCT; Heidelberg 
Engineering, Heidelberg, Germany) were carried out as described previously16. 
Fluorescein angiography was performed in one person. Patients harbouring MVK 
mutations underwent additional clinical examination and were interviewed about family 
history to evaluate symptoms related to MKD. Neurologic tests were performed to assess 
any neuronal abnormalities. Physical and radiologic examinations were applied to study 
the presence of lymphadenopathy. 
Genetic analysis 
Exome sequencing 
An amount of 3 µg genomic DNA was used for exome enrichment. For this purpose, the 
AB SOLiD optimised SureSelect Human All Exon kit version 2 (Agilent, Santa Clara, CA, 
USA) was used according to the manufacturer’s instructions. The enriched exome libraries 
were subsequently sequenced on a SOLiD4 machine (Life Technologies, Carlsbad, CA, 
USA), as described earlier 17. 
Variant calling and prioritisation 
Sequence reads were mapped to the hg19 reference genome using SOLiD Lifescope 
software version 2.1 (Applied Biosystems, Foster City, CA, USA). Single nucleotide 
variants were subsequently called by the high call stringency DiBayes algorithm using high 
stringency settings, and small insertions and deletions (indels) were detected using the 
SOLiD Small InDel Tool. Called single nucleotide variants and indels were combined and 
annotated using a custom analysis pipeline. Single nucleotide polymorphisms (SNPs) were 
extracted from dbSNP build 135 (Single nucleotide polymorphism database. Available at 
http://www.ncbi.nlm.nih.gov/SNP/). Filtering steps eliminated non-genic, intronic, and 3’- 
and 5’- untranslated regions, as well as synonymous variants. The upper frequency 
threshold for variants that were present in the dbSNP database, as well as in our in-house 
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database consisting of approximately 1100 exomes, was set to 1%. Quality filtering 
involved excluding variants below 5 variant reads and below 15% of variant reads.  
Given the availability of SNP data from Genome-Wide Human SNP Array 5.0 (Affymetrix, 
Santa Clara, CA, USA) analysis performed previously in both the sequenced proband and 
her affected brother18, an additional filtering step was added that removed variants present 
in genomic regions that displayed different haplotypes between the two affected siblings. 
The minimal size of shared haplotype regions was set to 2 Mb of genomic DNA. Candidate 
missense mutations were assessed using PhyloP44wayAll (scores for genome-wide 
multiple alignments of 44 vertebrate species, available at http://genome.ucsc.edu/cgi-
bin/hgTables), PolyPhen2 (available at http://genetics.bwh.harvard.edu/pph2)19 and SIFT 
(available at http://sift.jcvi.org)20. 
Mutation analysis 
Candidate variants remaining after filtering were validated in the proband using Sanger 
sequencing analysis. Confirmed variants were subsequently analysed in all available 
family members of the proband A-II:2. The c.1000G>A (p.(A334T)) and c.803T>C 
(p.(I268T)) MVK alterations were analysed in patient cohorts and Dutch control individuals 
using HhaI enzyme digestion and amplification refractory mutation system polymerase 
chain reaction, respectively. In addition, a recurrent MVK mutation found in patients with 
MKD with RP, c.185G>A (p.W62*), was screened using BfaI restriction fragment length 
polymorphism analysis. Identified mutations were confirmed by Sanger sequencing. 
Coding exons and exon-intron boundaries of MVK were screened in probands of both 
families in which MVK mutations were identified. Polymerase chain reaction primers and 
reaction conditions are available on request. 
Biochemical and metabolic analyses 
Cell culture and mevalonate kinase activity assay 
Epstein-Barr Virus-immortalised B-lymphocyte cell lines obtained from the three patients 
and one control21, were cultured in Roswell Park Memorial Institute medium supplemented 
with 10% fetal calf serum and 1% penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, 
USA). Cell pellets were washed once with phosphate buffered saline, twice with 0.9% 
NaCl, snap-frozen in liquid nitrogen and stored at -80ºC until further analysis. MVK activity 
was measured as described previously using 14C-labeled mevalonate (NEN; Perkin Elmer 
Life Sciences, Boston, MA, USA) as substrate22. The MVK activity in patients was 
expressed as the percentage of average MVK activity determined simultaneously in control 
lymphocyte cell lines. 
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Urinary mevalonic acid assay and other biochemical tests 
Patients’ urine samples were collected and analysed with gas chromatography. 
Immunoglobulin D levels were measured using radial immunodiffusion. Other markers in 
serum were determined via routine clinical chemistry procedures (Table 1). 
 
Table 1. Laboratory findings in patients carrying mevalonate kinase gene mutations 
Laboratory test A-II:1 A-II:2 B-II:1 Normal value Units 
B cells 0.16 0.14 0.2 0.10-0.40 109/l 
T cells 1.53 1.05 1.01 0.70-1.90 109/l 
CD4+ 0.93 0.52 0.68 0.40-1.30 109/l 
CD8+ 0.59 0.50 0.30 0.20-0.70 109/l 
NK cells 0.25 0.30 0.31 0.10-0.40 109/l 
Bilirubin 6 8 6 0-16 µmol/l 
Alkaline phosphatase 66 103 53 < 97 U/l 
GGT 26 57 41 < 37 U/l 
ASAT 23 35 25 < 30 U/l 
ALAT 23 79 30 < 33 U/l 
LDH 146 141 185 < 246 U/l 
CK 65 n.d. 167 < 144 U/l 
BUN 4.7 6.3 15.5 2.5-7.5 mmol/l 
Creatinine 82 78 224 55-90 µmol/l 
FSH 6.3 12.0 19.8 2.0-7.0 U/l 
LH 4.7 3.8 8.7 1.5-8.0 U/l 
Testosterone 17.9 n.d. 17.5 10.0-30.0 nmol/l 
IgG 10.4 7.2 11.6 7.0-16.0 g/l 
IgA 3.3 1.32 2.46 0.76-3.91 g/l 
IgM 0.95 1.01 0.40 0.45-2.30 g/l 
IgD 370 395 30 < 130 mg/l 
IgE 1947 12 26 19-21 IU/l 
ESR 14 7 2 < 14 mm 
Serum amyloid 4 1 <1 < 4 mg/l 
Cholesterol 5.4 5.7 5.8 2.9-6.5 mmol/l 
LDL 2.99 3.08 3.77 1.59-4.12 mmol/l 
HDL 1.89 2.23 1.55 > 1.89 mmol/l 
Mevalonic acid excretion 
Strongly 
increased 
Strongly 
increased 
Strongly 
increased 
Normal  
 
ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; BUN: blood urea nitrogen; CK: creatine 
kinase; ESR: erythrocyte sedimentation; FSH: follicle stimulating hormone; GGT: gamma glutamyl transferase; 
HDL: high density lipoprotein; Ig: immunoglobulin; LDH: lactate dehydrogenase; LDL: low density lipoprotein; 
LH: luteinising hormone; n.d. not determined; NK: natural killer 
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Results 
Family A consists of four siblings, two of whom were diagnosed with autosomal recessive 
RP (Figure 1A). At the time of diagnosis, the index patient (A-II:2) was 32 years old and 
she had an affected brother who was three years older (A-II:1). Their presenting symptom 
was visual field loss, rather than night blindness. However, in retrospect, the index patient 
appeared to have night blindness since childhood and her brother had it since the age of 
25 years. Visual acuity was well preserved in both of them and they hardly had any lens 
opacities. On fundoscopy, optic disc pallor, attenuated vessels and peripheral 
degeneration were noted (Figure 2A). In both siblings, tortuosity of the arterioles was 
observed in the posterior poles, with a few intraretinal haemorrhages in both eyes of 
patient A-II:1. Both patients displayed thickening of the nerve fiber layer (with greyish 
streaks) along the vascular arcade that was also visible on the OCT images. The OCT 
scans also showed preserved photoreceptor layer in the macular region in both patients 
and a foveal cyst in the right eye of patient A-II:1 (Figure 2B). Fundus autofluorescence 
analysis revealed a hyperfluorescent ring around the macula in both individuals, with 
perimacular hypofluorescent lesions corresponding with retinal pigment epithelium 
changes and atrophy (Figure 2C; A-II:1 not shown). The hyperfluorescent ring mirrored the 
transition of present/absent photoreceptors on OCT. Fluorescein angiography in patient A-
II:1 showed leakage along the vascular arcades and some staining at the fovea (Figure 
2C, left). The electroretinograms displayed a rod-cone pattern and Goldmann visual fields 
revealed mid-peripheral loss in patient II:2 and tunnel vision with peripheral islands in 
patient II:1. All ophthalmological data are summarised in Table 2. 
Both affected individuals were previously genotyped using genome-wide Affymetrix 5.0 
SNP arrays, followed by homozygosity mapping18. In addition, patient A-II:2 also 
underwent targeted resequencing of 111 genes associated with retinal dystrophies on a 
Roche 454 GS FLX Titanium sequencer (454 Life Sciences, Branford, CT, USA)23. None of 
these methods led to the identification of the genetic defect underlying RP in this family. 
Thus, exome sequencing was performed in patient A-II:2. 
After mapping and variant calling, a total of 40,924 variants were annotated, of which 
about 46% were located in exons and splice sites of known genes (Table 3). 
 
 
  
 
 
Table 2. Ophthalmological data of individuals with mevalonate kinase gene mutations 
BE: both eyes; ERG: electroretinography; F: female; FA: fluorescein angiography; FAF: fundus autofluorescence; ilm: inner limiting membrane; OD, oculus dexter, right eye; 
OS, oculus sinister, left eye; M: male; RP: retinitis pigmentosa; RPE: retinal pigment epithelium 
Patient A-II:1 A-II:2 B-II:1 
Gender M F M 
Origin Dutch Dutch Dutch 
Age at diagnosis 33 y 32 y  56 y 
Age recent examination 47 y 44 y 61 y 
History 
Night blindness since the age of 25 y, visual field loss since the age 
of 31 y 
Night blindness since childhood (1st decade), visual field 
loss noticed at the age of 30/31 y (since brother was 
diagnosed with RP) 
Subjectively no night blindness, but avoids driving at night, 
visual field loss since some years 
Visual acuity 
OD 20/16 20/25 20/25 
OS 20/20 20/20 20/32 
Refraction 
OD: +1.00-0.50x25 
OS: plano-1.00x145 
OD: +1.00-2.75x15 
OS: plano-1.00x135 
OD: +2.25-0.75x180 
OS: +0.75-0.25x180 
Lens Clear Posterior subcapsular cataract (trace) Posterior subcapsular cataract (trace) 
Ophthalmoscopy 
Mild pallor optic discs, severely attenuated vessels, preserved RPE 
macular region with fibrosis ilm, foveal cyst RE, normal foveal reflex 
OS, intraretinal haemorrhages and anomalies of the arterioles BE, 
RPE atrophy in the periphery with intraretinal pigmentations 
Moderate pallor optic discs, moderately attenuated 
vessels, preserved RPE macula region with wrinkling ilm, 
RPE atrophy periphery with intraretinal pigmentations 
Pink optic discs, mildly attenuated vessels, preserved RPE 
posterior pole and macular region with subtle changes at 
fovea and mild fibrosis ilm, RPE atrophy in the midperiphery 
with intraretinal pigmentations (OS >OD) 
Full field ERG 
Dark-adapted No measurable isolated rod function; remnant of mixed responses 
No measurable isolated rod function; remnant of mixed 
responses 
Measurable, but reduced, isolated rod and mixed responses 
with prolonged implicit times 
Light-adapted 
Measurable, but significantly reduced, responses in single flash and 
30 Hz with near normal implicit times 
Measurable, but significantly reduced responses in single 
flash and 30 Hz with prolonged implicit times 
Measurable, but significantly reduced, responses in single 
flash and 30 Hz with prolonged implicit times 
Perimetry 
Constricted up to 10 degrees with large temporal and small nasal 
crescent BE 
Large mid-peripheral, absolute, annular scotoma BE 
Intact periphery (with V-4e target) with mid-peripheral 
sensitivity loss OD, constricted up to 15-20 degrees OS with 
large peripheral crescent  
Colour vision test 
OD: (de)saturated normal 
OS: saturated normal; desaturated minor errors 
OD: (de)saturated minor errors, no specific axis  
OS: (de)saturated normal 
BE: (de)saturated major errors, no specific axis 
Optical coherence tomography 
Intact inner and outer segments in the macular region, foveal cyst 
OD; thickened retinal layers superior and inferior of the macula 
Intact inner and outer segments in the macular region; 
thickened retinal layers superior and inferior of the macula 
Intact inner and outer segments in the macular region, no 
thickening of retinal layers along the vascular arcade 
Fundus autofluorescence/ fluorescein 
angiography 
FAF: hyperfluorescent ring around the macula (not shown) 
FA: leakage along the superior and inferior vascular arcade and 
some staining at the fovea 
FAF: hyperfluorescent ring around the macula FAF: hyperfluorescent ring around the macula 
Miscellaneous  Strabismus surgery at ages 5, 6, 7 Exotropia 
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Figure 1. Pedigree structure and mutation analysis of the retinitis pigmentosa (RP) families 
In the family pedigrees, affected individuals are marked with filled symbols, whereas unaffected relatives are marked with 
open symbols. A square symbolises a male, a circle – female and a diamond represents individuals of both genders. An 
arrow indicates a proband. Genotypes are shown below the pedigree symbols. M1 and M2 represent the c.1000G>A 
(p.A334T) and c.803T>C (p.I268T) substitutions, respectively; + represents the wild-type allele. 
The initial filtering steps removed variants that were present in our in-house and dbSNP 
135 databases with a frequency of more than 1%, which resulted in 564 candidate 
variants. This number was further reduced to 134 alterations with the use of SNP array 
data, when considering only those variants that resided in genomic regions for which the 
haplotypes of the 2 siblings were identical. After applying quality filters, only 1 gene 
harboured mutations matching the recessive inheritance pattern observed in this family. In 
this candidate gene, MVK, two heterozygous variants were identified – c.803T>C 
(p.(I268T)) and c.1000G>A (p.(A334T)) – that each had a high PhyloP score (3.19 and 
4.24, respectively) and were predicted to be pathogenic by several bioinformatic prediction 
programs (SIFT, PolyPhen-2). 
Both MVK alterations that were found in the proband of family A have previously been 
reported to be causative for MKD in both its phenotypic forms, MEVA and HIDS23,24. The 
c.1000G>A (p.(A334T)) mutation was recurrent in MKD cases in which retinitis pigmentosa 
has been described as an additional symptom8-10 (Table 4). Segregation analysis within  
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Table 3. Exome sequencing variant statistics and filtering 
Bio-informatic filtering steps involved excluding untranslated regions (UTR) and intronic variants as well as 
synonymous variants and those variants previously found in more than 1% of 1151 exomes performed in 
house, as well as present with a frequency higher than 1% in dbSNP database build 135. After all quality filters 
were applied and only variants were included that were in shared haplotype regions, only one candidate gene 
that carried variants in line with an autosomal recessive mode of inheritance remained. 
the family confirmed that the affected brother (A-II:1) carried both alleles, whereas the 
c.803T>C (p.(I268T)) and c.1000G>A (p.(A334T)) changes were present heterozygously in 
the mother and father, respectively. The two unaffected siblings carried only the p.(A334T) 
mutation that was inherited from the father (Figure 1). Both variants were not detected in 
174 Dutch control samples. To determine whether these two mutations in MVK could be a 
more frequent cause of RP, the occurrence of the c.803T>C and c.1000G>A substitutions 
was analysed in 769 additional patients with RP without a genetic diagnosis, revealing one 
additional Dutch individual homozygously carrying the c.1000G>A variant. This patient (B-
II:1) was 61 years old and diagnosed with late-onset RP (Table 2) at the age of 56 years. 
The classical triad of RP symptoms (i.e. bone spicules, attenuated arterioles and pale optic 
disc) was present in both eyes, with significant asymmetry because the left eye presented 
Filtering step Total number of variants 
Number of variants present in 
shared haplotype regions 
Total variants called 40924 9913 
Exonic + splice sites variants 18821 4531 
In-house database frequency <1% 595 142 
dbSNP135 database frequency <1%  564 134 
Non-synonymous + splice site variants 
+ deletions/insertions 
415 97 
Quality filters applied (at least 5 variant 
reads; at least 15% variant reads) 
297 76 
Number of genes with homozygous 
variants (>90% of variant reads) 
1 0 
Number of genes with compound 
heterozygous variants (15%<n<90%) 
6 1 
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with more prominent retinal degeneration (Table 2). His initial symptom was the loss of 
visual field; visual acuity was well preserved. A third MVK mutation that was previously 
found to be associated with MKD including RP, c.185G>A (p.(W62*))8, was not detected in 
the Dutch RP cohort. 
After the identification of mutations in MVK, and given its associations with the 
autoinflammatory disease MKD, the three affected individuals from families A and B were 
clinically re-examined and subjected to several biochemical and metabolic tests (Table 1 
and Table 5). 
Table 4. Summary of mevalonate kinase gene mutations identified in individuals with retinitis 
pigmentosa-associated mevalonate kinase deficiency 
Patient 
Allele 1 Allele 2 
MK 
activity 
Reference 
cDNA Protein cDNA Protein 
A-II:1 c.1000G>A p.A334T c.803T>C p.I268T 0.64% This study 
A- II:2 c.1000G>A p.A334T c.803T>C p.I268T 0.53% This study 
B-II:I c.1000G>A p.A334T c.1000G>A p.A334T 0.22% This study 
P1.1 c.1000G>A p.A334T c.1000G>A p.A334T 2.4% Prietsch et al., 200310 
P1.2 c.1000G>A p.A334T c.1000G>A p.A334T 2.1% Prietsch et al., 200310 
P2 c.1000G>A p.A334T c.72dupT p.G25Wfs*55 0.4% Prietsch et al., 200310 
S1 c.1129G>A p.V377I c.185G>A p.W62* n.d. Simon et al., 20048 
S2 c.1129G>A p.V377I c.185G>A p.W62* 4.5% Simon et al., 20048 
S4 c.1000G>A p.A334T c.59A>C p.H20P 1.1% Simon et al., 20048 
S5 c.1000G>A p.A334T c.185G>A p.W62* <0.5% Simon et al., 20048 
B1 c.1000G>A p.A334T c.421dupG p.A141Gfs*46 <1% Balgobind et al., 20059 
n.d.: not determined. 
The index patient of family A (A-II:2) and her affected brother (A-II:1) had reported 
childhood fever episodes, which ceased to occur in adulthood. Because of abnormal 
(hepatitis B and C virus-negative) liver biochemistry, patient A-II:2 was subjected to 
ultrasound, liver biopsy and additional marker tests for auto-immune hepatitis, but no 
diagnosis was established. She had a history of scoliosis, eczema and infertility, as well as 
recurrent pain in the throat. In her affected brother, neurological examination revealed mild 
but evident ataxia. He also had from long-standing daily diarrhoea, profuse sweating 
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Table 5. Extraocular symptoms and selected laboratory findings in patients carrying mevalonate kinase 
gene mutations 
Family and 
patient ID 
A-II:1 A-II:2 B-II:1 HIDS MEVA Control 
Immunoglobulin 
D 
370 mg/l 395 mg/l 30mg/l 
Variable from 
normal 
between 
attacks to 
high, median 
600 IU/ml, 
range 92-
3560 IU/ml41 
Increased in all 
patients (250-
4400 IU/ml)14 
<130 mg/l 
Mevalonate 
kinase activity 
0.64% 0.53% 0.22% ~2-20% ~0-3% 100% 
Urinary 
mevalonic acid 
Strongly 
increased 
Strongly 
increased 
Strongly 
increased 
Normal 
between 
attacks, 
strongly 
increased 
during attacks 
(maximal 
value 14.4 
mg/g 
creatinine)41 
Normal to 
strongly 
increased24 
Negative 
Fever episodes 
Present in 
childhood 
Present in 
childhood 
Absent Present Present Absent 
Neurological 
symptoms 
Mild ataxia None None 
None, only in 
a subgroup: 
psychomotor 
retardation, 
ataxia and 
epilepsy 
Psychomotor 
retardation, 
progressive 
cerebellar 
ataxia 
None 
Other symptoms 
Abdominal 
pain and 
episodes of 
diarrhoea, 
profuse 
sweating 
without fever 
and morning 
stiffness 
Abnormal 
liver function 
episode 
(2004), 
infertility 
Ischemic heart 
disease, 
nephrolithiasis 
None 
Hepatospleno-
megaly, 
lymphadenopa
thy, abdominal 
symptoms, 
arthralgia and 
skin rashes, 
failure to thrive 
None 
HIDS: hyper-immunoglobulin D and periodic fever syndrome; MEVA: mevalonic aciduria 
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without fever and morning stiffness without arthritis or arthralgia. In addition, he had 
recurrent pneumonia in the past. The proband of family B (B-II:1) had ischemic heart 
disease, nephrolithiasis and allergy. Lymphadenopathy and hepatosplenomegaly were 
excluded. This individual was using 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) 
inhibitor because of his ischemic heart disease. 
Mevalonate kinase activity measured in cultured cells of all three patients was significantly 
lowered in comparison with control: 0.53% and 0.64% of the control value in individuals 
from family A and 0.22% in family B (Table 5), which are typical values for severe MKD. 
Mevalonic acid concentrations were found to be highly elevated in urine of all three 
patients, similar to those found in patients with MKD26. Furthermore, in patient B-II:1 
normal serum glucose level was observed, however with concomitant renal glucosuria. 
The results of clinical and laboratory re-examination of the affected individuals are 
displayed in Table 1 and Table 5. 
Discussion 
In this study, MVK, a gene associated with MKD, was found to be mutated in three patients 
of two families, who were initially diagnosed with non-syndromic RP. At present, 57 genes 
are known to be involved in the pathogenesis of RP (RetNet) and mutations in several of 
them may cause either syndromic or non-syndromic RP (e.g. Usher syndrome – USH2A, 
CLRN127,28; Joubert syndrome – OFD129; Bardet-Biedl syndrome – BBS130). Many studies 
provide indications that in these diseases, severe mutations cause the syndromic form, 
whereas mild, hypomorphic mutations result in RP being the sole symptom. In some 
cases, however, establishing a clear genotype-phenotype association is problematic. All 
these disorders result from malfunction of the cilia and are affecting the connecting cilium 
of the photoreceptor cells. To date, there is no evidence for a ciliary role of mevalonate 
kinase, and thus, mutations in MVK may exert their pathogenicity in a completely different 
way, namely via defective metabolic pathways. Other metabolic disorders associated with 
retinal dystrophies are adult Refsum disease (lipid metabolism defect)31 or gyrate atrophy 
(ornithine aminotransferase deficiency)32. 
An interesting ophthalmological finding in all three patients harbouring MVK mutations 
(especially in the oldest, B-II:1), was the relatively late onset of RP, with well-preserved 
central vision. Mild tortuosity of the retinal arterioles, visible in the two siblings, has 
occasionally been reported in patients with RP33. This may precede the development of 
telangiectatic vessels leading to Coats’-like exudative vasculopathy, having more far-
reaching consequences with regard to treatment and visual prognosis34,35. The foveal cyst 
Expanding the genetic heterogeneity of RP and LCA 
156 
 
in patient A-II:1 and the leakage along the arcade areas observed in both siblings of family 
A are indicative of the breakdown of the blood-retina barrier36,37. A hyperfluorescent ring 
around the macula on fundus autofluorescence analysis, as in our patients, has been 
described in several retinal dystrophies, for example RP, Leber congenital amaurosis, 
cone-rod dystrophy and X-linked juvenile retinoschisis, and demarcates areas of preserved 
retinal function38-42. The oldest patient (B-II:1) had the largest size of the ring, which 
seemed compatible with his relatively well preserved photoreceptor layer on OCT. 
After identification of MVK mutations, all three patients underwent extensive clinical re-
examination. In childhood, the patients of family A experienced fever episodes, a finding 
typical for HIDS, that had disappeared after adolescence. Their immunoglobulin D 
concentrations were above 350 IU/ml, which is also the hallmark of HIDS (median: 600 
IU/ml,43); patient B-II:1 had normal IgD levels. Patient A-II:1 displayed mild ataxia. The 
affected individual of family B had a history of nephrolithiasis in his childhood and ischemic 
heart disease for which he was still treated with HMGCR inhibitor. It is remarkable that 
these patients had only such mild systemic symptoms but had severely reduced activity of 
MVK. It was previously thought that such severely reduced enzyme activity would always 
lead to severe disease8. This suggests that a difference in the (epi)genetic background 
and/or environmental factors may have led to relatively mild disease in these individuals 
and provides profoundly important information for physicians counselling MKD patients. 
Retinitis pigmentosa is one of numerous symptoms that can manifest in patients with MKD. 
Two of the MKD phenotypes, HIDS and MEVA, previously considered to be separate 
entities, are now rather perceived as two ends of a single disease spectrum. Mevalonic 
aciduria is at its extreme end, being the most severe phenotype, with symptoms 
comprising psychomotor retardation, progressive cerebellar ataxia, dysmorphic features, 
recurrent febrile crises and failure to thrive. Febrile episodes are common for MEVA and 
the milder MKD type, HIDS. At present, >100 different recessive mutations in the MVK 
gene (Figure 3) have been identified to cause the clinical subtypes of MKD, without a clear 
genotype-phenotype correlation. A recent finding of Zhang et al.44 showed MVK to be 
mutated in patients with disseminated superficial actinic porokeratosis (DSAP), a skin 
disorder that displays an autosomal dominant mode of inheritance and is characterised by 
epidermal keratotic lesions that have an atrophic centre and a peripheral column of keratin 
(cornoid lamella). Great phenotypic variability was observed, even among individuals 
harbouring identical pathogenic mutations. The variable clinical features may be reflected 
in the parents of MKD patients, who are carriers of heterozygous mutations identified in  
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DSAP but do not display any DSAP symptoms. Together, these findings illustrate the 
extreme phenotypic heterogeneity associated with mutations in MVK. 
Mevalonate kinase is involved in the isoprenoid pathway45, with multiple end-products and 
outcomes, including the biosynthesis of glycoproteins, synthesis of coenzyme Q 
(ubiquinone), vitamin K and carotenoids (retinol biosynthesis)46. Thus far, RP was 
described in seven MKD cases8-10. Proposed mechanisms of retinal dystrophy included 
specific mevalonic acid toxicity for the retina10 or a unique retinal isoprenoid metabolism9. 
A viable hypothesis considering a genotype-phenotype correlation between different 
mutations has not yet been devised, although a connection between the severity of the 
phenotype and the activity of MVK was discovered. A model was proposed in which 
severe mutations would cause MEVA and relatively mild alterations would result in HIDS8. 
However, this correlation was not confirmed in our study. MVK activity assays conducted 
in cell lines derived from patients47,48, as well as using purified wild-type and mutant 
recombinant proteins24 showed a wide variety of enzymatic activities, regardless of the 
MVK genotype. For instance, a homozygous p.(I268T) HIDS patient displayed 7.2% of 
kinase activity, whereas in another study, in an MEVA individual with the same genotype, 
MVK activity was non-detectable49. This example illustrates that even the exact same 
mutation can result in variable enzyme activity and concomitant phenotypes, suggesting 
the presence of an additional, yet unidentified, genetic, epigenetic or environmental 
modifier. 
In all seven patients with MKD who also showed RP, the activity of MVK was severely 
reduced or non-detectable (8-10, Table 4). The three patients in our study harboured rather 
severe MVK mutations and showed virtually non-detectable levels of MVK activity. The 
combination of p.(I268T)/p.(A334T) alleles, which was identified in family A, has never 
been reported in literature. The patient from family B carried the homozygous p.(A334T) 
alteration and the activity of the corresponding mutated protein was previously determined 
to be very low (<0.5% of control values24). The alanine residue at position 334 is 
conserved in MVK proteins from bacteria to humans and, being one of the first MVK 
changes studied in detail, the p.(A334T) mutation was determined to affect the substrate 
binding region24. Also, using a bacterial expression system, the activity of recombinant 
mutant enzyme was determined to be significantly decreased10,50. 
Of the seven MKD cases with RP reported so far, five patients harboured the p.(A334T) 
alteration (Table 4). Although the substitution of a threonine for an alanine residue in 
codon 334 may be a common finding in patients with MEVA and RP, the reason why the 
same genotype would be carried by patients with mild MKD and apparent RP remains 
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elusive. In the isoprenoid pathway, directly upstream of MVK, the HMGCR is the tightly 
controlled, rate-limiting enzyme for the synthesis of mevalonic acid51. Physiologically, 
HMGCR activity is thought to be down-regulated by both sterols and mevalonate-derived 
nonsterols via a feedback-loop mechanism. In patients with MEVA, HMGCR protein levels 
are increased because of the depletion of these inhibiting agents, which in turn leads to 
even higher concentrations of mevalonic acid. Some MEVA features, such as psychomotor 
retardation, appear to directly result from toxic levels of mevalonic acid10. Thus, the evident 
lack of such symptoms in patients of family A and B, suggests the presence of additional 
modifiers altering the function or expression levels of other components in the isoprenoid 
pathway. However, retinal function is clearly affected in the three patients with RP carrying 
MVK mutations on both alleles. One explanation may be that increased mevalonic acid 
levels exert exceptional toxicity for retinal cells. Alternatively, because key photoreceptor 
proteins have a high demand of isoprenyl, geranylgeranyl and other residues produced in 
the mevalonate pathway, the decrease in efficiency of this synthesis may be responsible 
for retinal degeneration. 
The results of ophthalmological analyses in all patients carrying MVK mutations are 
characteristic of RP. These results may help ophthalmologists to distinguish between 
MVK-associated disease and RP caused by mutations in other genes and enable proper 
genetic counselling on identification of the causative mutation. 
In conclusion, our results reveal that mutations in MVK can be a cause of mild MKD, which 
may be diagnosed as non-syndromic RP. Even severely reduced MVK enzyme activity can 
be associated with only mild or no inflammatory or neurologic phenotype. Although 
mutations in this gene may be rare, ophthalmologists should be aware of the necessity of 
performing a detailed medical history and subsequent tests in a broader context, avoiding 
focusing solely on ocular symptoms. Complex inheritance, assuming additional modifier(s) 
of the phenotype, could be one explanation for the phenotypic diversity observed among 
patients with homozygous and compound heterozygous MVK mutations. Future extensive 
studies on the isoprenoid pathway, especially in the retina, are essential to unravel the 
exact underlying mechanism. In the coming years, the increasing availability of exome 
sequencing will undoubtedly yield a multitude of similar associations, which will require 
careful follow-up and vigilant genetic counselling. 
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Abstract 
Many proteins depend on posttranslational prenylation for a correct subcellular localisation 
and membrane anchoring. This involves the covalent attachment of farnesyl or 
geranylgeranyl residues to cysteines residing in consensus motifs at the C-terminal parts 
of proteins. Retinal photoreceptor cells are highly compartmentalised and membranous 
structures and therefore it can be expected that the proper function of many retinal 
proteins depends on prenylation, which has been proven for several proteins that are 
absent or defective in different inherited retinal diseases (IRDs). These include proteins 
involved in the phototransduction cascade, such as GRK1, the phosphodiesterase 6 
subunits and the transducin γ subunit or proteins involved in transport processes, such as 
RAB28 and retinitis pigmentosa GTPase regulator (RPGR). In addition, there is another 
class of general prenylation defects due to mutations in proteins such as AIPL1, PDE6D 
and RAB escort protein-1 (REP-1), which can act as chaperones for subsets of prenylated 
retinal proteins that are associated with IRDs. REP-1 also is a key accessory protein of 
geranylgeranyltransferase II, an enzyme involved in the geranylgeranylation of almost all 
members of a large family of Rab GTPases. Finally, mutations in the mevalonate kinase 
(MVK) gene, which were known to be principally associated with mevalonic aciduria, were 
recently associated with non-syndromic retinitis pigmentosa. We hypothesise that MVK 
deficiency results in a depletion of prenyl moieties that affects the prenylation of many 
proteins synthesised specifically in the retina, including Rabs. In this review, we discuss 
the entire spectrum of prenylation defects underlying progressive degeneration of 
photoreceptors, the retinal pigment epithelium and the choroid. 
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Introduction 
Many proteins require posttranslational modification to function in several cellular 
processes. Protein prenylation is a posttranslational lipid modification which allows protein-
protein interactions and ensures correct cellular localisation of the protein via covalent 
attachment of one or two prenyl groups (farnesyl or geranylgeranyl)1-4. Prenyl residues 
belong to a large family of chemicals consisting of terpenoids. In animals, these 
compounds may contain from one to six isoprene units, each containing a 5-carbon 
backbone; higher polyterpenoids are present in bacteria and plants (e.g. rubber, consisting 
of long chains of isoprene subunits). Farnesyl and geranylgeranyl residues consist of three 
and four C5 isoprene units, respectively. Protein farnesylation and geranylgeranylation 
may provide lipid residues necessary to anchor the respective proteins to cell membranes 
or intracellular membranous structures. The covalent attachment of prenyl groups occurs 
through a thioether bond to one or two cysteines at, or in close proximity of, the carboxy-
terminus of the protein. More than 100 proteins, collectively called the prenylome, are 
involved in the molecular pathways producing these lipid moieties or serve as potential 
substrates for prenylation5, PRENbase (see Links to databases). 
In vision-related phenotypes, the first prenylation defects were identified in persons with 
choroideremia (CHM). Mutations in the CHM gene that encodes RAB escort protein-1 
(REP-1), a subunit of the geranylgeranyltransferase II (GGTase II; also called Rab 
geranylgeranyltransferase) protein complex, were found to cause progressive atrophy of 
the choroid, retinal pigment epithelium (RPE) and photoreceptors, resulting in visual 
impairment that eventually leads to blindness7,8. Since then, variants in genes encoding 
prenylated proteins, chaperones of prenylated proteins or other proteins involved in 
prenylation, were discovered to underlie inherited retinal diseases (IRDs). Herewith, we will 
summarise the knowledge on these proteins and hypothesise on the underlying molecular 
mechanisms that may be common in these diseases. 
Prenylation 
Prenoid synthesis pathway 
Farnesyl and geranylgeranyl residues are synthesised from acetyl coenzyme A via the 
mevalonate pathway, which was discovered in the early 1950s9. This process, also called 
the terpenoid or isoprenoid backbone pathway, is a crucial mechanism of creating sterols, 
including cholesterol, ubiquinone, squalene and dolichol, which play key roles in various 
metabolic pathways. Noteworthy, unlike in plants, protozoa and bacteria, where the so-
called MEP/DOXP pathway represents an alternative to obtain these compounds, in higher 
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organisms these molecules must exclusively be synthesised through the mevalonate 
pathway (Supplementary figure 1). 
Supplementary figure 1. Mevalonate pathway. 
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Starting with two molecules of acetyl-coenzyme A, the terpenoid synthesis continues to 
mevalonic acid via 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA reductase is a 
rate-limiting enzyme of the pathway. Hence, it has been targeted as a crucial phase to 
reduce the endogenous cholesterol synthesis in patients with hypercholesterolemia10. Ever 
since then, HMG-CoA inhibitors (statins) have been successfully used for diminishing 
cholesterol levels. The product of the next step, mevalonic acid, is converted into 
phosphomevalonate by mevalonate kinase (MVK). At the end of this pathway, the farnesyl 
and geranylgeranyl residues are synthesised directly from isoprenyl diphosphate and 
subsequently attached to various proteins by prenyltransferases in the process called 
prenylation, which provides posttranslational modification essential for membrane 
attachment and protein-protein interactions. 
Prenylation process 
The prenyltransferases represented by farnesyltransferase (FTase) and 
geranylgeranyltransferase (GGTase-I), consist of two subunits, an α and β subunit; in 
FTase and GGTase-I the α subunit is encoded by the same gene, FNTA 
(farnesyltransferase, CaaX box, α; Figure 1). All genes encoding the α subunits of the 
prenyltransferases are members of the tetratricopeptide repeat family, which includes 
proteins that are functionally relevant in the process of transcription, transport, co-
chaperoning, control of the cell cycle and phosphorylation11. The β subunits, although less 
thoroughly investigated, are hypothesised to function in lipid anchor attachment or catalytic 
activity involving polyisoprenes. In general, the obtained products are processed to 
essential substances like cholesterol, steroid hormones or vitamin D and equivalents to 
these. 
The CaaX prenyltransferases, FTase and GGTase-I, can catalyse the modification of 
peptides and substrate proteins containing the Ca1a2X-motif (where C = cysteine, a1a2 = 
two aliphatic amino acids, being more flexible in a1, X = C, S, Q, A, M, T, H, V, N, F, G or I 
for FTase and L, F, I, V, M for GGTase-I)12,13. Subsequently, CaaX endoprotease causes 
removal of the “aaX” residue and methyl esterification of the carboxyl-group at the terminal 
cysteine. 
The third prenyltransferase, called non-CaaX-prenyltransferase, Rab 
geranylgeranyltransferase or geranylgeranyltransferase-II (GGTase-II; used hereafter), 
recognises Rab (member RAS oncogene family) proteins with a CC, CXC, CCX, CCXX, 
CCXXX or CXXX termination sequence, where methyl esterification only occurs in the 
CXC residues. In contrast to the CaaX-prenyltransferases, the heterodimer GGTase-II is 
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unable to prenylate any peptide without the use of an accessory REP as a substrate14,15. 
The gene encoding the α subunit of GGTase-II (RABGGTA, Rab 
geranylgeranyltransferase, α subunit) was found to be mutated in the gunmetal mouse, a 
model of Hermansky-Pudlak syndrome16; however, thus far no mutation in this gene was 
identified in humans with this syndrome. 
In the retina, the cyclic GMP phosphodiesterase 6α subunit, transducin γ subunit, 
rhodopsin kinase and ceroid lipofuscinosis neuronal 3 protein are substrates for FTase, 
whereas the cGMP phosphodiesterase 6β subunit and X-linked retinitis pigmentosa (RP) 
GTPase regulator (RPGR) are substrates for GGTase-I. These proteins will be discussed 
below. 
Genes implicated in general prenylation-associated retinal diseases 
Rab escort protein-1 
The first retinal prenylation defect was identified when protein-truncating mutations in or 
deletions of CHM, the gene encoding REP-1, a chaperone for Rabs and a crucial 
accessory protein of GGTase-II, were found to be the cause of X-linked choroideremia7,17. 
In this disease, there is a progressive mid-peripheral atrophy of the retina, retinal pigment 
epithelium (RPE) and the choroid, which results in night blindness, tunnel vision and 
eventually blindness. REP-1 is known to bind unprenylated Rabs and presents them to the 
GGTase-II heterodimer for geranylgeranylation (Figures 1 and 2)8,18. Despite the 
ubiquitous expression of CHM, only the retina and choroid are affected in male patients 
with mutations in this gene. This is explained by the compensation of geranylgeranylation 
of most Rab GTPases by REP-2 in all tissues except the eye. Indeed, REP-2 shows 
functional overlap with REP-119. Possibly, REP-1 preferentially prenylates a subset of 
retinal Rabs through a higher substrate affinity compared with REP-2. Larijani et al.20 
proved that in cells of choroideremia patients, Rab27a accumulated in an unprenylated 
state due to differences in its ability to bind REP-1 and REP-2. The REP-2-Rab27a 
complex was shown to have a lower affinity for GGTase II compared with REP-1-Rab27a. 
Defects in intracellular membrane traffic pathways, including melanosome transport and 
phagosome processing, were described for the defective REP-1 protein21. REP-1 was also 
shown to be essential for geranylgeranylation of RAB27A in lymphoblasts isolated from 
choroideremia patients, meaning that defective REP-1 results in an accumulation of 
unprenylated RAB27A, specifically in the RPE22. Missense mutations in RAB27A result in a 
dysfunction in melanosome transport and regulation, as RAB27A cannot recruit the 
effector MyRip (Myosin VIIA and Rab-interacting protein) that regulates melanosome 
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transport in the RPE in complex with RAB27A and MYO7A23,24. These mutations cause 
Griscelli syndrome, which is characterised by cutaneous albinism and immunodeficiency25. 
Both of these features are not described in choroideremia patients and thereby provide no 
clue as to the crucial cellular defect(s) underlying this disease. 
Several preclinical studies have been carried out to develop a therapy for choroideremia. 
Contrary to males with choroideremia that only show a chorioretinal defect, male Chm 
knockout mice are not viable due to trophoblast defects at embryogenesis26. To overcome 
this early lethality, Tolmachova and colleagues developed conditional knockout models in 
which Rep-1 was exclusively depleted either in the neural retina or in the RPE. In both 
models, defects were seen in the neural retina or RPE, respectively, suggesting cell-
autonomous pathologies27. This disease therefore requires a therapeutic approach 
preferably targeting both cell types. 
HIV-based lentiviral vectors have been used for in vivo CHM gene transfer studies28. Rep-
1-deficient mice received a subretinal injection with a vector that expresses CHM under the 
control of the elongation factor-1 α promoter and showed a specific transduction of the 
RPE for 6 months. Functional restoration was confirmed by a reduced number of 
unprenylated Rabs. 
A second therapeutic strategy involves the use of adeno-associated virus (AAV) serotype 
2-based vectors to transduce both photoreceptor cells and the RPE. In conditional 
knockout mice, it showed efficient RPE transduction and compared to the lentiviral 
approach allowed more potent transduction of neuroretinal cells28,29. The AAV2 vector, 
expressing REP-1 under the control of CMV-enhanced chicken β-actin promoter with a 
Woodchuck hepatitis virus post-translational regulatory element to enhance transgene 
expression vector, was able to provide efficient, functional and non-toxic transgene 
expression in diseased and healthy RPE and photoreceptor cells30. 
Currently, the first gene augmentation clinical trials using this vector are ongoing 
(clinicalTrials.gov; identifier: NCT01461213). No adverse effects of subretinal injections 
have been noticed in two groups consisting of three patients each31. 
Aryl-hydrocarbon-interacting protein-like 1 
Aryl-hydrocarbon-interacting protein-like 1 (AIPL1) functions as a chaperone for 
farnesylated proteins (Figures 1 and 2)32. AIPL1 has been found to be mutated in persons 
with autosomal-recessive Leber congenital amaurosis (LCA) or autosomal-dominant cone-
rod dystrophy33. AIPL1 is expressed in rods and cones in the early stages of retinal 
development34, whereas in later stages expression is restricted to the rod photoreceptor 
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cells35. In Aipl1-/- mice, an LCA model, rapid rod degeneration is described, followed by 
cone degeneration36,37. Kirschman et al. described a slower development of cone-rod 
degeneration in the absence of Aipl1, which was restricted to cone photoreceptor cells38. 
 
Figure 1. Schematic representation of the proteins which are prenylated and proteins taking part in prenylation 
processes in the retina. 
Mutations in some of their corresponding genes were discovered to cause choroideremia (CHM), cone-rod dystrophy (CRD), 
congenital stationary night blindness (CSNB), Joubert syndrome (JS), Leber congenital amaurosis (LCA), mevalonate kinase 
deficiency (MKD), retinal disease (RD) and retinitis pigmentosa (RP). Proteins for which knockout mice displayed retinal 
disease are marked with a hash (#). Alpha (α) and beta (β) subunits of the prenylation enzymes encoded by different genes 
are depicted in different shades of grey. 
This protein interacts with DnaJ (Hsp40) homologue, subfamily A, member 2 (DNAJA2), γ-
transducin32 and the α and β subunits of rod phosphodiesterase39 in the presence of 
FTase. In the light of newly published research, it may be hypothesised that, similarly to 
chaperoning PDE6 subunits37, AIPL1 may function as a chaperone of other retinal Rab 
GTPases or proteins crucial in cone photoreceptors. 
Prenyl binding protein δ 
PrBP/δ, encoded by the phosphodiesterase 6D, cGMP-specific, rod, delta (PDE6D) gene, 
facilitates intracellular trafficking40. PrBP/δ was shown to interact in vitro with RPGR41, the 
prenyl side chains of GRK1 and the PDE6α and PDE6β subunits42. Due to its ability to 
solubilise prenylated proteins, a role in transport was suspected43. Interestingly, through its 
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binding to carboxy-terminal prenyl groups of the phototransduction proteins PDE6α and 
PDE6β, PrBP/δ dissociates the PDE6αβγγ complex from the rod segment membrane 
discs. Likewise, it is thought that PrBP/δ can dissociate RAB13 from the membrane44. As 
RAB13 is also predicted to be farnesylated, PrBP/δ may also interact with other prenylated 
proteins, such as RAB2845. Pde6d-/- mice present with a slowly progressive rod-cone 
dystrophy34, thereby making it an excellent candidate gene to be mutated in human retinal 
degeneration. Very recently, mutations in this gene were discovered to result in Joubert 
syndrome46. It was also shown that PrBP/δ function is required for ciliary targeting of 
INPP5E. INPP5E is also a farnesylated protein and the loss of its CaaX box was earlier 
proven to cause MORM (mental retardation, truncal obesity, retinal dystrophy and 
micropenis syndrome), with features similar to Bardet-Biedl syndrome47,48. 
Mevalonate kinase 
As mentioned above, MVK is an enzyme catalysing the transformation of mevalonic acid 
into phosphomevalonate. In a group of disorders called mevalonate kinase deficiency 
(MKD), this reaction is significantly hindered due to mutations in the MVK gene that 
encodes this enzyme. The metabolic block results in two distinct phenotypes of MKD: 
mevalonic aciduria (MEVA) or hyper-immunoglobulin D and periodic fever syndrome 
(HIDS). Both diseases may result from the same mutations within MVK; however, the 
clinical outcome is different49,50. MEVA is a severe condition characterised by progressive 
cerebellar ataxia, psychomotor retardation and recurrent febrile crises, the latter usually 
being the only symptom occurring in HIDS. Several additional symptoms of MKD include 
abdominal complications and retinal dystrophy. Being a rare disorder, MKD has only been 
described in approximately 300 cases worldwide, 7 of which were diagnosed with retinal 
degeneration51-53. Recently, we reported that mutations in MVK cause late-onset non-
syndromic RP, which may be accompanied by mild MKD features54. 
It was previously hypothesised that neuronal degeneration observed in MEVA could be a 
result of toxic mevalonic acid levels in the brain. The same process may also underlie 
photoreceptor degeneration52. However, the spectrum of disorders associated with MVK 
mutations is wide and it is difficult to assess the role of external factors in this process. 
Recently, in an attempt to lower the toxic levels of mevalonate, lovastatin and simvastatin 
were applied in MKD. However, the results were ambiguous. The administration of 
lovastatin in patients with classic MEVA caused severe crisis (high fever, acute myopathic 
changes, diarrhoea) and the trial had to be terminated55. Conversely, in HIDS, the 
administration of simvastatin resulted in reduced excretion of mevalonic acid and a 
decreased number of febrile days56. In patients displaying retinal dystrophy these 
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medications have not yet been tested. It has also been hypothesised that the unique 
isoprenoid metabolism in photoreceptors is responsible for MVK-associated retinal 
degeneration51. Intriguingly, the same mutations that have previously been described to 
cause MEVA were shown to result in MKD displaying predominantly the RP phenotype. 
Clearly, we still lack fundamental knowledge on the action of other proteins, often referred 
to as the “genetic background”. It may be hypothesised that mutations in other proteins 
may rescue the severe neurological phenotype, perhaps by alleviating the toxicity of 
mevalonic acid in these tissues, while the retina would remain affected. The contribution of 
epigenetic and/or environmental factors should also be taken into consideration. For 
example, an enhanced expression of a downstream enzyme may set the prenylated 
residues to a level acceptable in neurons. However, it may be still insufficient for the 
correct function of photoreceptors, which possess many membranous structures and 
therefore are more dependent on prenylated proteins. 
Prenylated proteins mutated in non-syndromic retinal diseases 
Guanine nucleotide-binding protein subunit gamma, Tγ 
The γ chain of transducin is encoded by GNGT1 (guanine nucleotide binding protein 
gamma transducing activity polypeptide 1). Transducin is a membrane-bound heterotrimer 
containing α, β and γ subunits and in its inactive state it is bound to a guanosine 
diphosphate (GDP) molecule. Activation by metarhodopsin II results in binding of 
guanosine triphosphate (GTP) and detachment of the α subunit from the membrane, which 
results in the activation of PDE6. The remaining subunits (called Tβγ) then diffuse to the 
inner photoreceptor segment. A CaaX motif is present on the α and γ subunits of rod 
transducin, but only the γ subunit has been found to be farnesylated57. This modification is 
neither necessary for rhodopsin binding nor for the interaction with the α subunit. During 
dark adaptation dislocated transducin subunits must return to the outer segment for rod 
sensitivity restoration58. It was established that this process may be mediated by the 
farnesyl residue59; the potential Tγ partners include PrBP/δ and phosducin. 
In the study by Lebanova et al.60, knockout of the gene encoding the transducin γ subunit 
in mice resulted in severe downregulation of α and β subunits of PDE6, despite normal 
mRNA levels. The mice also underwent fairly rapid photoreceptor degeneration. In 
contrast, Kolesnikov et al.61 described no retinal degeneration during the early stages of 
postnatal life. GNGT1 has previously been suggested to play a role in human retinal 
degeneration disorders62, but thus far no mutations have been found in this gene in human 
IRDs63, which may be due to its relatively small size (225 bp open-reading frame) and the 
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associated low mutation frequency. Mutations in the gene encoding the transducin α 
subunit, GNAT1, were identified in Nougaret-type congenital stationary night blindness. 
These findings, along with the lack of photoreceptor degeneration in one of the mouse 
models, suggest that mutations in GNGT1 may be involved in a similar disease. 
Phosphodiesterase 6α and 6β subunits 
Several proteins essential for the process of vision require farnesyl and geranylgeranyl 
residues for proper functionality. Among them, rod cyclic guanosine monophosphate 
(cGMP)-specific phosphodiesterase 6 (PDE6) consists of catalytic α and β subunits, two 
inhibitory γ subunits and a δ subunit. This enzyme is crucial for the phototransduction 
pathway. Briefly, in response to a photon, rhodopsin is activated and stimulates GTP 
synthesis (Figure 2). In turn, a G-protein, transducin, is activated and displaces the 
inhibitory γ subunits thus activating PDE6. This phosphodiesterase is involved in the 
reduction of cGMP concentration, which leads to closure of cGMP-gated channels. As a 
direct result of ensuing transient hyperpolarisation, at the synapse glutamate release is 
then reduced and the signal travels via the optic nerve to the brain. 
PDE6 is anchored to the membrane through isoprenyl residues attached to the C-termini 
of PDE6α and PDE6β. Mammalian PDE6A was proven to contain one farnesyl residue; in 
comparison, PDE6B is geranylgeranylated64. These modifications are thought to facilitate 
membrane attachment65. The prenyl moieties of PDE6 subunits were recently shown to 
bind AIPL1, the aforementioned chaperone protein involved in LCA66. PDE6 subunits form 
a complex containing prenyl-binding protein delta (PrBP/δ), which is highly expressed in 
photoreceptors. Mutations in both PDE6A and PDE6B (phosphodiesterase 6A, cGMP-
specific, rod, α and β, respectively), encoding the α and β subunits, are responsible for a 
small subset of autosomal-recessive RP cases67,68. 
RAB28, member RAS oncogene family 
Rab GTPases are key regulators in trafficking of proteins and function as molecular 
switches to regulate fusion steps in vesicle transport, vesicle budding, motility, tethering69 
and membrane fission70. The human genome contains more than 60 Rab genes71,72 and 
for at least 16 different Rab proteins the structure in either the active (GTP-bound) or 
inactive (GDP-bound) state has been elucidated73-75. The first prenylated small Rab 
GTPase demonstrated to be involved in retinal disease is RAB28, as protein-truncating 
mutations in RAB28 cause cone-rod dystrophy76. Although the exact role of RAB28 in cone 
and rod photoreceptors remains to be determined, a unique feature is that isoforms 1 and 
2 of RAB28 are predicted to be farnesylated at their CaaX-motifs6,77-79, in contrast to the 
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large majority of other RAB GTPases that are geranylgeranylated by GGTase-II. The 
farnesylation was experimentally proven for isoform 1 of RAB28. 
Other Rabs, like Rab8 and Rab11, are found to coordinate primary ciliogenesis35. Together 
with Rab3a and Rab6, they are involved in rhodopsin transport through the connecting 
cilium to the outer segments of photoreceptor cells80-83. Interestingly, a single mutation in 
the RAB3A-interacting molecule, RIMS1, was associated with dominant cone-rod 
dystrophy (Figure 1)84. RAB28 is also localised to the basal body and ciliary rootlet, which 
suggests a role in ciliary transport (Figure 2)76. In addition, Rab17 and Rab23 were found 
to be essential for ciliogenesis, but are not present in the cilium85. 
The disease mechanism underlying photoreceptor degeneration due to protein-truncating 
mutations in RAB28 remains to be elucidated. The retina-specific phenotype is surprising 
in view of the wide expression of this gene in the human body. Either there is functional 
redundancy outside the eye through the action of other Rabs or RAB28 may be involved in 
the transport of crucial retina-specific proteins. 
Retinitis pigmentosa GTPase regulator 
Another prenylated protein involved in retinal dystrophy is RPGR, a ubiquitously expressed 
protein. RPGR can act as a GTP-GDP exchange factor for RAB886, a protein involved in 
ciliary transport and rhodopsin trafficking to the photoreceptor outer segment87. Since 
some disease-causing RPGR mutations do not affect this GTP-GDP exchange function, 
RPGR may have additional roles in the photoreceptors. The geranylgeranylation of RPGR 
is required for its correct localisation in the Golgi apparatus88, but the lack of this 
isoprenylation does not seem to disrupt the retinal function89. Several splice variants are 
found in different tissues and the RPGR ORF15 isoform is crucial for normal functioning of 
the retina. Mutations in this part of RPGR were shown to be involved in the majority of X-
linked retinal dystrophy cases90,91. However, the RPGR ORF15 transcript lacks the CaaX 
prenylation signal at its C-terminus. Therefore, although both transcripts are expressed in 
photoreceptors, it remains unclear whether this modification is necessary for retinal 
function. 
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Figure 2. General overview of visual phototransduction and ciliary transport. 
Depicted is a scheme of rod phototransduction and transport processes crucial for vision. Prenylated proteins, as well as 
proteins involved in the prenylation process discussed in this review are marked in colours: prenylated proteins are in 
orange, while chaperones are in green. Farnesyl and geranylgeranyl residues are depicted as red and blue tags, 
respectively. PrBP/δ is depicted by delta (Pδ) in a green balloon. PDE6 subunits are marked as alpha (Pα), beta (Pβ), 
gamma (Pγ); transducin subunits are marked as (Tα), beta (Tβ), gamma (Tγ); and GGTase-II subunits are marked as GGTα 
and GGTβ; activated rhodopsin (a), phosphorylation (P), guanosine monophosphate (GMP) and its cyclic counterpart 
(cGMP), guanosine-5'-triphosphate (GTP), guanosine diphosphate (GDP). Activation of rhodopsin with a photon is indicated 
by a lightning symbol. PC – photoreceptor. 
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G protein-coupled receptor kinase 1 
G protein-coupled receptor kinases specifically recognise and phosphorylate the numerous 
G protein-coupled receptors after the release of bound G proteins. Rhodopsin kinase 
(GRK1), which belongs to this group, regulates cellular responses. It is activated 
allosterically by its own substrate, the light-activated form of rhodopsin. Membrane 
association of GRK1 occurs after its farnesylation. Since in PDE6D knockout mice GRK1 
is absent in the photoreceptor outer segments, it is suggested that PrBP/δ is required for 
its correct trafficking34. GRK1 mutations are a cause of Oguchi disease, a form of 
stationary night blindness with prolonged dark adaptation. Since GRK1 is crucial for visual 
processes, it is hypothesised that in cones GRK7 compensates for the loss of GRK1 
activity and hence patients with mutations in GRK1 only display a relatively mild 
phenotype92,93. 
Ceroid lipofuscinosis neuronal 3 
Mutations in ceroid lipofuscinosis, neuronal 3 (CLN3), encoding a lysosomal 
transmembrane protein, are a cause of Batten disease. Vision loss often is the first clinical 
feature in Batten disease, preceding severe and progressive neurodegeneration leading to 
death in the second decade of life94. Recently, a mutation has been described in a patient 
with non-syndromic LCA95. This previously described mutation (p.Y199*) was found to 
result in a milder, protracted phenotype due to the escape of nonsense-mediated decay, 
hypothetically leaving a partially functional protein96. The CLN3 protein is described to be 
farnesylated97 and it has been shown that mutations in the CLN3-binding motif of FTase 
display normal trafficking, but result in a functionally impaired protein98. 
Are there overlapping mechanisms of disease due to defects in the retinal 
prenylome? 
The photoreceptors are highly compartmentalised and membranous structures and 
therefore it can be expected that many retinal proteins depend on prenylation for a proper 
subcellular localisation and trafficking. This is true for several proteins found to be mutated 
in different IRDs. The mechanisms underlying retinal degeneration due to defects in the 
prenylated proteins described above are not fully understood, but can be inferred from 
their known roles in the phototransduction cascade (GNGT1, PDE6A, PDE6B), transport 
processes close to or at the connecting cilium (RAB28, RPGR) or lysosomes (CLN3). 
Apart from these “gene-specific” defects, mutations affecting AIPL1 and PrBP/δ exert a 
more general effect as both are chaperones for a subset of prenylated retinal proteins. 
Prenylation defects in inherited retinal diseases 
181 
 
Defects in the corresponding genes thereby may affect the function of the respective 
proteins with which they normally interact. 
REP-1 does not only act as a chaperone for RABs but it also is a key accessory protein of 
GGTase-II, which is involved in the geranylgeranylation of almost all RABs. It is thus far 
not understood how REP-1 deficiency, despite the presence of a functional homologue 
REP-2 (encoded by choroideremia-like gene, CHML) that is also widely expressed, results 
in a specific chorioretinal disease. The same is true for the surprising recent finding that 
mutations in mevalonic kinase, which were known to be principally associated with MEVA, 
were associated with non-syndromic RP. We hypothesise that MVK deficiency results in a 
depletion of prenyl moieties, which affects the prenylation of many proteins synthesised 
specifically in the retina. It stands to reason that the prenylated proteins illustrated in 
Figures 1 and 2 would most prominently be affected, though some of the associated retinal 
phenotypes differ from the RP phenotype observed in persons with MVK deficiencies. 
Assuming that the depletion of isoprenyl moieties underlies RP in MKD, there may be an 
overlap with another “general” prenylation defect, that is the underprenylation of one or 
several RABs due to mutations in the CHM gene. Clearly, future studies are needed to 
shed light on these issues. 
Concluding remarks 
The mechanisms underlying retinal dystrophies due to variants in prenylated proteins in 
the retina are straightforward as each of these proteins, maybe except for RAB28, plays a 
unique function in the retina. Similar to other geranylgeranylated RABs, the farnesylated 
RAB28 is synthesised widely in human tissues. Nevertheless, it apparently fulfils a crucial 
function in the transport of as yet unknown molecules. Possibly, it also is involved in the 
shuttling of key molecules towards the connecting cilium, such as rhodopsin. The 
chaperone proteins AIPL1 and PrBP/δ play diverse roles in the assembly and transport of 
several key protein complexes, but the full spectra of their function are not yet known. 
Mutations in CHM result in X-linked choroideremia and MVK variants are associated with a 
late-onset form of autosomal-recessive RP in a small subset of MKD cases. There is a 
conspicuous phenotypic overlap between these two diseases. Although choroideremia is 
characterised by the degeneration of all posterior cell layers (neural retina, RPE, choroid) 
and RP is characterised by the dystrophy of the neural retina and RPE, their similarity is 
striking. Both display a midperipheral-to-centre degeneration, primarily affecting rods, 
preserving the macular region for a long time. Both result from general prenylation defects, 
although at different levels. MKD potentially leads to a widespread shortage of prenoids, 
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which include farnesyl and geranylgeranyl moieties. CHM mutations, on the other hand, 
cause an insufficiency of GGTase-II to geranylgeranylate the large majority of RABs. We 
hypothesise that the comparable phenotypes result from depletion of prenylated RABs. 
Many studies suggest that the retina displays specific requirements for proteins 
possessing lipid moieties, most probably due to the membranous structure of the 
photoreceptors. The retina therefore may be particularly susceptible to underprenylation of 
proteins, which would give rise to retinal symptoms before (if at all) affecting other tissues. 
Several genes implicated in IRDs encode proteins that either require prenylation or are 
crucial in the prenylation process. Mutations in these genes may result in diminished or 
abolished protein synthesis, but can also cause loss of function and accumulation of 
inactive prenylated proteins, which may be toxic to photoreceptor cells. The recent finding 
of LCA-specific features in a patient with CLN3 variants may also point to a disease 
mechanism involving the accumulation of toxic molecules in retinal lysosomes. 
Many IRD genes are being explored as targets for gene augmentation therapy and it may 
be hypothesised that targeting the prenylation process could provide a more generic 
treatment. However, in view of the diversity of the proteins and cellular processes in 
question, the development of a more generalised therapy does not seem plausible at the 
moment. 
Although a general prenylation therapy seems incredibly challenging, steps are currently 
being made to devise a therapy directed to specific geranylgeranyl or farnesylation 
defects. One of the deficiencies that may be addressed is retinal degeneration caused by 
the loss of MVK functionality. Although it was proven that patients with RP and mild MKD 
symptoms display the same, severe decrease in MVK activity compared with MEVA 
patients, it may be hypothesised that boosting the concentration of substrates for prenyl 
synthesis, either by direct supplementation or by targeting one of the downstream 
enzymes in mevalonate pathway, would increase the overall supply of prenyl residues and 
rescue the phenotype. However, it is very difficult to predict how this would affect the target 
cells. FTase inhibitors have been previously used as a target for decreasing prenylation in 
treatment of some cancer types99-102. Nevertheless, the K-RAS protein that is involved in 
some neoplasms appears to be geranylgeranylated in the absence of FTase103. Therefore, 
a similar method involving both farnesyltransferase and geranylgeranyltransferase 
inhibitors was investigated, but the dual prenylation of proteins caused the agent to exhibit 
dose-limited toxicities in the clinic and were withdrawn for further investigation104,105. 
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Considering all of the above issues, stimulating the synthesis of prenyl residues in the 
retina may cause undesirable side effects, such as neoplastic growth. It is also possible 
that manipulating these levels will have no effect at all, since there are multiple feedback 
loops in the isoprenoid pathway and increased concentration of one of the compounds 
may result in inhibition rather than stimulation of prenyl synthesis. 
Targeting the inhibitors of prenyltransferases was already tested in other genetic disorders. 
In progeria, a disease of rapid aging, farnesyltransferase inhibitors have shown their 
potential in vitro by blocking the expression of the defective farnesylated protein laminin A 
(or progerin), as well as in vivo with respect to longevity, body weight and bone integrity 
phenotypes106. 
In retinal diseases, for example in case of a malfunctioning chaperone, it is conceivable 
that a prenylated protein might accumulate at an improper location and result in retinal 
degeneration. However, general inhibition of either farnesylation or geranylgeranylation 
would probably result in underprenylation of other targets. Therefore, it is not certain 
whether such therapies should be considered. At this point, gene augmentation therapy 
still presents the best option for treatment of such diseases. Although the eye has 
excellent properties for the development of treatment, the bottleneck will remain that each 
prenylation defect requires a different therapeutic approach, posing significant challenges 
for the future. 
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Abstract 
Purpose: The gene encoding nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) 
was recently found to be mutated in a subset of Leber congenital amaurosis (LCA) cases 
with macular atrophy. The aim of this study was to determine the occurrence and 
frequency of NMNAT1 mutations and associated phenotypes in different types of inherited 
retinal dystrophies. 
Methods: DNA samples of 161 LCA patients without genetic diagnosis were analysed for 
variants in NMNAT1 using Sanger sequencing. Variants in exon 5 of NMNAT1, which 
harbours the majority of the previously identified mutations, were screened in 532 
additional patients with retinal dystrophies. This cohort encompassed 108 persons with 
isolated or autosomal recessive cone-rod dystrophy (CRD), 271 with isolated or autosomal 
recessive retinitis pigmentosa (RP) and 49 with autosomal dominant RP, as well as 104 
persons with LCA in whom the causative mutation was previously identified. 
Results: Compound heterozygous alterations were found in six patients with LCA and in 
one person with early-onset RP. All except one carried the common p.E257K variant on 
one allele. Macular atrophy was absent in one patient, who carried this variant in 
combination with a truncating mutation on the other allele. The p.E257K alteration was 
also found in a heterozygous state in five individuals with LCA and one with RP while no 
mutation was detected on the other allele. Two individuals with LCA carried other NMNAT1 
variants in a heterozygous state, whereas no NMNAT1 variants in exon 5 were identified in 
individuals with CRD. The p.E257K variant was found to be enriched in a heterozygous 
state in LCA individuals (0.94%) compared to Caucasian controls (0.18%), although the 
difference was statistically insignificant (p=0.12). 
Conclusions:  Although macular atrophy can occur in both LCA and CRD, no NMNAT1 
mutations were found in the latter cohort. NMNAT1 variants were also not found in a large 
group of cases with sporadic or autosomal recessive RP. The enrichment of p.E257K in a 
heterozygous state in LCA cases vs. controls suggests that this allele could act as a 
modifier in other genetic subtypes of LCA. 
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Introduction 
Inherited retinal dystrophies (IRDs) represent a heterogeneous group of disorders 
characterised by the degeneration of photoreceptor cells. Variable ages of onset and 
diverse grades of involvement of rod and cone photoreceptor cells divide it into various 
clinical subsets1. The most severe form of retinal degeneration is Leber congenital 
amaurosis (LCA, OMIM #204000) with severely impaired visual function from birth and 
strongly reduced or undetectable ERG responses within the first year of life2. Another form 
of retinal dystrophy, involving initially rod photoreceptor degeneration which is followed by 
cone cell death, is retinitis pigmentosa (RP, OMIM #268000)3. RP is characterised by night 
blindness, progressive visual field deterioration and eventual loss of central vision. In 
persons with cone-rod dystrophy (CRD, OMIM #120970)4, cones are primarily involved 
whereas rods are concomitantly or later affected. One of the additional symptoms that may 
occur in LCA or CRD is a macular atrophy (also called pseudocoloboma), which is not 
related to embryonic fissure closure5. Until now, mutations in 204 genes were found to be 
involved in the pathogenesis of IRDs (RetNet, https://sph.uth.edu/retnet). Recently, 
NMNAT1, a gene involved in nicotinamide adenine dinucleotide (NAD) synthesis, was 
found to be responsible for a subset of LCA cases, mainly with macular lesions6-9. 
Earlier studies described three nicotinamide mononucleotide adenylyltransferases 
catalysing the reaction of nicotinamide mononucleotide with ATP to form NAD+ 10, which is 
a crucial agent in many redox reactions especially important in the central nervous system. 
Whereas NMNAT2 and NMNAT3 localise to the Golgi apparatus and mitochondria, 
respectively, NMNAT1 is a nuclear isoform that was previously studied in the Wlds 
(wallerian degeneration, slow) mouse model. In these mice, a fusion protein (Wlds) was 
identified, consisting of Ube4b and the complete coding sequence of Nmnat1. 
Subsequently, this fusion protein was found to have a protective effect on axonal 
degeneration after neuronal injury11,12 and Nmnat1 activity was found to be required for this 
phenomenon13-15. Homozygous null mutations in this gene in Drosophila melanogaster and 
murine models result in early lethality. Heterozygous knockout mice displayed normal 
development16 and a retinal knockout in the fruit fly resulted in progressive retinal 
degeneration17. NAD+ levels rapidly decreased in axons prior to their degeneration. 
However, retinal degeneration cannot probably be attributed to enzymatic activity of 
NMNAT1. An inactive Nmnat1 in Drosophila was able to prevent photoreceptor 
degeneration17. Therefore, Perrault et al. hypothesized that this protein may have an 
additional chaperone function9. 
Expanding the genetic heterogeneity of RP and LCA 
198 
 
The NMNAT1 mutations reported so far were found throughout the entire coding 
sequence. Most of the mutations (58%), however, are clustered in exon 5. The vast 
majority of variants identified in patients with LCA (31/39) are missense mutations. Only six 
mutations result in carboxy-terminal truncations of NMNAT1, one extends the protein and 
one abolishes the start codon. The most common mutation, p.(E257K), was reported in 27 
cases (in one case homozygously) and proven via an NAD/NADH assay to impede 
NMNAT1 activity when present in homozygous state in vivo and in a mutant construct in 
vitro8. The purpose of this study was to assess the prevalence of NMNAT1 mutations in a 
mixed ethnicity LCA cohort and to investigate its involvement in other progressive retinal 
degenerations. 
Materials and methods 
Patient cohorts 
A cohort of 693 patients with inherited retinal dystrophies participating in this study had 
been collected over a period of 17 years. DNA was extracted from 8 ml of peripheral blood 
using standard salting-out procedure18 and the aliquots were stored at -20°C. The group 
consisted of 265 LCA patients (104 with and 161 without a genetic diagnosis). In addition, 
an extended cohort with no established causative mutation was included in the study: 271 
isolated or autosomal recessive RP probands, 49 unrelated cases with autosomal 
dominant RP, as well as 108 persons with isolated or autosomal recessive CRD. The 
patients were of mixed ethnic and geographic origin (European, African or Asian). At least 
204 healthy, unrelated individuals from the Western European population were included in 
this study as controls. Written or verbal informed consent was obtained from all 
participants. The study was approved by the local Ethics Committee and adhered to the 
tenets of the Declaration of Helsinki. Ophthalmic examination in seven patients with 
NMNAT1 variants included best corrected visual acuity, ophthalmoscopy and fundus 
photography, if feasible. 
NMNAT1 sequence analysis 
DNA samples of genetically unsolved LCA patients were screened for mutations in all 
coding exons of NMNAT1. Samples underwent amplification by polymerase chain reaction 
(PCR) and were analysed by Sanger sequencing. In addition, RP and CRD samples, as 
well as LCA cases with previously established genetic diagnosis, were subjected to 
sequence analysis of exon 5 of NMNAT1. In this group, upon identification of a mutation in 
exon 5, all exons of NMNAT1, including the non-coding exon 1, were tested by 
sequencing. All identified mutations were assessed for pathogenicity using the nucleotide 
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conservation score in 44 vertebrate species (PhyloP), as well as amino acid substitution 
prediction programs (SIFT, PolyPhen2). To detect the p.(E257K) mutation in control 
individuals, BspCNI restriction of amplified genomic DNA fragments was performed, 
followed by agarose gel electrophoresis. The other mutations were assessed in the control 
group using either amplification refractory mutation system (ARMS) PCR (p.(H206R), 
p.(V244A)) or restriction fragment length analysis with appropriate enzymes: BsmFI 
(p.(N18S)), CviAII (p.(W85R)), BaeGI (p.(D158H)) and AseI (p.(E199*)). All enzymes were 
purchased from New England Biolabs, Inc., Hitchin, UK. All PCR reactions were performed 
in a volume of 20 µl containing 40 ng genomic DNA, 0.2 µM of each primer, 2 mM MgCl2, 
1 mM dNTPs, PCR buffer provided by the manufacturer and 0.5 U Taq polymerase 
(Invitrogen, Breda, The Netherlands). Primers are listed in Supplementary table 1. 
Statistical analysis was performed using IBM SPSS Statistics version 20 software (IBM 
Corporation, New York, NY, USA). 
Supplementary table 1. Primer sequences for the amplification of the NMNAT1 gene 
Primer Sequence 
Product size 
(base pairs) 
NMNAT1 exon 1 F GCCAGTCCCAGAGTTTAGGG 
287 
NMNAT1 exon 1 R GACTCCACCACACCATCCTG 
NMNAT1 exon 2 F TGGCAGAGCAAGACCTTATC 
289 
NMNAT1 exon 2 R ACCCGGCTGGTTCTCTAGTC 
NMNAT1 exon 3 F ATTGATCGTAATATTTCCTGTGC 
380 
NMNAT1 exon 3 R CAACACACGTGACAGTTTTGC 
NMNAT1 exon 4 F TGATATATTCTAATGGAGCATGTGAG 
264 
NMNAT1 exon 4 R GGGTTTGCTCAGCTACAGAATC 
NMNAT1 exon 5 F ATACCCCAAAGCTCTGTTTTATTCTTC 
545 
NMNAT1 exon 5 R AACTTTTAAGCTTTAGTTTAGGCAACAG 
NMNAT1 exon 3 F_p.W85R_CviAII GCATCATCTCTCCTGTTGGT 
207 
NMNAT1 exon 3 R_p.W85R_CviAII AGCCATTTACACAGAACTGACA 
NMNAT1 exon 5 F_p.E257K_BspCNI GGCCAGAGCATTCGCTACT 
185 
NMNAT1 exon 5 R_p.E257K_BspCNI ATCCCCAAATGGGAAGTCTG 
NMNAT1 exon 5_p.H206R_wt_F GAATCGGATGTGCTGTGGAAAGG 
287 NMNAT1 exon 5_p.H206R_mut_F GAATCGGATGTGCTGTGGAAAGA 
NMNAT1 exon 5_p.H206R_R ATCCCCAAATGGGAAGTCTG 
NMNAT1 exon 5_p.V244A_wt_R AATTATGCTTTTCAATGTATTCTTGCA 
349 NMNAT1 exon 5_p.V244A_mut_R AATTATGCTTTTCAATGTATTCTTGCG 
NMNAT1 exon 5_p.V244A_F ATACCCCAAAGCTCTGTTTTATTCTTC 
 
F: forward primer; mut: mutant-specific; R: reverse primer; wt: wild-type-specific 
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Segregation analysis 
To ensure that the two compound heterozygous mutations in exon 5 were located on 
different alleles and since DNA samples of the parents of the affected individuals were not 
available, both allelic copies of exon 5 were tested by cloning. The PCR products 
encompassing both mutations were cloned in the TOPO vector containing an ampicillin 
resistance cassette using the TOPO TA cloning kit according to manufacturer’s 
instructions (Invitrogen, Breda, the Netherlands). Plasmid DNA was isolated using the Roti 
Prep plasmid Mini kit (Carl Roth, Karlsruhe, Germany) and the vector was sequenced 
using the NMNAT1 exon 5 specific primer. 
Results 
Among all patients in this study, compound heterozygous mutations were found in six 
families. All patients carrying NMNAT1 mutations were of European origin. Six of the 
identified mutations, five missense and one nonsense variant, had not been described 
earlier (Table 1). 
Table 1. Mutations in NMNAT1 detected in LCA patients 
Patient Variants Segregation 
1 c.53A>G (p.(N18S))/c.472G>C (p.D158H) n.d. 
2 c.769G>A (p.(E257K))/c.253T>C (p.(W85R)) n.d. 
3.1 c.769G>A (p.(E257K))/c.617A>G (p.(H206R)) 
yes 
3.2 c.769G>A (p.(E257K))/c.617A>G (p.(H206R)) 
4 c.769G>A (p.(E257K))/c.595G>T (p.(E199*)) yes 
5 c.769G>A (p.(E257K))/c.731T>C (p.(V244A)) yes 
6 c.769G>A (p.(E257K))/c.619C>T (p.(R207W)) yes 
arRP, autosomal recessive retinitis pigmentosa; LCA, Leber congenital amaurosis; n.d., not determined; + 
represents a wild-type allele. Novel mutations are marked with bold font. 
Two other variants were previously reported: p.(R207W) and p.(E257K). The pathogenicity 
assessment is presented in Table 2. Single heterozygous c.769G>A (p.(E257K)) alleles 
were present in seven probands with LCA. None of the RP or CRD patients carried 
NMNAT1 exon 5 mutations. The control population did not show the presence of any of the 
aforementioned alleles, with the exception of p.(E257K), which was present in a 
heterozygous state in 1/271 persons. In all cases containing two mutations in exon 5, 
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segregation was confirmed by allelic cloning. All sequencing results are presented in Table 
1. 
Table 2. Mutations in NMNAT1: pathogenicity predictions and population frequencies 
 
All patients with compound heterozygous variants were legally blind and only displayed 
either light or hand movements perception, depending on their age. Patient 4, the only one 
who did not have macular atrophy, did not retain any light perception already when he was 
six years of age. His fundus pictures are unavailable, since the right eye was enucleated 
because of corneal pain and the examination of the left eye was impossible due to corneal 
damage. In patient 6, macular atrophy was suspected but not possible to determine, since 
the degeneration was too far advanced; on fundoscopy, panretinal chorioretinal atrophy 
was visible. In sibship 3, the boy (3.1) had distinct macular atrophy at the age of 6 months, 
while his sister (3.2) developed macular atrophy within the first two years of life. In all 
patients in whom electroretinography was performed, the signals were not detectable. 
Abnormal peripheral fundus pigmentation was visible in six patients. Patient 1 had 
subcapsular cataracts, whereas patient 6 already underwent cataract extraction. The 
results of all clinical examinations are presented in Table 3. 
Variant PhyloP SIFT PolyPhen2 
Heterozygous Exome Variant 
Server occurrence  
(European American) 
per 4.289 persons 
c.53A>G (p.(N18S)) 4.08 tolerated probably damaging 0 
c.115+3A>G (p.?) 0.53 - - 46 
c.253T>C (p.(W85R)) 4.81 deleterious probably damaging 0 
c.472G>C (p.D158H) 6.02 deleterious probably damaging 0 
c.595G>T (p.(E199*)) 2.79 - - 0 
c.617A>G (p.(H206R)) 4.89 deleterious probably damaging 0 
c.619C>T (p.(R207W)) 1.90 deleterious benign 2 
c.731T>C (p.(V244A)) 4.48 deleterious probably damaging 0 
c.769G>A (p.(E257K)) 3.84 tolerated benign 11 
  
 
Table 3. Clinical characteristics of patients with two NMNAT1 variants 
ERG: electroretinography; F: female; IOL: intraocular lens; OS: oculus sinister, left eye; M, male; n.p., not performed; OD: oculus dexter, right eye; RPE: retinal pigment 
epithelium; * the accurate time of diagnosis could not be established. Individuals 3.1 and 3.2 are siblings. 
Patient ID 1 2 3.1 3.2 4 5 6 
Age 23 25 7 2 64 16 72 
Variants 
c.53A>G (p.(N18S)) 
/c.472G>C (p.D158H) 
c.769G>A (p.(E257K)) 
/c.253T>C (p.(W85R)) 
c.769G>A (p.(E257K)) 
/c.617A>G (p.(H206R)) 
c.769G>A (p.(E257K)) 
/c.617A>G (p.(H206R)) 
c.769G>A (p.(E257K)) 
/c.595G>T (p.(E199*)) 
c.769G>A (p.(E257K)) 
/c.731T>C (p.(V244A)) 
c.769G>A (p.(E257K)) 
/c.619C>T (p.(R207W)) 
Gender M F M F M F M 
Origin German / French German Dutch Dutch Danish German Dutch 
Age at 
diagnosis 
~4 months ~6 months ~6 months ~4 months ~12 months ~18 months 1-8 years* 
Refraction 
OD: S+7.0 
OS: S+7.5 
n.p. 
OD: S+4.0=C-2.25 
OS: S+4.0=C-1.0 
OD: S+8.50=C-4.0 
OS: S+8.50=C-4.0 
n.p. 
OD: S-0.25 
OS: S-0.25 
n.p. 
Visual acuity Light perception Light perception 2/60 Light perception No light perception Light perception 
OD: Light perception 
OS: Hand movements 
Macular 
atrophy 
Present Present Present Present Absent Present 
Panretinal chorioretinal 
atrophy 
Fundoscopy 
Peripheral 
pigmentation 
Macular 
pseudocoloboma, 
large atrophic optic 
discs, in the periphery 
RPE-atrophy and mild 
pigmentary changes, 
vessels narrowed 
Macular 
pseudocoloboma, with 
hyperpigmented 
border, pink optic discs, 
subtle RPE changes in 
periphery 
Abnormal pigmentation 
of the macula at 
diagnosis, peripheral 
pigmentation; macular 
atrophy at age 2 
Temporal parapapillary 
chorioretinal lacunar 
atrophies; heavy 
peripheral 
pigmentations 
Periphery normal 
Pallor of the optic disc, 
severely attenuated 
vessels, abundant bone 
spicules spread in 
midperiphery and macula 
Full field ERG 
Non-detectable since 
7 years of age 
Non-detectable Non-detectable n.p. n.p. 
Non-detectable since 2 
years of age 
Non-detectable at 31 
years of age 
Remarks 
Subcapsular cataract 
OS>OD 
None None None 
Keratoconus in both 
eyes, OD enucleated 
due to corneal pain 
None 
OD: aphakia and corneal 
oedema after cataract 
extraction 
OS: IOL 
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Discussion 
Due to its high energy consumption, the retina may be sensitive to deficiencies in 
substrates associated with cellular energy supply. NAD+, being the product of a reaction 
catalysed by NMNAT1, is such a substrate. It is also indirectly responsible for 
posttranslational covalent modifications of key proteins (such as mono- and poly-ADP 
ribosylation)19. Therefore, it is not surprising that NMNAT1 mutations cause a severe form 
of hereditary retinal degeneration (Figure 1). In this study, none of the RP or CRD patients 
carried NMNAT1 exon 5 mutations. A separate question is the origin of the macular 
atrophy. Atrophic macular lesions may arise secondary to photoreceptor death, as it has 
been described in CRD4, but also in blue cone monochromacy20 and achromatopsia21. In 
LCA the macular lesions may evolve in time: patient 3.2 showed abnormal central 
pigmentations at the age of 4 months, which developed into macular atrophy at the age of 
2 years. In our study, one of the seven patients (patient 4) in whom we identified NMNAT1 
mutations, did not exactly display this feature, but rather a parafoveal atrophy. The genetic 
data gathered from our study, as well as other research, suggest that LCA patients with 
NMNAT1 variants have a significant residual NMNAT1 activity. Most of the variants 
represent combinations of nonsense mutations or missense mutations predicted by in 
silico prediction programs to be severe, with other alterations that are presumed to exert a 
milder effect on the protein. Only one patient with a homozygous null mutation (p.(W169*)) 
has been reported9. The lethality of Nmnat1 knockout mice suggests that human embryos 
with such a genotype would not be viable16. It is not clear how the p.(W169*) variant would 
retain any NMNAT1 activity; however, it was suggested that this phenomenon can rather 
be ascribed to NMNAT1 chaperone function, which is predicted to remain intact9. 
The p.(E257K) mutation is of particular interest. Deemed to be neutral by prediction 
programs SIFT and PolyPhen2, this missense alteration displays also a very low level of 
nucleotide conservation and the physico-chemical difference between these amino acids, 
measured by Grantham score is only marginal. Nevertheless, a previous study showed 
that this mutation not only disrupts NMNAT1 activity, but also has the most profound 
impact of all five mutations identified in that study8. The mechanism of this negative effect 
is yet unknown. Perrault and colleagues speculated that the p.(E257K) variant is in linkage 
disequilibrium with a yet undiscovered regulatory variant in the same gene,  
causing the mRNA to be expressed at a low level. However, the  
experiments in question were performed by expressing recombinant NMNAT1  
protein in cell lines, using constructs that did not contain regulatory parts of the gene. 
  
 
 
Figure 1. Schematic representation of the location of mutations reported in NMNAT1. 
On top are shown missense and in-frame mutations, whereas mutations below the gene have a truncating or extending effect. Variants that were identified in this study are indicated by white 
letters in black boxes. The most common mutation, p.(E257K), is underlined. 
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Another peculiar finding is the enrichment of heterozygotes for this mutation in LCA 
patients compared to control groups, which was previously found to be present in 4.4% of 
the patient alleles vs. none in 400 control alleles in one study9, which was a statistically 
significant difference. Nonetheless, the considered group consisted only of pre-screened, 
unsolved LCA probands. In this study, we also screened our LCA cohort with patients in 
which causal mutations were previously identified. In this cohort, the p.(E257K) variant was 
present heterozygously in 5 LCA proband alleles (0.94%; Table 2) vs. only 1 in 271 
Caucasian control alleles (0.18%; Fisher’s exact test, p=0.12). Moreover, when comparing 
the LCA cohort to European American frequency in Exome Variant Server data, a 
statistically significant difference was observed between LCA patients and controls (0.13%, 
Fisher’s exact test, p=0.002). It can be inferred that this variant is specific for the Western 
European population; however, the enrichment in LCA patients may indicate that this 
variant acts as a modifier in one or several other genetic subtypes of LCA. Whole exome 
sequencing of these cases may further shed light on a potential modifier effect of this 
NMNAT1 allele on other genetic subtypes of LCA. 
Besides the p.(E257K) change, one other mutation, p.R207W, was detected in multiple 
patients. The combination of p.(R207W) and p.(E257K) variants was by far (8/311 pre-
screened cases from our and two other studies) the most prevalent among NMNAT1-
mutated LCA patients. Eight individuals of French origin were found to carry this 
combination of variants by two research groups8,9, which may indicate that p.(R207W) is a 
founder mutation in this population. 
Two additional, potentially harmful mutations were identified only heterozygously in LCA 
patients: c.12dup (p.E5Rfs*4) and a putative splice site mutation c.115+3A>G (p.?). Given 
the fact that they were identified in cases with LCA and RP, these mutations may be 
present in compound heterozygous state with a missing “second hit” on the other allele; for 
example an unidentified alteration either deep within an intron or in a regulatory sequence. 
The c.115+3A>G variant, although predicted to diminish the strength of the splice site, may 
however be a benign alteration, since it is rather frequent in the Caucasian population 
(Table 2). All other mutations were predicted to have a deleterious effect. Functional 
studies are required to evaluate the potential effect of these alterations on the protein. The 
indirect assessment of NMNAT1 activity by NAD measurement in patient’s erythrocytes 
and lymphoblast cells was previously used for evaluating the pathogenicity of a given 
mutation. Since other tissues appear to be unaffected by NMNAT1 mutations, it cannot be 
certain whether the results of these measurement reflect the in vivo situation in the retina. 
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In conclusion, there is a strong association between NMNAT1 mutations and macular 
atrophy, although this feature is not always present. NMNAT1 seems to be involved in a 
small subset of LCA cases, being responsible for 2.3% of the cases in our cohort of 265 
LCA patients. Although the difference was not significant, the p.(E257K) mutation was 
found to be enriched in a heterozygous state in LCA individuals compared to ethnically-
matched controls, suggesting that this allele potentially acts as a modifier in other genetic 
subtypes of LCA. 
Acknowledgements 
The research of A.M.S. and R.W.J.C. was supported by the Netherlands Organization for 
Scientific Research (TOP-grant 91209047, to F.P.M.C. and A.I.d.H.). The research of 
F.P.M.C. and A.I.d.H. was supported by the Algemene Nederlandse Vereniging ter 
Voorkoming van Blindheid, the Gelderse Blinden Stichting, the Landelijke Stichting voor 
Blinden en Slechtzienden, the Macula Degeneratie Fonds, the Rotterdamse Stichting 
Blindenbelangen and the Stichting Blinden-Penning. 
Novel compound heterozygous NMNAT1 variants associated with LCA 
207 
 
References 
1. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human 
retinal and vitreoretinal diseases. Prog Retin Eye Res 2010;29:335-75. 
2. den Hollander AI, Black A, Bennett J, Cremers FPM. Lighting a candle in the dark: 
advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 
2010;120:3042-53. 
3. Sahel J, Bonnel S, Mrejen S, Paques M. Retinitis pigmentosa and other dystrophies. 
Dev Ophthalmol 2010;47:160-7. 
4. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis 2007;2:7. 
5. Heckenlively JR, Foxman SG, Parelhoff ES. Retinal dystrophy and macular 
coloboma. Doc Ophthalmol 1988;68:257-71. 
6. Chiang PW, Wang J, Chen Y, Fu Q, Zhong J, Chen Y, Yi X, Wu R, Gan H, Shi Y, 
Chen Y, Barnett C, Wheaton D, Day M, Sutherland J, Heon E, Weleber RG, Gabriel LA, 
Cong P, Chuang K, Ye S, Sallum JM, Qi M. Exome sequencing identifies NMNAT1 
mutations as a cause of Leber congenital amaurosis. Nat Genet 2012;44:972-4. 
7. Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, Chakarova 
C, Audo I, Mackay DS, Zeitz C, Borman AD, Staniszewska M, Shukla R, Palavalli L, 
Mohand-Said S, Waseem NH, Jalali S, Perin JC, Place E, Ostrovsky J, Xiao R, 
Bhattacharya SS, Consugar M, Webster AR, Sahel JA, Moore AT, Berson EL, Liu Q, Gai 
X, Pierce EA. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet 
2012;44:1040-5. 
8. Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, Ren H, Chen Y, Li Y, 
Fishman GA, Genead M, Schwartzentruber J, Solanki N, Traboulsi EI, Cheng J, Logan 
CV, McKibbin M, Hayward BE, Parry DA, Johnson CA, Nageeb M, Finding of Rare 
Disease Genes Canada C, Poulter JA, Mohamed MD, Jafri H, Rashid Y, Taylor GR, Keser 
V, Mardon G, Xu H, Inglehearn CF, Fu Q, Toomes C, Chen R. Mutations in NMNAT1 
cause Leber congenital amaurosis and identify a new disease pathway for retinal 
degeneration. Nat Genet 2012;44:1035-9. 
9. Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, 
Delphin N, Fares-Taie L, Gerber S, Xerri O, Edelson C, Goldenberg A, Duncombe A, Le 
Meur G, Hamel C, Silva E, Nitschke P, Calvas P, Munnich A, Roche O, Dollfus H, Kaplan 
J, Rozet JM. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset 
severe macular and optic atrophy. Nat Genet 2012;44:975-7. 
10. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and 
differential catalytic properties of the three human nicotinamide mononucleotide 
adenylyltransferase isoforms. J Biol Chem 2005;280:36334-41. 
11. Coleman MP, Freeman MR. Wallerian degeneration, wld(s), and nmnat. Annu Rev 
Neurosci 2010;33:245-67. 
Expanding the genetic heterogeneity of RP and LCA 
208 
 
12. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, 
Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, 
Magni G, Ribchester RR, Perry VH, Coleman MP. Wallerian degeneration of injured axons 
and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001;4:1199-
206. 
13. Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR. Wld S requires Nmnat1 
enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell 
Biol 2009;184:501-13. 
14. Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S, Adalbert R, Silva A, 
Bridge K, Huang XP, Magni G, Glass JD, Coleman MP. NAD(+) and axon degeneration 
revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration. Cell Death 
Differ 2007;14:116-27. 
15. Yahata N, Yuasa S, Araki T. Nicotinamide mononucleotide adenylyltransferase 
expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 
2009;29:6276-84. 
16. Conforti L, Janeckova L, Wagner D, Mazzola F, Cialabrini L, Di Stefano M, 
Orsomando G, Magni G, Bendotti C, Smyth N, Coleman M. Reducing expression of NAD+ 
synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. FEBS J 
2011;278:2666-79. 
17. Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, Schulze KL, Verstreken P, Bellen 
HJ. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis 
activity. PLoS Biol 2006;4:e416. 
18. S. A. Miller, D. D. Dykes and H. F. Polesky. A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. 
19. L. Sorci, F. Cimadamore, S. Scotti, R. Petrelli, L. Cappellacci, P. Franchetti, G. 
Orsomando and G. Magni. Initial-rate kinetics of human NMN-adenylyltransferases: 
substrate and metal ion specificity, inhibition by products and multisubstrate analogues, 
and isozyme contributions to NAD+ biosynthesis. Biochemistry. 2007;46:4912-22. 
20. Ayyagari R, Kakuk LE, Coats CL, Bingham EL, Toda Y, Felius J, Sieving PA. Bilateral 
macular atrophy in blue cone monochromacy (BCM) with loss of the locus control region 
(LCR) and part of the red pigment gene. Mol Vis 1999;5:13. 
21. Thiadens AAHJ, Slingerland NW, Roosing S, van Schooneveld MJ, van Lith-
Verhoeven JJC, van Moll-Ramirez NG, van den Born LI, Hoyng CB, Cremers FPM, Klaver 
CCW. Genetic etiology and clinical consequences of complete and incomplete 
achromatopsia. Ophthalmology 2009;116:1984-9 
  
 210 
 
Adapted from: JAMA Ophthalmology, 2014 
Anna M. Siemiatkowska1, Janneke H.M. Schuurs-Hoeijmakers1,2, Danielle G.M. Bosch1,3, F. 
Nienke Boonstra3,5, Frans C.C. Riemslag3,4, Mariken Ruiter1, Bert B.A. de Vries1,2,5, Anneke 
I. den Hollander1,2,6, Rob. W.J. Collin1,2, Frans P.M. Cremers1,2 
1Department of Human Genetics, Radboud University Medical Center, Nijmegen, The 
Netherlands; 2Radboud Institute for Molecular Life Sciences, Radboud University Medical 
Center, Nijmegen, The Netherlands; 3Bartimeus Institute for the Visually Impaired, Zeist, 
The Netherlands; 4The Rotterdam Eye Hospital, Rotterdam, The Netherlands; 5Donders 
Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, 
The Netherlands; 6Department of Ophthalmology, Radboud University Medical Center, 
Nijmegen, The Netherlands. 
 211 
 
 
Non-penetrance of the most frequent 
autosomal recessive Leber congenital 
amaurosis mutation in NMNAT1 
Chapter 5b 
 212 
 
Abstract 
Importance: The NMNAT1 gene was recently found to be mutated in a subset of patients 
with Leber congenital amaurosis and macular atrophy. The most prevalent NMNAT1 
variant was p.(E257K), which was observed in 38 of 106 (35.8%) of alleles. On the basis of 
functional assays, it was deemed a severe variant. 
Observations: The p.(E257K) variant was 80-fold less frequent in a homozygous state in 
patients with Leber congenital amaurosis than predicted based on its heterozygosity 
frequency in the European American population. Moreover, we identified this variant in a 
homozygous state in a patient with no ocular abnormalities. 
Conclusions and relevance: On the basis of these results, the p.(E257K) variant is 
considered not fully penetrant. Homozygotes of the p.(E257K) variant in most persons are 
therefore not associated with ocular disease. Consequently, genetic counsellors should 
exercise great caution in the interpretation of this variant. 
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In the September 2012 issue of Nature Genetics, 4 research groups reported NMNAT1 
(OMIM #608700) mutations in patients with Leber congenital amaurosis (LCA)1-4. Most 
patients with these mutations had severe, early-onset vision loss accompanied by macular 
atrophy. Homozygous Nmnat1 knockout mice displayed early lethality, whereas 
heterozygous animals remained unaffected5. In our LCA cohort, we found compound 
heterozygous NMNAT1 variants in 6 probands. In previous studies, the most prevalent 
NMNAT1 variant was c.769G>A (p.(E257K)), observed in 38 of106 (35.8%) of alleles. 
Collectively, this variant was found in 43 of 957 patients with LCA1-4. 
Eleven of 4,289 “healthy” European Americans are p.(E257K) heterozygotes 
(http://evs.gs.washington.edu/EVS/). When the Hardy-Weinberg principle is applied, 
homozygous alleles should be present in approximately 1 in 600,000 individuals. Because 
LCA occurs in 1 in 50,000 individuals, it can be inferred that this homozygous variant, if 
fully penetrant, should be responsible for approximately 8% of patients with LCA. Only 1 in 
957 (0.1%) patients with LCA, however, carried the p.(E257K) variant in a homozygous 
state3. This 80-fold discrepancy between true and expected homozygosity rates in LCA led 
us to hypothesise that p.(E257K) is a hypomorphic variant that is not fully penetrant. 
The activity of NMNAT1 was measured in erythrocytes in the one homozygous patient and 
was significantly lower than in his heterozygous mother3. This variant was also tested in a 
gene construct in HeLa cells and was suggested to be the most severe allele of 4 
NMNAT1 variants3. 
In our in-house (Department of Human Genetics, Radboud University Medical Center, 
Nijmegen) exome database, the p.(E257K) variant was found in 10 of 850 persons. One of 
these individuals (patient II:4), who had intellectual disability, was carrying this substitution 
in a homozygous state (Figure 1). Interestingly, an unaffected sibling (II:1) was also 
homozygous for p.(E257K). After clinical and ophthalmological examination, individuals II:1 
and II:4 did not have any ocular abnormalities. On the basis of these findings, we assume 
that in persons of European descent, there is a much larger group of healthy individuals 
who carry the p.(E257K) variant in a homozygous state than there are patients with LCA 
who carry this variant on both alleles. In patients with LCA carrying one p.(E257K) variant, 
the other NMNAT1 allele would then be predicted to be more severe. Additional evidence 
for this assumption was obtained using haplotype analysis. The patient with LCA who was 
previously found to be homozygous for the p.(E257K) mutation was analysed for single-
nucleotide polymorphisms in NMNAT1 and proven to harbour this variant on 2 different 
haplotypes3. In our patients, one of these haplotypes was present in every person with the 
p.(E257K) variant, including the healthy individual II:1 (data not shown). Consequently, we  
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Figure 1. Non-penetrance of NMNAT1 variant p.(E257K) in a family with intellectual disability. 
In patient II:4, exome sequencing had revealed a homozygous NMNAT1 variant (p.(E257K)), which did not fully segregate 
with the intellectual disability in this family. Individual II:1 also carries this variant in a homozygous state and on 
ophthalmologic examination (i.e. electroretinography and optical coherence tomography) had no ocular abnormalities. 
hypothesise that there may be differential expression of the 2 alleles harbouring the 
p.(E257K) mutation, due to trans- or cis-acting elements. This would render one of them 
more severe, which might explain the non-penetrance observed in individuals II:1 and II:4. 
Similarly behaving variants were previously found in ABCA4 (OMIM #601691) and BBS1 
(OMIM #209901). A frequent ABCA4 variant, p.(G863A), was identified in a compound 
heterozygous manner in one-third of Dutch persons with Stargardt disease and in a 
heterozygous state in 3% of healthy controls6. In several thousands of patients with 
Stargardt disease this variant was never found in a homozygous state (F.P.M.C., 
unpublished data). Consequently, it was deemed a hypomorphic allele causing Stargardt 
disease only if in combination with a severe ABCA4 variant. The most frequent Bardet-
Biedl syndrome-associated variant, p.(M390R) in BBS1, was observed in a homozygous 
state in individuals with Bardet-Biedl syndrome, with non-syndromic retinitis pigmentosa, 
and healthy persons7,8. The presence of low-penetrant variants has also been observed in 
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more common human hereditary conditions, such as cystic fibrosis9. Reduced penetrance 
is frequently observed in both dominant and recessive disorders. The relevant variants can 
be hypomorphic for several reasons. Besides environmental factors (such as in the case of 
breast cancer in BRCA1/2 (OMIM #113705/600185) mutation carriers), incomplete 
penetrance may be due to trans- or cis- acting elements, which would influence its 
expression rendering the variant mild and benign. An example of a trans-acting modifier 
was provided for the PRPF31 gene implicated in autosomal-dominant retinitis pigmentosa 
with reduced penetrance10. A haploinsufficiency model was proposed for PRPF31-
associated retinitis pigmentosa. CNOT3 (OMIM #604910) was found to act as a 
transcriptional repressor of PRPF31, thereby influencing the expression level of the wild-
type PRPF31 gene11,12. The identification of this kind of transcriptional regulators is 
possible if the target gene of interest and its regulators are expressed highly enough in 
accessible patient cells. The identification of this kind of modifiers through high-throughput 
sequencing is challenging in view of the enormous genetic variability observed in the 
human population. 
Taken together, we propose that the NMNAT1 p.(E257K) variant is a hypomorphic variant 
that almost without exception causes LCA in combination with more severe NMNAT1 
variants. Other variants in NMNAT1 are far less frequent and therefore have not been 
observed in a homozygous state. However, it may be speculated that they also represent 
combinations of mild and severe mutations or 2 alterations exerting a moderate effect, 
which cumulatively result in disease. In a homozygous state, the mild variants would 
generally not cause LCA, unless one or both gene copies show reduced transcription, 
possibly due to trans- or cis-acting modifier elements. This conclusion should be taken into 
consideration when families carrying this variant are genetically counselled, especially 
when the retinal phenotype lacks the macular atrophy and does not occur early in life. In 
those cases, the causal variants are most likely situated in other genes. 
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In this thesis, the genetic defects underlying retinitis pigmentosa (RP) and Leber 
congenital amaurosis (LCA) were investigated. Patients’ samples were initially analysed 
with homozygosity mapping or linkage analysis using genome-wide single nucleotide 
polymorphism (SNP) microarrays. If no genetic diagnosis was established, the samples 
underwent exome sequencing. 
Molecular analysis of Indonesian retinitis pigmentosa families 
In Chapters 2a and 2b, the genetic analysis of RP families from Indonesia is described. In 
35 probands and their affected relatives genome-wide SNP analysis was performed. 
Subsequent homozygosity mapping revealed the mutated gene underlying the disease in 
nine families. After screening for these variants in the entire Indonesian cohort, two more 
families were found to harbour the same CRB1 mutation, c.3914C>T (p.(P1305L)). In the 
original family, it was discovered in the largest homozygous region of 19.3 Mb. In the 
second family the mutation was located in an even larger region of 37.4 Mb. In the third 
family p.(P1305L) was found also in the first ranking homozygous stretch, but it was only 
2.4 Mb long. Haplotype analysis revealed that this variant resided on the same haplotype 
in different families: the first two shared 700 kb, whereas the last one had only 6 kb of the 
common haplotype. The limited size of the shared haplotype suggests that this mutation 
might represent an old founder mutation in the Indonesian population. It cannot be 
excluded, though, that in the last family the same mutation arose de novo due to a 
mutational hotspot in the CRB1 gene. 
In one family without reported consanguinity, a MERTK mutation was localised in a 20.2 
Mb homozygous region shared between the two affected individuals. In comparison to 
other non-consanguineous families, this region was disproportionally large and rather 
within the size range of homozygous regions observed in affected siblings whose parents 
are related. In Indonesian culture marriages between relatives are socially accepted. The 
Indonesian population is heterogeneous as a whole and spreads across approximately 
1000 islands. Consequently, this archipelago forces spatial division between populations. 
Hence, an increased level of consanguinity is expected in these isolated communities. This 
may be responsible for the phenomenon observed in the family carrying the MERTK 
mutation. 
In a family with apparent autosomal recessive inheritance, a homozygous RP1 p.(R338*) 
mutation was identified. Since the majority of RP1 alterations are inherited in autosomal 
dominant manner, this finding resulted in speculations on potential pathophysiological 
mechanisms associated with mutations in this gene. In RP1 the correlation between 
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mutation type and location and the inheritance pattern is complicated. Mutations in 
autosomal dominant RP are mainly protein-truncating and since they are located in the last 
exon, they are predicted to escape nonsense-mediated mRNA decay (NMD). Clustering in 
a “hot-spot” region between amino acid residues 500 and 1053, these variants most 
probably exert a dominant-negative effect due to retained binding with microtubule-
associated proteins, subsequently competing with wild-type RP1. Truncating mutations in 
other regions may either be subjected to NMD (stop codons in exons 2 and 3) or interrupt 
interactions with other proteins. Therefore, they would simply result in the absence of 
functional RP1 and cause autosomal recessive RP, as predicted in case of p.(R338*) 
mutation. 
Similar disease mechanisms in other genes have previously been reported. For instance, 
RHO was proven to harbour different mutations causing either autosomal dominant or 
recessive retinitis pigmentosa. In this gene, initially, heterozygous mutations were found to 
cause dominant inheritance1. The vast majority of those are substitutions of crucial, 
conserved amino acids. In contrast, null mutations cause recessively inherited RP2,3. 
Haploinsufficiency was determined not to be the cause of autosomal dominant inheritance, 
since none of the mutations have a null effect4. It was proven that these variants rather 
result in a dominant-negative disease mechanism5-7. This finding has profound implications 
for gene therapy. At the moment, a dual therapeutic approach is being tested: suppressing 
the mutated RHO gene with appropriate interfering RNA (RNA-i) followed by gene 
replacement8. If this method proves successful, it will open a whole new range of 
possibilities for treatment of autosomal dominant disorders. 
CRX-binding regions: exome NGS data prioritisation and candidate gene approach 
Chapter 3 discusses the effectiveness of utilising the knowledge of CRX regulation of the 
retinal genes in exome NGS candidate variant prioritisation. CRX is a transcription factor 
that is particularly crucial for photoreceptor development. In murine retinae, both in wild-
type and cone-dominated Nrl-/- mutants, the genes were ranked according to the number of 
CRX-positive reads identified in ChIP-Seq data, representing potential CRX-binding sites. 
About two-thirds of genes known to be involved in inherited retinal diseases (IRDs) had the 
highest score among 50 other genes located in their neighbourhood. The rest of the IRD 
genes were known or presumed to be mainly involved in the RPE and are thus not 
regulated by CRX. 
After prioritisation of all variants identified by exome sequencing in a patient with arRP and 
filtering for homozygous regions due to consanguinity, only two candidate genes remained: 
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FRYL and MAK. Variants present in FRYL were classified as benign and thus were 
excluded from further analysis. MAK plays a crucial role in ciliary maintenance and a 
homozygous nonsense mutation in this gene was identified as the cause of RP in this 
patient. Encouraged by this result, we hypothesised that the highest ranking genes in 
ChIP-seq data of CRX-binding regions in a wild-type mouse model may be candidate 
genes for RP and LCA, while those identified and in a cone-dominated Nrl-/- mutant model 
may represent candidate genes for CRD. 
Subsequently, we screened multiple genes with high CRX binding scores that were 
located in the largest homozygous regions of our IRD patients. Candidate genes C18orf25, 
CADM2, CEP250, CPLX4, CROCC, CRY2, FZD5, ING2, MSI1, PPP2R2B and STX3 
underwent Sanger sequencing in 31 RP patients. Despite their high ranking in CRX 
binding sites in the locus, no mutations were identified. In conclusion, prioritisation of 
exome NGS data using CRX binding site scores may prove useful in some cases, though 
in general it is a poor predictor for the identification of candidate genes residing in largest 
homozygous regions. 
Shared haplotype-based exome NGS data analysis 
In Chapter 4a, the discovery of MVK mutations is presented. For the purpose of exome 
NGS data filtering and to facilitate the prioritisation of variants, software for haplotype 
analysis was devised (Henkes et al., unpublished). Briefly, families displaying autosomal 
recessive inheritance with multiple affected individuals were subjected to genome-wide 
SNP array analysis. The program utilises SNP array data to extract common haplotypes 
between the affected family members. The principle is similar to PLINK homozygous 
region analysis9; however, it extracts all shared haplotype regions, regardless of the 
zygosity. With the aid of this software, we prioritised the variants in RP patients and found 
only a single gene harbouring compound heterozygous mutations which was left after 
exome sequencing data filtering: MVK, previously described to cause mevalonate kinase 
deficiency (MKD). Surprisingly, not all mutations affecting crucial amino acids of this 
protein result in photoreceptor degeneration; only nine patients (of about 300 patients 
carrying mutations in this gene) have been reported to display retinal dystrophy. Two of 
them, from our recent study described in Chapter 4a, display only very mild MKD features 
and were initially not diagnosed as MKD by their physicians. Seven others had rather 
severe disease presentation with full involvement of the neurological system10-12. It has 
recently been demonstrated that the neurons die due to apoptosis and pyroptosis caused 
by inflammation13. This is consistent with the autoinflammatory clinical picture of MKD. The 
RP patients (described in Chapter 4a) carrying MVK mutations which were reported 
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previously in severe MKD, have only mild features of this syndrome. This suggests that the 
neurons are, for the most part, able to avoid this degenerative process. The protective 
factor is yet to be discovered. 
Many of the proteins taking part in visual processes undergo prenylation – a process of 
covalent attachment of farnesyl or geranylgeranyl moieties (discussed in Chapter 4b). 
Mevalonate kinase is at the very beginning of this pathway, being an enzyme responsible 
for synthesis of all isoprenoids. Most probably, the shortage of these residues, crucial for 
correct localisation and transport to membranous outer segment structures of many retinal 
proteins, is responsible for the retinal dystrophy phenotype due to MVK mutations. 
Choroideremia is caused by mutations in the gene encoding REP-1, a protein also 
involved in the prenylation process. Hence, an overlap of the pathogenic mechanism may 
exist, namely the underprenylation of crucial proteins. Still, the variability of MVK-
associated diseases remains unexplained. 
Interpretation of the identity-by-descent mapping and exome NGS data 
In 2010, when this research project started, about 50% of non-syndromic IRD cases were 
estimated to carry the causative mutation in the coding sequence or splice sites of ~150 
genes known to be mutated in IRDs14. It was presumed that a significant percentage of 
IRD cases would be caused by alterations in genes previously not associated with IRDs. 
Since then, the number of genes proven to be involved in syndromic and non-syndromic 
IRD has reached ~200. Comprehensive sequence analysis of known IRD genes yielded 
causal variants in ~75% of Pakistani IRD families (Khan et al., unpublished)15,16, although 
this number was slightly lower in a larger cohort (68.5%17) and even lower in a targeted 
panel of 163 IRD genes (36.5%18). The relatively low mutation rate in the latter study may 
to some degree be due to incomplete capturing of several exons in two commonly mutated 
genes, EYS and USH2A. There may also be technical reasons for these low yields, such 
as low coverage of GC-rich sequences due to enrichment problems or missed calling of 
sequence variants located only in unidirectional reads. Alternative explanations may be 
related to mutation location and type (such as deep intronic mutations or copy number 
variations). 
In the IRD cohorts described in this thesis (Chapter 1a) and in patients newly ascertained 
by ophthalmologists, exome NGS was performed in 13 LCA and 72 RP patients. Six LCA 
and 29 RP patients had mutations in previously known IRD-associated genes. A new 
genotype-phenotype correlation for MVK was found. Seven LCA and 41 RP patients 
received no genetic diagnosis, which accounts for 54% and 57%, respectively. Many of 
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these patients were previously screened with various techniques; therefore, these results 
may differ from those that would be obtained with exome NGS of unscreened patients. 
Still, the yield of novel IRD-associated genes resulting from exome NGS data is generally 
poorer than initially expected. Aside from technical reasons, this may be due to the fact 
that many mutations in known IRD-associated genes may remain undetected via widely 
used techniques, such as Sanger sequencing, high resolution genome-wide SNP 
genotyping arrays or even exome NGS. Such mutations include exon-level deletions or 
amplifications, inversions, translocations, as well as variants present deep in the introns, 
which may affect splicing. These alterations require a different approach, such as whole 
genome sequencing (WGS) or transcriptome sequencing of iPSC-derived photoreceptor-
like cells from the patient (see Chapter 1b). A recent publication by Nishiguchi et al.19 
presented such variants detected with WGS in two out of 16 (12.5%) of the unsolved IRD 
cases; this percentage may be different in a larger cohort. In yet another study, a 
diagnostic yield of 70% was obtained in a mixed cohort of ar/ad/isolated RP and LCA 
patients20. This approach involved high-coverage exome NGS, which enabled an 
additional copy number variation (CNV) analysis. This led to the identification of a 
heterozygous deletion in non-coding exon 1 of EYS, which appeared to cause RP in 
combination with a truncating mutation on the other allele. It was proposed that the loss of 
exon 1 may impair transcription of the mutant gene copy and result in a null allele. 
Additionally, heterozygous CNVs were found to be common in PRPF31, a gene 
responsible for adRP. Some of these variations showed incomplete penetrance. Such 
findings will most probably appear to be more common with the widespread application of 
WGS in the coming years. 
Some of the missing genetic causes of non-syndromic IRDs may be attributed to 
hypomorphic mutations. In these cases, mutations may be considered non-causative due 
to “benign” assessment by prediction programs or too stringent exome NGS data filtering. 
In the present thesis, NMNAT1 was found to harbour such a mutation, p.(E257K) (see 
Chapters 5a and b). In this gene, the combination of two null alleles (with the exception of 
p.(W169*) in one case) is likely lethal, as proven by animal studies21,22. The p.(E257K) 
mutation was commonly found in combination with other alleles and only one patient 
harboured this variant in a homozygous state. This, supported by Hardy-Weinberg 
calculations and the identification of a homozygous p.(E257K) mutation in a healthy 
individual, led to the speculation that NMNAT1 LCA-causing mutations are likely a 
combination of a mild (hypomorphic) allele and a severe variant or two variants exerting a 
moderate effect. 
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In a broader context, hypomorphic alleles are thought to underlie many hereditary 
disorders with reduced penetrance. For example, the p.(R117H) mutation of the CFTR 
gene was found to cause cystic fibrosis in 3 out of 19 homozygous newborns, yielding a 
penetrance of only 16%. This variant also shows variable expressivity, as it may cause 
wide range of disease severity, including mild symptoms which do not manifest until later 
in life23. An interesting case is a polymorphic variant in intron 8 of the CFTR gene. The 
positions c.1210-12_1210-6 in the reference sequence contain a seven-nucleotide poly-T 
stretch. The less common, polymorphic variants contain nine and five thymines. In 
combination with a severe mutation (e.g. p.(F508del)), the mild 5T variant results in 
congenital bilateral absence of the vas deferens only (male infertility), without any other 
cystic fibrosis symptoms24. In an adult-onset disease, haemochromatosis, the most 
prevalent mutation is an amino acid substitution in HFE, p.(C282Y). This alteration was 
previously presumed to be highly penetrant (up to 95% in males). It was believed that 
nearly all homozygotes would develop iron overload symptoms23. However, it was recently 
proven that the disease does not necessarily occur in all individuals that carry this variant 
in a homozygous state, who are present in European populations with a frequency of 
~1/20025, which is approximately the prevalence of the disease caused by all HFE variants 
combined. So far, 47 other HFE mutations have been described to be associated with this 
disease. The p.(C282Y) allele may be hypomorphic due to cis- or trans- acting elements, 
which would then influence its expression rendering it mild or non disease-causative. 
Interestingly, some genes involved in syndromic disorders encompassing retinal 
degeneration were discovered to harbour milder mutations in non-syndromic IRD cases. 
An example is USH2A involved in Usher syndrome. In 2000, a missense mutation, 
p.(C759F), was attributed to non-syndromic RP26. This variant is present in heterozygous 
state in 18 out of 4,300 European descent individuals in Exome Variant Server data 
(http://evs.gs.washington.edu/EVS/). Applying the Hardy-Weinberg principle, it would 
mean that ~1/230,000 individuals of the general population are homozygous for this allele. 
This would in turn imply the homozygous p.(C759F) variant to be responsible for ~2% of 
RP cases, which is not observed. This allele is, however, frequently found in RP cases in 
combination with other, possibly more severe, mutations on the other allele, suggesting 
that it represents a mild mutation. 
Another instance of a gene involved in syndromic disease (Meckel-Gruber, Joubert and 
Senior-Løken syndromes), which was also found to cause non-syndromic IRD (LCA), is 
CEP290. The most frequent variant causing LCA is an intronic substitution causing the 
insertion of an additional exon, which leads to a premature termination codon27. This 
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variant, even when present in a homozygous state, allows significant production of 
normally spliced transcript, which causes it to be milder than other nonsense and 
frameshift mutations present in syndromic forms. Interestingly, this variant has never been 
found homozygously in syndromic IRD patients. 
A subgroup of a large family of lysosomal storage disorders, neuronal ceroid 
lipofuscinoses (Batten disease), is caused by mutations in 13 different genes28. In one of 
these genes, CLN3, new mutations were reported in non-syndromic IRDs18,29. The 
combination of an apparent null variant (p.(Y322*)) with a mild missense change 
(p.(V290L)) caused non-syndromic RP18. 
Taken together, mild mutations in an increasing number of syndromic IRD genes have 
been described to cause non-syndromic IRDs. Therefore, another approach to identify 
novel causes of non-syndromic IRDs may be to scrutinise all sequence variants in exome 
NGS data for the presence of “mild” variants in genes that are known to be mutated only in 
syndromic forms of IRD. 
Future outlook 
As discussed in the previous section, there are many reasons for the poor yield of genetic 
diagnosis obtained from Sanger sequencing supported by homozygosity mapping and 
microarray CNV analysis, as well as exome NGS (with average coverage ~30x). For 
example, in our total cohort of 234 autosomal recessive/isolated RP patients, only 118 
(50.4%) were genetically diagnosed. However, many patients have not been consistently 
tested for variants in known genes. As novel techniques come into light, new possibilities 
arise. Recently, a cost-effective massively parallel sequencing technique was developed, 
in which up to 100 genes may be sequenced using a novel strategy (so-called molecular 
inversion probe strategy, MIP), with an ultra-low reagent cost of only 1€ per DNA sample 
per gene30. Therefore, large cohorts of patients without genetic diagnosis can be analysed 
for all known non-syndromic IRD genes at a relatively low cost. It will probably allow the 
detection of molecular causes of IRDs in about half of them, where mutations in known 
genes were thus far missed for various reasons. This method also allows detection of 
CNVs at the single exon level. Its significant advantage is also a possibility of scaling 
down, e.g. devising tests for groups of genes specific only for a certain type of disease 
(e.g. LCA or RP genes) or for large cohorts of patients with homogenous diseases with 
only a limited number of genes mutated (such as Usher syndrome). 
Despite the numerous benefits of the MIP technique, among the remaining, “unsolved” 
group there will still be patients with variants in known genes. Such mutations, for example 
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alterations deep within introns and regulatory sequences or inversions, can neither be 
detected using the MIP technique, nor any other strategy that focuses on analysing the 
protein-coding sequences. For this purpose, whole genome sequencing or transcriptome 
sequencing should be applied. The latter until recently seemed unrealistic given the 
specific expression patterns in the retina. Lately, new possibilities emerged to culture 
human induced pluripotent stem cells, which may be differentiated into photoreceptor-like 
cells with a retinal gene expression pattern. Therefore, transcriptome sequencing in IRDs 
may soon become a reality31. 
The remaining, yet undiscovered genes involved in IRDs are thus far elusive. Hitherto, 
many genes whose mutations cause non-syndromic IRDs, were discovered either focusing 
on candidates mutated in animal disease models (e.g. NRL, PRCD, RBP3) or their 
functionality and retina-specific protein expression (e.g. genes encoding phototransduction 
or ciliary proteins). Since there are still many animal models with a clear retinal dystrophy 
phenotype in which the causative mutation has been identified, it may be hypothesised 
that some of these genes are also responsible for IRDs in humans. Moreover, novel 
genotype-phenotype correlations will probably emerge from exome NGS for genes 
previously known to be responsible for syndromic forms of IRD. Examples such as Usher 
and Bardet-Biedl syndromes, Batten disease or MKD, encourage us to look for novel non-
syndromic IRD genes within these syndromic gene sets. Additionally, new candidate 
genes emerge daily from exome NGS data, but it is still very difficult to pinpoint the 
causative mutation. This is partly due to the fact that many causal variants in IRDs are 
non-recurrent and the majority of IRD-associated genes are responsible for less than 1% 
of the cases. There are examples of IRD-associated genes which are causal in only one 
family15,32 (European Retinal Disease Consortium, unpublished data). Therefore, it is very 
important to share the data between research groups to identify multiple individuals or 
families with mutations in a novel gene and it is crucial to further develop quick and robust 
methods of functional characterisation using recombinant protein studies and animal 
models. 
The genetic heterogeneity of inherited retinal diseases is expanding at a linear rate. The 
current number of IRD-associated genes (both syndromic and non-syndromic) is around 
two hundred. With the development of new techniques, the genetic diagnosis of hereditary 
diseases becomes increasingly available. The knowledge of underlying genetic defects is 
especially important in cases where gene augmentation therapy may become available. 
After the promising results in RPE65 gene therapy in LCA33, a clinical benefit was recently 
also shown for choroideremia (NCT0146121334). Gene therapies are also being conducted 
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for ABCA4 in Stargardt disease (NCT01367444) and MERTK in RP (NCT01482195). The 
immense genetic heterogeneity of IRDs poses challenges to develop gene therapy for all 
of these disorders. Gene augmentation treatments described above will likely only be 
developed for the genetic defects present in a relatively large proportion of the cases. 
Current laws demand separate clinical trials for efficacy and toxicity for all gene therapies, 
even when using the same vector, promoter and method of delivery. Therefore, the cost of 
clinical trials for genes which are mutated only in a handful of individuals can never 
balance the actual benefit for the patients and the society. 
In the light of this knowledge, other therapies, not dependent on the genetic defect, are 
being explored. Clinical trials are performed with autologous bone marrow-derived or 
umbilical cord-derived pluripotent stem cells. Various agents, such as valproic acid, ciliary 
neurotrophic factor or 9-cis-retinal analogues are also being tested. Finally, for the people 
at the late stages of the disease where photoreceptor death has already occurred, 
electronic epi- or subretinal implants allow for basic object discrimination and recognition 
tasks, raising hopes for sight improvement with technological advancements in the future. 
Retinal disorders, especially those with an early-onset and progressive nature, are 
diseases with great impact on the quality of life. Therefore, they not only require careful 
diagnostics and informing the patients about their prognosis, but also genetic counselling 
for patients who wish to have offspring. The knowledge of the underlying genetic defects is 
crucial for enrolling in the emerging therapeutic programs. Patients frequently request a 
genetic diagnosis, since they undergo a period of uncertainty as to the basis of their 
disorder. The clinician must explain the terms of chance and probability, as well as the risk 
of transmitting the disease to the next generation. In case of couples who already have 
one child with retinal dystrophy there may be a misplaced guilt, which needs to be 
managed by the counsellor. The couple must be presented with available reproductive 
choices and possible psychological impact must be taken into consideration. 
At the moment, there is also a possibility of in vitro fertilisation and subsequent selection of 
an embryo that does not carry the mutant allele(s) (pre-implantational diagnostics). These 
choices are crucial for patients. With therapy still being a far future perspective, counselling 
and the possibility for pre-implantational diagnostics remain the most important outcome of 
molecular analyses. 
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Summary 
Inherited retinal diseases (IRDs) display an enormous spectrum of clinical and genetic 
heterogeneity. To date, about two hundred genes underlying IRDs have been identified. In 
this thesis, the genetic defects and clinical characteristics of patients with two subtypes of 
IRD, retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA), were investigated. 
Initially, positional information of causative genetic defects was obtained using genome-
wide SNP arrays and subsequent homozygosity mapping or linkage analysis. In a later 
phase of the study exome sequencing was performed, occasionally supported by genome-
wide SNP homozygosity mapping or haplotype analysis. These results are summarised at 
the end of Chapter 1a, which also provides a brief introduction to the history of genetics, 
retinal anatomy and visual processes. 
Chapter 1b summarises the contemporary approaches that led to the discovery of genes 
mutated in IRDs. For homogenous monogenic diseases, the analysis is limited to Sanger 
sequencing of all coding exons and flanking intronic sequences of the gene associated 
with the disease. Since the vast majority of IRD genes are mutated in only ~1% of affected 
persons, other strategies for heterogeneous monogenic diseases have to be applied. For 
the time being, targeted resequencing of all known genes (e.g. 61 genes mutated in RP) is 
indicated, using various massively parallel sequencing technologies. If this method fails to 
identify the responsible gene, exome sequencing, with its constantly decreasing cost, may 
be applied. If no causative mutation is found in the protein-coding regions, the whole 
genome can be sequenced, allowing in particular the detection of heterozygous structural 
abnormalities (such as deletions, duplications and inversions). Additionally, deep-intronic 
mutations can be detected in this manner, but their effect can only be proven by 
sequencing of mRNA, preferably derived from patient-specific retinal cells. These cells can 
be obtained by transformation of somatic cells (e.g., fibroblasts) into induced pluripotent 
stem cells, which can then be differentiated into retinal cells. The assessment of the 
pathogenicity of identified variants remains a crucial step in the determination of causality. 
Chapter 2a describes the molecular genetic analysis of fourteen families with RP from 
Indonesia. Using genome-wide SNP analysis, causative mutations in genes previously 
found to be implicated in RP were identified in seven of the fourteen families. In three 
consanguineous families, linkage analysis led to the identification of underlying genetic 
defects in ABCA4, EYS and NR2E3. In four other families, homozygosity mapping was 
utilised to pinpoint mutations in CRB1, MERTK and PDE6A. Although no consanguinity 
was reported, in one family the MERTK mutation was localised in a large homozygous 
region shared between the two affected individuals. The size of this region suggested a 
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close relationship between the parents. Since Indonesia consists of many different tribes, 
some of which are located on islands, it is likely that a certain level of consanguinity is 
present in some of these closed communities even if the individuals are not aware of it. 
Twenty-one additional Indonesian families with RP were ascertained. In one of these 
families, an RP1 nonsense mutation (p.R338*) was found to be involved in arRP, which is 
discussed in Chapter 2b. The vast majority of the mutations in this gene cause an 
autosomal dominant form of RP. Our findings led to speculations on potential 
pathophysiological mechanisms associated with RP1 mutations, which are outlined in this 
chapter. 
In Chapter 3 the discovery of a new ciliary gene mutated in arRP is reported. The analysis 
of exome data poses a significant challenge given the number of variants identified with 
this technique. Many approaches have been applied to distinguish pathogenic mutations 
from benign polymorphisms. This project utilised the results of a previous study, which 
investigated binding patterns of Crx, a transcription factor crucial in the development and 
maintenance of the retina, in wild-type and Nrl-/- knockout mice. The genes were assigned 
Crx-binding regions (CBR) scores as a measure of their expression level in 
photoreceptors. Using these data, variants obtained by exome sequencing of an arRP 
individual from a consanguineous Turkish family were prioritised. In addition, SNP 
homozygosity data were used for filtering of the variants. A homozygous nonsense 
mutation in MAK, a gene encoding a ciliary protein, was identified. Subsequently, five 
additional arRP families were found to harbour MAK mutations. 
Chapter 4a describes the detection of MVK mutations in patients with non-syndromic RP. 
These variants were previously found in classic forms of mevalonate kinase deficiency 
(MKD). After careful re-examination the patients appeared to have very mild MKD signs, 
which consist of recurrent childhood febrile crises in two patients, mild ataxia in one of 
them and renal failure in another. However, these symptoms were not initially linked to RP. 
Comparably to MKD patients, these individuals showed an almost undetectable MVK 
activity. It is still unclear why severe characteristics of MKD, such as psychomotor 
retardation, progressive cerebellar ataxia and failure to thrive, were not present in these 
RP patients. The hypotheses include exceptional toxicity of high mevalonic acid levels for 
photoreceptors in the retina, which may be decreased by an unknown factor in other types 
of neurons. Alternatively, as a result of the MVK deficiency, too few prenyl groups would 
be present in the retina. Hence, many crucial prenylated proteins in photoreceptors would 
not be able to properly perform their function and retinal degeneration would occur. 
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Inspired by the discovery of novel correlations of mutations in MVK and recently found 
variants in RAB28 with IRDs, Chapter 4b reviews the common theme of prenylation in 
proteins mutated in IRD patients. These proteins are either farnesylated (e.g. PDE6A, 
RAB28) or geranylgeranylated (e.g. PDE6B, RPGR), which influences their capacity of 
membrane attachment and cellular trafficking. Additionally, many proteins taking part in 
synthesis or processing of these residues, as well as chaperones (e.g. AIPL1, PrBP/δ) and 
other interactors of prenylated proteins (RIMS1) were previously found to be associated 
with various IRD types. We hypothesise that the shortage of prenyl residues, crucial for 
correct localisation and transport through membranous outer segment structures of many 
retinal proteins, is responsible for this phenotype. This stresses the importance of the 
isoprenoid synthesis pathway and prenylation processes in the retina. 
Chapter 5a refers to a sequence analysis of NMNAT1 in an IRD cohort of mixed origin, 
which led to the identification of six novel mutations in this gene in LCA patients. Except for 
one individual with parafoveal atrophic lesions, all patients displayed macular atrophy, 
which was previously reported as a hallmark of NMNAT1-associated LCA. Since NMNAT1 
knockout mice are not viable, it may be hypothesised that LCA can only be associated with 
NMNAT1 variants if there is residual NMNAT1 activity. Hence, a severe (e.g. introducing a 
premature translation termination) allele must be accompanied by a mild allele. In a 
subsequent study, presented in Chapter 5b, the frequency and haplotype surrounding the 
most common NMNAT1 variant, p.E257K, was investigated. These analyses led to the 
conclusion that p.E257K is a hypomorphic allele, which in a homozygous state is not 
associated with ocular disease in more than 95% of persons. 
Finally, in Chapter 6 all results that are described in this thesis are discussed and put in 
the contemporary perspective. Homozygosity mapping proved to be a powerful tool in 
searching for the underlying mutation in RP patients from Indonesia. Mutations that were 
found in this cohort were novel, which may indicate that the Indonesian population has a 
unique set of mutations that is different than in previously studied cohorts. After the 
invention of exome sequencing, variant prioritisation has been the most important 
challenge. Relying on the score of CRX binding, a transcription factor, which is particularly 
crucial for photoreceptor development, led to successful identification of MAK, a ciliary 
gene mutated in arRP. Exome NGS for RP and LCA did not yield as many novel genes as 
it was initially assumed and possible reasons for this discrepancy are discussed. The 
findings of MVK suggest that there may be many other genes that are not only associated 
with syndromes, but also with non-syndromic retinal diseases. The phenotypic difference, 
which is not yet well explained, will be elucidated by factors acting in cis-, trans-, or by the 
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difference in severity of the underlying mutations. Overall, the findings contained within this 
thesis are important for proper diagnostics and genetic counselling. At the moment it is the 
most significant outcome of molecular diagnosis. Since IRDs are very heterogeneous 
disorders, it would be very challenging to develop gene augmentation therapy for each 
gene that is involved in IRD. Possibly other, gene-independent strategies will be developed 
to stop or slow down photoreceptor degeneration and restore vision. 
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Samenvatting 
Erfelijke netvliesaandoeningen (inherited retinal diseases, IRDs) vertonen een groot 
spectrum aan klinische en genetische heterogeniteit. Tot op heden zijn ongeveer 
tweehonderd genen geïdentificeerd, die geassocieerd kunnen zijn met IRDs. In dit 
proefschrift werden de genetische afwijkingen en klinische kenmerken onderzocht van 
patiënten met twee subtypes van IRD, namelijk retinitis pigmentosa (RP) en amaurosis 
congenita van Leber (LCA). De positionele informatie van oorzakelijke genetische defecten 
werd aanvankelijk verkregen met behulp van genoom-wijde SNP arrays en 
daaropvolgende homozygotie mapping of koppelingsonderzoek. Daarnaast werd exoom 
sequencing uitgevoerd, soms ondersteund door genoom-wijde SNP homozygotie-mapping 
of haplotype-analyse. Deze resultaten zijn samengevat aan het einde van Hoofdstuk 1a. 
Dit hoofdstuk geeft ook een korte inleiding op de geschiedenis van de genetica, en op de 
anatomie van en de moleculaire processen in het netvlies. 
Hoofdstuk 1b vat de huidige benaderingen samen die toegepast kunnen worden voor de 
ontdekking van de genen die gemuteerd zijn in IRD. Voor homogene monogene 
aandoeningen wordt Sanger sequentie analyse uitgevoerd van alle coderende exonen en 
flankerende intron sequenties van het gen, welke geassocieerd is met de betreffende 
ziekte. Aangezien het grootste deel van IRD genen echter gemuteerd is in slechts ~1% 
van de getroffen personen, zullen andere methoden moeten worden toegepast bij 
heterogene monogene ziekten. Momenteel wordt resequencing van alle bekende IRD-
geassocieerde genen (bijvoorbeeld 61 genen gemuteerd in RP) uitgevoerd, met behulp 
van diverse grootschalige sequentie analyse technologieën. Als met deze methode het 
verantwoordelijke gen niet geïdentificeerd wordt, kan exome sequencing worden 
toegepast. Indien er geen oorzakelijke mutatie wordt gevonden in eiwitcoderende delen 
van de diverse genen, kan het hele genoom worden gesequenced, waarmee met name 
heterozygote structurele afwijkingen (o.a. deleties, duplicaties, inversies) kunnen worden 
aangetoond. Ook diep-intronische mutaties kunnen hiermee worden gevonden, maar het 
effect hiervan kan alleen worden bewezen door ook de mRNA sequenties te sequencen, 
bij voorkeur van patiëntspecifieke retinale cellen. Deze kunnen verkregen worden door 
somatische cellen (bv. fibroblasten) te transformeren naar geïnduceerde pluripotente 
stamcellen, die daarna gedifferentieerd kunnen worden naar netvliescellen. De 
beoordeling van de pathogeniciteit van de variant is een cruciale stap in het bepalen van 
causaliteit. 
Hoofdstuk 2a beschrijft de moleculaire genetische analyse van veertien families met RP 
uit Indonesië. Met behulp van genoom-wijde SNP analyse werden oorzakelijke mutaties in 
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genen gevonden die eerder betrokken waren bij RP in 7 van de 14 families. In 3 families 
waarin de ouders bloedverwant waren leidde koppelingsonderzoek tot de identificatie van 
de onderliggende genetische defecten in ABCA4, EYS en NR2E3. In vier andere families 
werd homozygotie mapping gebruikt om mutaties op te sporen in CRB1, MERTK en 
PDE6A. Aloewel er geen bloedverwantschap bekend was in deze families, werd in één 
familie een MERTK mutatie gevonden in een grote homozygote regio die aanwezig was in 
beide aangedane personen. De grootte van dit chromosomale gebied is vergelijkbaar met 
de omvang van homozygote gebieden die normaal gesproken in personen gevonden 
worden van wie de ouders neef en nicht zijn. Aangezien Indonesië bestaat uit vele 
verschillende stammen, waarvan sommige op eilanden leven, is er vaak een bepaalde 
mate van bloedverwantschap aanwezig in sommige gesloten gemeenschappen, zelfs als 
de familieleden zelf zich hiervan niet bewust zijn. 
In een vervolgstudie werden nog 21 Indonesisch families met RP bestudeerd. In een van 
deze families werd een RP1 nonsense mutatie (p.(R338*)) gevonden die wordt besproken 
in Hoofdstuk 2b. De overgrote meerderheid van de mutaties in dit gen veroorzaken een 
autosomaal dominante vorm van RP. Onze bevindingen hebben geleid tot speculaties 
over mogelijke pathofysiologische mechanismen geassocieerd met RP1 mutaties, die 
worden bediscussieerd in dit hoofdstuk. 
In Hoofdstuk 3 wordt de ontdekking van een nieuw arRP gen gerapporteerd dat codeert 
voor een ciliair eiwit. De analyse van exome sequencing data is een grote uitdaging 
gegeven het grote aantal varianten dat wordt gevonden met deze techniek. Vele 
benaderingen zijn toegepast om pathogene mutaties te onderscheiden van goedaardige 
polymorfismen. Deze studie gebruikte de bindingspatronen van Crx, een transcriptiefactor 
die cruciaal is voor de ontwikkeling en het onderhoud van het netvlies, in wildtype en Nrl-/- 
knockout muizen. Genen werden gerangschikt op basis van het aantal Crx-bindende 
sequenties als maat voor de expressie in fotoreceptoren. Met behulp van deze gegevens 
werden varianten, verkregen middels exome sequencing van een arRP patiënt van een 
bloedverwante Turkse familie, geprioritiseerd. Daarnaast zijn SNP homozygotie data 
gebruikt voor het filteren van varianten. In deze patiënt werd een homozygote nonsense 
mutatie geïdentificeerd in MAK, een gen dat codeert voor een ciliair eiwit. Vervolgens 
werden bij nog vijf arRP families MAK mutaties gevonden. 
Hoofdstuk 4a beschrijft de detectie van MVK mutaties in patiënten met niet-syndromale 
RP. Deze varianten werden eerder gevonden in personen met de klassieke vormen van 
mevalonaat kinase deficiëntie (MKD). Na uitgebreid heronderzoek, bleken patiënten zeer 
milde MKD verschijnselen te vertonen, bestaande uit terugkerende periodieke koorts in 
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hun kindertijd bij twee patiënten waarvan een ook een milde ataxie had, en 
nierinsufficiëntie bij een andere patiënt. Echter, deze symptomen waren niet direct 
gekoppeld aan RP. Vergelijkbaar met MKD patiënten, vertoonden deze personen een 
vrijwel niet-detecteerbare activiteit van het MVK enzym. Het is nog onduidelijk waarom 
ernstige kenmerken van MKD, zoals psychomotorische retardatie, progressieve 
cerebellaire ataxie en een ontwikkelingsachterstand, niet aanwezig waren bij de RP 
patiënten met MVK varianten. Een hypothese is dat hoge concentraties mevalonzuur 
toxisch zijn voor de fotoreceptoren in het netvlies. In andere neuronen zijn deze niveaus 
mogelijk lager door nog onbekende factoren. Een alternatieve verklaring zou kunnen zijn 
dat, als gevolg van de MVK deficiëntie, er te weinig prenyl-groepen in het netvlies worden 
gemaakt waardoor cruciale geprenyleerde fotoreceptor eiwitten hun functie niet goed 
kunnen uitoefenen en er netvliesdegeneratie zal optreden. 
Geïnspireerd door de ontdekking van nieuwe correlaties van mutaties in MVK en recent 
gevonden RAB28 varianten in IRD, geeft Hoofdstuk 4b een overzicht van defecten in 
eiwit prenylering die een rol spelen bij IRD. Deze eiwitten zijn gefarnesyleerd (bijv. PDE6A, 
RAB28) of geranylgeranyliseerd (bijv. PDE6B, RPGR, de meeste RAB GTPases). Dit 
beïnvloedt hun capaciteit om aan membranen te hechten en daarmee hun diverse rollen in 
intracellulair transport processen. Bovendien werden eiwitten die betrokken zijn bij de 
synthese of verwerking van deze prenyl groepen, zoals chaperones (bijv. AIPL1, PrBP/δ) 
en andere interactoren van geprenyleerde eiwitten (RIMS1) eerder geassocieerd met 
verschillende vormen van IRD. We veronderstellen dat het tekort aan prenyl groepen een 
groot effect heeft op de lokalisatie en het transport van vele eiwitten in het netvlies, en 
daardoor mogelijk verantwoordelijk is voor deze aandoening. Dit benadrukt het belang van 
de isoprenoid synthese en prenyleringsprocessen in het netvlies. 
Hoofdstuk 5a beschrijft een sequentie analyse van NMNAT1 in diverse IRD cohorten, 
hetgeen leidde tot de identificatie van zes nieuwe mutaties in dit gen bij patiënten met 
LCA. Behalve een persoon met parafoveale atrofische afwijkingen, vertonen alle patiënten 
atrofie van de macula zoals eerder werd gerapporteerd als een typisch kenmerk van 
NMNAT1-geassocieerde LCA. Aangezien NMNAT1 knockout muizen niet levensvatbaar 
zijn, kan worden verondersteld dat LCA alleen veroorzaakt wordt door NMNAT1 varianten 
als er resterende NMNAT1 activiteit is. Daarom wordt bij LCA patiënten een ernstige 
variant (bijvoorbeeld een mutatie waardoor de translatie voortijdig wordt beëindigd) 
vergezeld worden van een milde variant. In een hierop volgende studie, beschreven in 
Hoofdstuk 5b, werd de frequentie van en het haplotype rondom de meest voorkomende 
NMNAT1 variant, p.(E257K), onderzocht. Deze analyses hebben geleid tot de conclusie 
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dat p.(E257K) een mild (hypomorf) allel is, dat in een homozygote vorm in meer dan 95% 
van de personen niet geassocieerd is met netvliesdegeneratie. 
In Hoofdstuk 6 tenslotte werden alle resultaten die beschreven werden in dit proefschrift 
bediscussieerd en in het huidige perspectief geplaatst. Homozygotie mapping bleek een 
krachtig hulpmiddel bij het zoeken naar de oorzakelijke mutaties in RP patiënten uit 
Indonesië. Alle mutaties die in dit cohort werden gevonden waren niet eerder beschreven, 
hetgeen er op wijst dat de Indonesische bevolking unieke mutaties draagt die verschillen 
van eerder bestudeerde cohorten. Na de introductie van exome sequencing, is variant 
prioriterising een belangrijke uitdaging geworden. Het gebruik van Crx-bindings informatie, 
een transcriptiefactor die cruciaal is voor fotoreceptor ontwikkeling, leidde tot de 
succesvolle identificatie van MAK, een gen dat codeert voor een ciliair eiwit, en gemuteerd 
is in personen met autosomaal recessieve RP. Exoom NGS voor personen met RP en 
LCA resulteerde in minder nieuwe oorzakelijke genen dan aanvankelijk werd 
aangenomen, en de mogelijke oorzaken voor deze discrepantie worden besproken. De 
bevindingen voor MVK wijzen er op dat er mogelijk nog vele andere genen zijn die niet 
alleen betrokken zijn bij syndromen, maar ook bij niet-syndromale netvliesaandoeningen. 
De fenotypische verschillen kunnen nog niet worden verklaard. Gedacht wordt aan cis- of 
trans-werkende genetische factoren of door verschillen in de ernst van de onderliggende 
mutaties. De bevindingen in dit proefschrift zijn op de eerste plaats belangrijk voor een 
betere diagnostiek. Gezien de grote mate van genetische heterogeniteit, is het 
onwaarschijnlijk dat er een generieke behandeling ontwikkeld kan worden voor elk gen dat 
betrokken is bij IRD. Enkele gen-onafhankelijke strategieën worden momenteel ontwikkeld 
om de fotoreceptor degeneratie te stoppen of te vertragen. 
 245 
 
Links to databases 
  
 247 
 
Links to databases 
1000 genomes    http://www.1000genomes.org 
Ciliome database   http://www.sfu.ca/~leroux/ciliome_database.htm 
dbSNP     http://www.ncbi.nlm.nih.gov/projects/SNP 
EVS      http://evs.gs.washington.edu/EVS 
HapMap     http://hapmap.ncbi.nlm.nih.gov 
MASS     http://mutationassessor.org/ 
MGI      http://www.informatics.jax.org 
The ocular tissue database https://genome.uiowa.edu/otdb 
OMIM     http://www.omim.org 
PLINK     http://pngu.mgh.harvard.edu/~purcell/plink/ 
PolyPhen2    http://genetics.bwh.harvard.edu/pph2 
PhyloP     http://genome.ucsc.edu/cgi-bin/hgTables 
PRENbase    http://mendel.imp.ac.at/PrePS/PRENbase 
RefSeq     http://www.ncbi.nlm.nih.gov/refseq 
RetNet     https://sph.uth.edu/retnet 
SIFT      http://sift.jcvi.org 
SKIPPY     http://research.nhgri.nih.gov/skippy/input.shtml 
UCSC Genome Browser   http://genome-euro.ucsc.edu 
ZFIN      http://zfin.org/ 
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